

CITATION REPORT

List of articles citing

Chronic hepatitis B: update 2009

DOI: 10.1002/hep.23190
Hepatology, 2009, 50, 661-2.

Source: <https://exaly.com/paper-pdf/46061438/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2346	Hepatitis B therapies and antiviral resistance detection and management. 2009 , 3, 693-9		2
2345	Peginterferon-alpha-2a (40 kD): A review of its use in chronic hepatitis B. 2009 , 69, 2633-60		14
2344	Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients. 2010 , 15, 1171-8		23
2343	New approaches to optimize treatment responses in chronic hepatitis B. 2010 , 15 Suppl 3, 61-8		7
2342	Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B. 2010 , 15, 1185-90		32
2341	Effect of newer oral antiviral agents on future therapy of chronic hepatitis B. 2010 , 15, 13-22		5
2340	A personalized approach to optimize hepatitis B treatment in treatment-naive patients. 2010 , 15 Suppl 3, 53-9		8
2339	Antiviral therapy for hepatitis B in special populations. 2010 , 15, 1067-75		1
2338	Reactivation of hepatitis B virus in HBsAg-negative patients with multiple myeloma: two case reports. 2010 , 91, 844-9		18
2337	Viral resistance in hepatitis B: prevalence and management. 2010 , 12, 62-9		6
2336	Treatment of Acute Hepatitis B with Nucleoside and/or Nucleotide Analogues. 2010 , 9, 119-123		
2335	Immune-Tolerant Hepatitis B Infection: To Treat or Not to Treat?. 2010 , 9, 60-64		
2334	A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B. 2010 , 9, 75-90		26
2333	Histologic Disease in Patients with Chronic Hepatitis B, High HBV DNA, and Normal Alanine Aminotransferase Levels. 2010 , 9, 65-74		3
2332	Chemoprevention of Patients with Hepatitis B Receiving Chemotherapy or Bone Marrow Transplant. 2010 , 9, 178-186		1
2331	Hepatitis B Biomarkers: Clinical Significance of the Old and the New. 2010 , 9, 187-196		1
2330	HBV Drug Resistance Development, Testing, and Prevention. 2010 , 9, 223-230		1

2329	The Role of Interferon in Hepatitis B Therapy. 2010 , 9, 231-238		30
2328	Hepatitis B Therapy in Pregnancy. 2010 , 9, 197-204		48
2327	Factors associated with hepatitis B testing among Vietnamese Americans. 2010 , 25, 694-700		48
2326	Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. 2010 , 55, 2727-34		73
2325	Trends in the indication and method of liver biopsy for hepatitis B and C. 2010 , 55, 2971-6		9
2324	Non-hepatic insults are common acute precipitants in patients with acute on chronic liver failure (ACLF). 2010 , 55, 3188-92		61
2323	Viral hepatitis and HIV co-infection. 2010 , 85, 303-15		155
2322	Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery. 2010 , 88, 269-75		43
2321	Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine. 2010 , 137, 190-8		15
2320	Routine hepatitis B virus DNA testing in human immunodeficiency virus-infected patients with positive hepatitis B core antibody but negative hepatitis B surface antigen is not justified by current evidence. <i>Hepatology</i> , 2010 , 51, 1087-8	11.2	3
2319	Think twice if you consider entecavir treatment in cases with lamivudine refractoriness. <i>Hepatology</i> , 2010 , 52, 397-8	11.2	2
2318	Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. <i>Hepatology</i> , 2010 , 51, 1933-44	11.2	324
2317	Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. <i>Hepatology</i> , 2010 , 52, 454-61	11.2	188
2316	Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. <i>Hepatology</i> , 2010 , 52, 1611-20	11.2	164
2315	Viral hepatitis and inflammatory bowel disease. 2010 , 16, 925-32		55
2314	Entecavir treatment for chronic hepatitis B infection in end-stage renal disease and kidney transplantation. 2010 , 39, 397-400		10
2313	Preventing hepatitis B reactivation in immunosuppressed patients: is it time to revisit the guidelines?. 2010 , 62, 585-9		12
2312	Clinical use of liver biopsy for the diagnosis and management of inactive and asymptomatic hepatitis B virus carriers in Bangladesh. 2010 , 82, 1350-4		14

2311	Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients. 2010 , 82, 1494-500	48
2310	Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. 2010 , 82, 1835-42	45
2309	Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. 2010 , 32, 851-8	85
2308	Occult hepatitis B virus infection: a covert operation. 2010 , 17, 1-15	128
2307	Do we need to determine viral genotype in treating chronic hepatitis B?. 2010 , 17, 601-10	32
2306	Transient elastography. 2010 , 25, 1726-31	64
2305	Review article: Hepatitis B and dialysis. 2010 , 15, 137-45	102
2304	Liver transplant from Anti-HBc-positive, HBsAg-negative donor into HBsAg-negative recipient: is it safe? A systematic review of the literature. 2010 , 24, 735-46	34
2303	New developments in antiviral therapy for chronic hepatitis B. 2010 , 98, 481-94	9
2302	Hepatitis B genotype G and high frequency of lamivudine-resistance mutations among human immunodeficiency virus/hepatitis B virus co-infected patients in Brazil. 2010 , 105, 770-8	16
2301	Fatigue and depressive symptoms associated with chronic viral hepatitis patients health-related quality of life (HRQOL). 2010 , 9, 419-427	44
2300	Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. 2010 , 48, 3641-7	50
2299	Hepatitis B reactivation and rituximab in the oncology practice. 2010 , 15, 1113-21	20
2298	Rituximab administration and reactivation of HBV. 2010 , 2010, 182067	19
2297	Modulation of serum interleukin-18 concentrations and hepatitis B virus DNA levels during interferon therapy in patients with hepatitis B e-antigen-positive chronic hepatitis B. 2010 , 30, 901-8	4
2296	A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. 2010 , 105, 1762-9	71
2295	Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. 2010 , 2, 2696-739	31
2294	Antiviral treatment of chronic hepatitis B virus (HBV) infections. 2010 , 2, 1279-305	40

2293	Chronic hepatitis B: perceptions in Asian American communities and diagnosis and management practices among primary care physicians. 2010 , 122, 165-75	35
2292	Pathology of chronic hepatitis B and chronic hepatitis C. 2010 , 14, 555-75	16
2291	Chronic hepatitis B: past, present, and future. 2010 , 14, 531-46	25
2290	Thrombocytopenia with abnormal liver function tests. 2010 , 8, 920-3	
2289	Management of chronic hepatitis B in pregnancy. 2010 , 14, 495-504	40
2288	Natural history of chronic hepatitis B. 2010 , 14, 381-96	127
2287	Molecular methods in the diagnosis and management of chronic hepatitis B. 2010 , 10, 921-35	12
2286	Telbivudine: a review of its use in compensated chronic hepatitis B. 2010 , 70, 1857-83	16
2285	Does chemotherapy prevent HBV-related hepatocellular carcinoma? Cons. 2010 , 42 Suppl 3, S298-301	3
2284	Hepatitis B surface antigen (HBsAg): a 40-year-old hepatitis B virus seromarker gets new life. 2010 , 139, 380-2	10
2283	Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. 2010 , 139, 1207-17	127
2282	Review of hepatitis B therapeutics. 2010 , 51, 1201-8	64
2281	A review of oral antiretroviral therapy for the treatment of chronic hepatitis B. 2010 , 44, 1271-86	7
2280	Entecavir in decompensated HBV cirrhosis: the future is looking brighter. 2010 , 52, 147-9	18
2279	Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy. 2010 , 53, 261-6	31
2278	Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. 2010 , 53, 449-54	42
2277	[Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab]. 2010 , 33, 377-81	3
2276	Usefulness of transient elastography for assessment of liver fibrosis in chronic hepatitis B: Regression of liver stiffness during entecavir therapy. 2010 , 40, 853-61	47

2275	Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. 2010 , 116, 2875-83	65
2274	Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge. 2010 , 51, 1592-5	8
2273	Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs. 2011 , 46, 760-6	14
2272	Liver involvement in subjects with rheumatic disease. 2011 , 13, 226	43
2271	Effectiveness of entecavir in the management of acute hepatitis B developing in a patient with Hodgkin's lymphoma: a case report. 2011 , 43, 750-2	4
2270	Managing patients with hepatitis-B-related or hepatitis-C-related decompensated cirrhosis. 2011 , 8, 285-95	24
2269	Liver Biopsy and Laparoscopy. 2011 , 44-57	
2268	Recent advances in the treatment of chronic hepatitis B. 2011 , 12, 2025-40	23
2267	Current status of liver transplantation for hepatitis B virus. 2011 , 15, 753-64	13
2266	Care of the liver transplant candidate. 2011 , 15, 779-806	1
2265	Care of chronic liver disease. 2011 , 38, 483-98; viii-ix	2
2264	Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. 2011 , 9, 274-6	133
2263	Emerging pipeline drugs for hepatitis B infection. 2011 , 16, 713-29	20
2262	Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. 2011 , 141, 1220-30, 1230.e1-3	222
2261	Rheumatologic disease and the liver. 2011 , 15, 153-64	22
2260	Antiviral drugs for viruses other than human immunodeficiency virus. 2011 , 86, 1009-26	162
2259	Natural history of chronic HBV infection: special emphasis on the prognostic implications of the inactive carrier state versus chronic hepatitis. 2011 , 43 Suppl 1, S8-14	40
2258	Reactivation of hepatitis B in a patient with spondyloarthritis after the suspension of methotrexate and efficacy of treatment with antivirals in association to adalimumab. 2011 , 7, 200-202	

2257	HBV-carriers: When is monitoring and surveillance sufficient? (point of view). 2011 , 35, 813-8	7
2256	Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates). 2011 , 43, 589-95	39
2255	[Reactivation of hepatitis B in a patient with spondyloarthritis after the suspension of methotrexate and efficacy of treatment with antivirals in association to adalimumab]. 2011 , 7, 200-2	9
2254	Hepatitis B: modern end points of treatment and the specter of viral resistance. 2011 , 40, 495-505	8
2253	Replicative activity of hepatitis B virus is negatively associated with methylation of covalently closed circular DNA in advanced hepatitis B virus infection. 2011 , 54, 316-25	52
2252	Antiviral drugs for HBV liver disease. 2011 , 11, 285-300	19
2251	Hepatitis B prevention, diagnosis, treatment and care: a review. 2011 , 61, 531-40	92
2250	Hepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients. 2011 , 9, 891-9	14
2249	Hepatitis B immunoglobulin for prevention of hepatitis B virus infection and recurrence after liver transplantation. 2011 , 7, 429-36	9
2248	Management of hepatitis B. 2011 , 9, 385-91	1
2247	Clinical pearls in gastroenterology 2011. 2011 , 86, 1104-8	1
2246	[Virological response to adefovir dipivoxil predicts the long-term development of resistance in previously untreated patients with HBeAg-negative chronic hepatitis B]. 2011 , 34, 69-74	
2245	[Current treatment of hepatitis B infection: where do the new nucleos(t)ide analogues fit in?]. 2011 , 34, 492-503	2
2244	Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? NO. 2011 , 22, 576-81	5
2243	Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. 2011 , 50, 292-6	67
2242	Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: implications for antiviral therapy. 2011 , 54, 195-200	24
2241	Study of adherence comes to the treatment of chronic hepatitis B. 2011 , 54, 6-8	32
2240	Focus. 2011 , 54, 189-90	

2239	Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. 2011 , 55, 522-528	30
2238	Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. 2011 , 12, 568-74	427
2237	Long-term antifibrotic action of interferon- α treatment in patients with chronic hepatitis B virus infection. 2011 , 10, 151-7	12
2236	Hepatitis B therapy. 2011 , 8, 275-84	198
2235	Polymyositis associated with hepatitis B: management with entecavir and prednisolone. 2011 , 14, e38-41	5
2234	Acute hepatitis B in Japan: Incidence, clinical practices and health policy. 2011 , 41, 39-45	26
2233	Recommendation of lamivudine-to-entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial. 2011 , 41, 505-11	4
2232	Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites. 2011 , 41, 1017-24	21
2231	5' Triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice. 2011 , 141, 696-706, 706.e1-3	57
2230	Management of hepatitis B virus infection in the pre-transplant setting. 2011 , 5, 10-14	
2229	Impact of Fibroscan [®] on management of chronic viral hepatitis in clinical practice. 2011 , 10, 469-476	13
2228	Management and treatment of hepatitis B virus in patients with HIV infection: A practical guide for health care professionals. 2011 , 22, 88-96	2
2227	Clinical, demographic and epidemiological characteristics of patients with hepatitis B followed at a university hospital in southeastern Brazil: predominance of HBeAg negative cases. 2011 , 44, 13-7	11
2226	Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device. 2011 , 5, 587-99	5
2225	Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change. 2011 , 25, 538-41	2
2224	Safety and efficacy of entecavir for the treatment of chronic hepatitis B. 2011 , 4, 55-64	22
2223	Reactivated hepatitis B due to medical interventions: the clinical spectrum expands. 2011 , 16, 947-9	1
2222	Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues. 2012 , 17, 53-60	20

2221	Phyllanthus species for chronic hepatitis B virus infection. 2011 , CD008960	10
2220	High rate of complete viral suppression with combination therapy in patients with chronic hepatitis B and prior treatment failure. 2011 , 45, 900-5	10
2219	Comparison of clevudine and entecavir for treatment-naive patients with chronic hepatitis B virus infection: two-year follow-up data. 2011 , 45, 893-9	19
2218	Update of chronic hepatitis B. 2011 , 27, 217-23	4
2217	Screening for hepatocellular carcinoma after HBsAg clearance age before cirrhosis?: age before cirrhosis?. 2011 , 45, 4-5	1
2216	Management of chronic hepatitis B. 2011 , 23, 642-50	10
2215	Hepatitis B. 2011 , 367-392	3
2214	Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir. 2012 , 17, 61-70	12
2213	Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensation. 2012 , 17, 605-12	12
2212	The role of adherence in virological suppression in patients receiving anti-HBV analogues. 2012 , 17, 395-400	27
2211	Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients. 2011 , 26, 461-8	13
2210	Treatment of chronic hepatitis B: Evolution over two decades. 2011 , 26 Suppl 1, 138-43	130
2209	To stop or not to stop: the quest for long-term viral suppression. 2011 , 26, 420-2	2
2208	Evaluation of current treatment recommendations for chronic hepatitis B: a 2011 update. 2011 , 26, 829-35	25
2207	Management of chronic Hepatitis B infection in the remote primary health care setting: the search for a suitable guideline. 2011 , 19, 95-100	7
2206	Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers. 2011 , 33, 455-65	63
2205	Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?. 2011 , 33, 501-13	31
2204	Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. 2011 , 33, 1104-12	134

2203	Dual cut-off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation. 2011 , 34, 353-62	63
2202	Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. 2011 , 34, 424-31	19
2201	The efficacy of entecavir therapy in chronic hepatitis B patients with suboptimal response to adefovir. 2011 , 34, 767-74	11
2200	Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. 2011 , 34, 972-81	14
2199	Review article: current antiviral therapy of chronic hepatitis B. 2011 , 34, 1145-58	66
2198	Virologic and biochemical responses to clevudine in patients with chronic HBV infection-associated cirrhosis: data at week 48. 2011 , 18, 287-93	8
2197	Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B. 2011 , 18, 738-44	38
2196	Is chronic hepatitis B being undertreated in the United States?. 2011 , 18, 377-83	126
2195	Development of a protocol for the quantitative determination of HBeAg using the Elecsys [®] HBeAg immunoassay. 2011 , 18, e179-83	13
2194	Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study. 2011 , 18, e200-5	44
2193	Discriminant value of serum HBV DNA levels as predictors of liver fibrosis in chronic hepatitis B. 2011 , 18, e217-25	24
2192	HBV lamivudine resistance among hepatitis B and HIV coinfecting patients starting lamivudine, stavudine and nevirapine in Kenya. 2011 , 18, e447-52	19
2191	Hepatitis B virus resistance to antiviral drugs: where are we going?. 2011 , 31 Suppl 1, 111-6	95
2190	Viral infections associated with the clinical use of monoclonal antibodies. 2011 , 17, 1769-75	11
2189	Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice. 2011 , 65, 866-70	17
2188	Antiviral resistance mutations potentiate HBV surface antigen-induced transcription of hfgl2 prothrombinase gene. 2011 , 76, 1043-50	2
2187	Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. 2011 , 104, 559-63	39
2186	Development and validation of a hepatitis B virus DNA sequencing assay for assessment of antiviral resistance, viral genotype and surface antigen mutation status. 2011 , 177, 31-7	27

2185	TNF alpha antagonist therapy and safety monitoring. 2011 , 78 Suppl 1, 15-185	54
2184	Tim-3 expression on peripheral T cell subsets correlates with disease progression in hepatitis B infection. 2011 , 8, 113	58
2183	Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. 2011 , 8, 393	49
2182	Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective study. 2011 , 8, 444	7
2181	Impact of body mass index and viral load on liver histology in hepatitis B e antigen-negative chronic hepatitis B. 2011 , 30, 647-52	18
2180	Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B. 2011 , 16, 77-87	38
2179	Drug safety evaluation of adefovir in HBV infection. 2011 , 10, 809-18	30
2178	Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. 2011 , 33, 619-33	87
2177	Hepatitis B and hepatocellular carcinoma screening among Asian Americans: survey of safety net healthcare providers. 2011 , 56, 1516-23	46
2176	Performance parameters of the conventional serological markers for autoimmune hepatitis. 2011 , 56, 545-54	51
2175	Defining virologic relapse in chronic hepatitis B. 2011 , 56, 2432-8	4
2174	Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. 2011 , 56, 2423-31	44
2173	The management of chronic hepatitis B in Asian Americans. 2011 , 56, 3143-62	58
2172	Access to care and optimal treatment of chronic hepatitis B in Asian Americans: an evolving agenda. 2011 , 56, 3106-8	
2171	Alteration of interferon- α receptors in chronic hepatitis B patients. 2011 , 31, 521-32	9
2170	Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. 2011 , 46, 9-16	71
2169	Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. 2011 , 46, 556-64	113
2168	Development of immunity against hepatitis B virus after donor lymphocyte infusion in a peripheral blood stem cell transplantation recipient with chronic hepatitis B. 2011 , 39, 363-5	5

2167	The use of transient elastography in the management of chronic hepatitis B. 2011 , 5, 868-875	13
2166	Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment. 2011 , 26, 239-44	23
2165	Hepatitis B--more treatments, more testing, not enough data. 2011 , 26, 232-3	
2164	Current Management of HBV Antiviral Drug Resistance. 2011 , 10, 120-127	
2163	Combination Therapy for Chronic Hepatitis B: Current Indications. 2011 , 10, 98-105	7
2162	Hepatitis B Genotypes: Role of Testing in Clinical Practice. 2011 , 10, 79-86	
2161	Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. 2011 , 10, 235-243	21
2160	Update on Diagnosis and Treatment within the Four Clinical Phases of Chronic Hepatitis B Infection. 2011 , 10, 229-234	
2159	Epigenetic Regulation of Hepatitis B Virus Infection. 2011 , 10, 277-284	5
2158	Hepatitis B virus Resistance to Antivirals : Diagnosis and Management. 2011 , 10, 244-254	
2157	Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials. 2011 , 11, 165	24
2156	Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil. 2011 , 11, 247	7
2155	Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment. 2011 , 8, 388	4
2154	Stability of hepatitis B surface antigen over time: implications for studies using stored sera. 2011 , 83, 1900-4	7
2153	HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo. 2011 , 83, 1917-23	2
2152	Number of mutations within CTL-defined epitopes of the hepatitis B Virus (HBV) core region is associated with HBV disease progression. 2011 , 83, 2082-7	20
2151	Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. <i>Hepatology</i> , 2011 , 53, 62-72	11.2 242
2150	No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. <i>Hepatology</i> , 2011 , 53, 763-73	11.2 144

2149	Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. <i>Hepatology</i> , 2011 , 53, 1486-93	11.2	110
2148	Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection. <i>Hepatology</i> , 2011 , 53, 1839-45	11.2	34
2147	Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. <i>Hepatology</i> , 2011 , 53, 1854-63	11.2	99
2146	Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. <i>Hepatology</i> , 2011 , 54, 91-100	11.2	155
2145	Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy. <i>Hepatology</i> , 2011 , 54, 101-8	11.2	29
2144	Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. <i>Hepatology</i> , 2011 , 53, 2121-9	11.2	67
2143	Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. <i>Hepatology</i> , 2011 , 54, 820-8	11.2	262
2142	Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. <i>Hepatology</i> , 2011 , 54, E1-9	11.2	52
2141	Changes in hepatitis A and B vaccination rates in adult patients with chronic liver diseases and diabetes in the U.S. population. <i>Hepatology</i> , 2011 , 54, 1167-78	11.2	26
2140	Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve?. <i>Hepatology</i> , 2011 , 54, 1454-62	11.2	42
2139	Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. <i>Hepatology</i> , 2011 , 54, 1591-9	11.2	153
2138	Liver dysfunction and immunosuppressive therapy. 2011 , 17, 2404-5		
2137	Serum paraoxonase and arylesterase activities in various forms of hepatitis B virus infection. 2011 , 25, 311-6		16
2136	Subtle hepatocellular carcinoma: a persisting role for alpha-fetoprotein monitoring in high-risk patients with cirrhosis. 2011 , 5, 565-8		
2135	Recurrent Disease Following Liver Transplantation. 2011 , 1152-1171		
2134	Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. 2011 , 106, 1264-71		117
2133	Risk assessment of esophageal variceal bleeding in B-viral liver cirrhosis by a liver stiffness measurement-based model. 2011 , 106, 1654-62, 1730		48
2132	Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. 2011 , 106, 1766-73		51

2131	Diagnostic and Clinical Relevance of HBV Mutations. 2011 , 42, 488-496	7
2130	A Review of Commonly Prescribed Antiviral and Antiretroviral Agents. 2011 , 27, 99-110	
2129	The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma. 2011 , 2011, 416459	9
2128	Treatment of hepatitis B in decompensated liver cirrhosis. 2011 , 2011, 918017	23
2127	Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients. 2011 , 2011, 405390	9
2126	A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective. 2011 , 30, 340-8	26
2125	Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients. 2011 , 84 Suppl 1, 23-8	13
2124	Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. 2011 , 66, 2715-25	139
2123	An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening. 2011 , 16, 579-84	21
2122	HLA-DRB1*010101 allele is closely associated with poor virological response to lamivudine therapy in patients with chronic hepatitis B. 2011 , 84 Suppl 1, 35-42	4
2121	Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. 2011 , 25, 73-9	60
2120	Multicenter evaluation of the Elecsys hepatitis B surface antigen quantitative assay. 2011 , 18, 1943-50	32
2119	Economic analysis of hepatitis B screening and treatment. 2011 , 52, 1307-9	4
2118	Severe acute hepatitis B treated with entecavir. 2011 , 3, e2011010	12
2117	TGF- β down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistence. 2012 , 8, e1002594	144
2116	The treatment strategies of autoimmune disease may need a different approach from conventional protocol: a review. 2012 , 44, 665-71	41
2115	Hepatitis B viral breakthrough associated with inappropriate preservation of entecavir. 2012 , 44, 136-7	1
2114	Recurrent Viral Diseases after Liver Transplantation. 2012 , 883-909	

2113	Therapy for HBV Infection in Hemodialysis Patients: Is it Possible?. 2012 , 12, 153-7	2
2112	Hepatitis B vaccination in chronic kidney disease: review of evidence in non-dialyzed patients. 2012 , 12, e7359	27
2111	High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B. 2012 , 18, 75-83	13
2110	Low rates of hepatitis B virus screening at the onset of chemotherapy. 2012 , 8, e32-9	64
2109	Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma. 2012 , 5, 515-9	6
2108	Accuracy of routine clinical ultrasound for staging of liver fibrosis. 2012 , 2, 58	39
2107	Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy. 2012 , 56, 5511-9	14
2106	ARHA: antiviral resistance. 2012 , 67 Suppl 1, i65-8	2
2105	Diagnosis and personalized management of hepatitis B including significance of genotypes. 2012 , 25, 570-7	13
2104	New advances in chronic hepatitis B. 2012 , 28, 193-7	16
2103	Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir. 2012 , 56, 2941-7	25
2102	Is ultrasound elastography of the liver ready to replace biopsy? A critical review of the current techniques. 2012 , 20, 24-32	11
2101	Treatment of chronic hepatitis B and C in children. 2012 , 7, 955-972	1
2100	Chronic Viral and Autoimmune Hepatitis. 2012 , 973-979	1
2099	Management of hepatitis B reactivation in patients receiving cancer chemotherapy. 2012 , 5, 359-70	15
2098	Epidemiology, responses, and way forward: the silent epidemic of viral hepatitis and HIV coinfection in Vietnam. 2012 , 11, 311-20	18
2097	Assessment of the quality of evidence underlying international guidelines in liver disease. 2012 , 107, 1276-82	13
2096	References. 2012 , 2, 259-274	9

2095	Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs. 2012 , 6, 187-98	26
2094	Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. 2012 , 11, 361-8	46
2093	Association of reduced renal function with hepatitis B virus infection and elevated alanine aminotransferase. 2012 , 7, 1561-6	12
2092	Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. 2012 , 30, 3167-73	84
2091	Risk assessment of development of hepatic decompensation in histologically proven hepatitis B viral cirrhosis using liver stiffness measurement. 2012 , 85, 219-27	17
2090	Prediction of esophageal variceal bleeding in B-viral liver cirrhosis using the P2/MS noninvasive index based on complete blood counts. 2012 , 86, 264-72	2
2089	A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice. 2012 , 67, 696-9	26
2088	Fatal hepatitis B reactivation treated with entecavir in an isolated anti-HBs positive lymphoma patient: a case report and literature review. 2012 , 18, 277-81	12
2087	Acute and chronic viral hepatitis. 2012 , 361-401	5
2086	Update on entecavir in the management of severe forms of Hepatitis B. 2012 , 4, 39-47	1
2085	Predictive effect of serial serum alanine aminotransferase levels on spontaneous HBeAg seroconversion in chronic genotype B and C HBV-infected children. 2012 , 54, 97-100	34
2084	Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B. 2012 , 55, 648-52	15
2083	High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy. 2012 , 46, 865-70	53
2082	Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir. 2012 , 17, 1255-62	15
2081	Optimal time for restoring the reliability of liver stiffness measurement in patients with chronic hepatitis B experiencing acute exacerbation. 2012 , 46, 602-7	12
2080	Barriers to treatment of hepatitis B in an urban Chinatown community. 2012 , 46, e66-70	12
2079	Hepatitis B: Treatment to prevent perinatal transmission. 2012 , 55, 541-9	6
2078	Simple scoring system predicting genotypic resistance during rescue therapy for Lamivudine-resistant chronic hepatitis B. 2012 , 46, 243-50	4

2077	Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon α : progressive decrease in hepatitis B surface antigen in responders. 2012 , 24, 1012-9	10
2076	Chronic hepatitis B infection and pregnancy. 2012 , 67, 37-44	23
2075	Viral infections in patients with inflammatory bowel disease on immunosuppressants. 2012 , 343, 227-32	16
2074	Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. 2012 , 156, 743-5	59
2073	Long-term therapy with nucleoside/nucleotide analogues for chronic hepatitis B in Asian patients. 2013 , 18, 841-52	13
2072	Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir. 2012 , 17, 973-9	11
2071	Chronic HBV infection outside treatment guidelines: is treatment needed?. 2013 , 18, 229-35	13
2070	A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine. 2012 , 17, 1563-70	12
2069	A randomized controlled trial of sequential pegylated interferon- α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B. 2013 , 18, 57-64	15
2068	High frequency of viremia after hepatitis B e antigen seroconversion and consolidation therapy: setting realistic expectations. 2012 , 46, 807-8	
2067	Impairment of the retinoic acid-inducible gene-I-IFN- β signaling pathway in chronic hepatitis B virus infection. 2012 , 30, 1498-504	8
2066	A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy. 2012 , 1	0
2065	Hepatitis crónica por virus B. Historia natural y tratamiento. 2012 , 11, 521-528	
2064	Prevalence and significance of Hepatitis B reverse transcriptase mutants in different disease stages of untreated patients. 2012 , 32, 1535-42	18
2063	Review article: the reversibility of cirrhosis. 2012 , 36, 824-32	49
2062	Significance of liver histology in HBsAg-positive, IgM anti-HBc-negative acute hepatitis B virus-related hepatitis. 2012 , 61, 881-8	1
2061	Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. 2012 , 19, 732-43	77
2060	Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance. 2012 , 27, 1454-60	4

2059	Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma. 2012 , 27, 1528-34	13
2058	Prevention and management of drug resistant hepatitis B virus infections. 2012 , 27, 1432-40	11
2057	Internist diagnosis and management of chronic hepatitis B virus infection. 2012 , 125, 1063-7	5
2056	Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. 2012 , 57, 2423-9	91
2055	Selection of chronic hepatitis B therapy with high barrier to resistance. 2012 , 12, 341-53	111
2054	HBsAg Quantification in Clinical Practice. 2012 , 2, 75-80	4
2053	Hepatitis B virus management to prevent reactivation after chemotherapy: a review. 2012 , 20, 2999-3008	25
2052	Chronic hepatitis B in patients coinfectd with human immunodeficiency virus in Japan: a retrospective multicenter analysis. 2012 , 18, 883-90	12
2051	The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. 2012 , 13, 663-76	24
2050	Predictors of mental and physical health in non-cirrhotic patients with viral hepatitis: a case control study. 2012 , 73, 218-24	25
2049	Role of molecular diagnostics in the management of viral hepatitis B. 2012 , 6, 395-406	6
2048	Peginterfero a na co-infecçã VHB V/H delta Um caso de duplo sucesso terapũtico. 2012 , 19, 151-155	
2047	Tenofovir como 1a opçã terapũtica na hepatite B. 2012 , 19, 165-166	
2046	Virologic response to therapy increases health-related quality of life for patients with chronic hepatitis B. 2012 , 10, 291-6	12
2045	Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. 2012 , 10, 520-6	121
2044	Virus suppression, eradication, or tolerance to treatment in patients with chronic hepatitis B. 2012 , 12, 746-7	
2043	Focus. 2012 , 57, 1161-2	1
2042	Incidence and determinants of spontaneous seroclearance of hepatitis B e antigen and DNA in patients with chronic hepatitis B. 2012 , 10, 527-34.e1-2	25

2041	Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate. 2012 , 22, 470-473	18
2040	Adherence, persistence, healthcare utilization, and cost benefits of guideline-recommended hepatitis B pharmacotherapy. 2012 , 15, 1159-66	10
2039	Adefovir dipivoxil in chronic hepatitis B: history and current uses. 2012 , 13, 245-54	19
2038	IL-22 and non-ELR-CXC chemokine expression in chronic hepatitis B virus-infected liver. 2012 , 90, 611-9	47
2037	Chapter 9: Infection-related glomerulonephritis. 2012 , 2, 200-208	24
2036	Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure. 2012 , 12, 159-64	40
2035	Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. 2012 , 12, 193-207	73
2034	[Management of the risk of hepatitis B virus reactivation in patients receiving immunosuppressive and immunomodulatory agents in internal medicine: data from the REACTI-B survey and proposal for a management algorithm]. 2012 , 33, 4-12	8
2033	Interferon- β suppresses hepatitis B virus enhancer II activity via the protein kinase C pathway. 2012 , 432, 452-9	13
2032	Upper normal threshold of serum alanine aminotransferase in identifying individuals at risk for chronic liver disease. 2012 , 32, 937-44	25
2031	Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir. 2012 , 32, 1179-85	8
2030	Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing. 2012 , 18, E404-11	20
2029	Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. 2012 , 56, 520-6	107
2028	High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B. 2012 , 56, 775-81	77
2027	Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. 2012 , 56, 1006-1011	133
2026	Peginterferon- α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. 2012 , 56, 1239-46	58
2025	HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. 2012 , 56, 1254-8	29
2024	Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. 2012 , 57, 442-50	133

2023	Focus: Long-term treatment with lamivudine in HBeAg negative patients with chronic hepatitis B: to switch or not to switch?. 2012 , 56, 1219-20	1
2022	Chronic hepatitis B in children and adolescents. 2012 , 57, 885-96	60
2021	Minimization of hepatitis B infection by a 25-year universal vaccination program. 2012 , 57, 730-5	138
2020	Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. 2012 , 57, 953-9	59
2019	The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation. 2012 , 54, 66-72	32
2018	Converting cancer therapies into cures: lessons from infectious diseases. 2012 , 148, 1089-98	126
2017	Current practice of chronic hepatitis B treatment in Southern Italy. 2012 , 23, e124-7	12
2016	[Treatment adherence and persistence in patients with chronic hepatitis B virus infection]. 2012 , 35, 293-4	1
2015	A cross sectional assessment of knowledge, attitude and practice towards Hepatitis B among healthy population of Quetta, Pakistan. 2012 , 12, 692	69
2014	Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients. 2012 , 9, 239	17
2013	Effect of antiviral therapy on the survival and incidence of major complications in HBV-associated cirrhotic patients after splenectomy for hypersplenism and portal hypertension. 2012 , 9, 273	1
2012	The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantation. 2012 , 26, E561-9	16
2011	Factors associated with access to antiviral treatment in a multicentre cross-sectional study of patients with chronic hepatitis B in Italy. 2012 , 19, 881-9	12
2010	Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs. 2012 , 6, 683-93; quiz 694	18
2009	Antiviral therapy for hepatitis B virus-related decompensated cirrhosis. 2012 , 13, 555-7	2
2008	Is hepatitis virus resistance to antiviral drugs a threat?. 2012 , 142, 1369-72	8
2007	Effectiveness of hepatitis B treatment in clinical practice. 2012 , 142, 1360-1368.e1	104
2006	Viral hepatitis in liver transplantation. 2012 , 142, 1373-1383.e1	156

2005	Noninvasive methods to assess liver disease in patients with hepatitis B or C. 2012 , 142, 1293-1302.e4	455
2004	New virologic tools for management of chronic hepatitis B and C. 2012 , 142, 1303-1313.e1	97
2003	Identifying hepatitis B carriers at low risk for hepatocellular carcinoma. 2012 , 142, 1057-60	19
2002	Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. 2012 , 143, 619-628.e1	120
2001	Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. 2012 , 13, 817-26	281
2000	Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. 2012 , 67, 1349-61	35
1999	Significant rate of hepatitis B reactivation following kidney transplantation in patients with resolved infection. 2012 , 55, 233-8	48
1998	Entecavir treatment of children 2-16 years of age with chronic hepatitis B infection. 2012 , 13, 41-4	9
1997	What do patients with chronic hepatitis B know about their illness?. 2012 , 36, e131-3	
1996	[Consensus document of the Spanish Association for the Study of the Liver on the treatment of hepatitis B infection (2012)]. 2012 , 35, 512-28	28
1995	Cost-effectiveness analysis of antiviral treatments for HBeAg-positive chronic hepatitis B in Canada. 2012 , 15, 894-906	16
1994	Liver stiffness measurement in cirrhotic patient -- implications of disease activity and treatment efficacy. 2012 , 28, 641-8	
1993	[Pharmacological treatment of acute hepatitis B]. 2012 , 138, 633-7	2
1992	Subgenotype D5, BCP and MHR mutations in hepatic complications among hepatitis B virus infected patients from Orissa, India. 2012 , 12, 1622-9	6
1991	Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. 2012 , 6, 413-21	10
1990	Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. 2012 , 6, 696-706	7
1989	Serum cytokine levels in chronic hepatitis B patients receiving peginterferon alpha-2a therapy. 2012 , 11, 499-506	9
1988	Hepatitis B virus genotypes, precore mutations, and basal core promoter mutations in HBV-infected Chinese patients with persistently normal alanine aminotransferase and low serum HBV-DNA levels. 2012 , 16, 52-6	5

1987	Chronic hepatitis B infection. 2012 , 16, 347-69	44
1986	Safety of long-term nucleos(t)ide treatment in chronic hepatitis B. 2012 , 11, 357-60	24
1985	Immunotherapies in infectious diseases. 2012 , 96, 455-74, ix	14
1984	Hepatic injury due to drugs, herbal compounds, chemicals and toxins. 2012 , 645-760	12
1983	Anti-HBV efficacy of combined siRNAs targeting viral gene and heat shock cognate 70. 2012 , 9, 275	10
1982	A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B. 2012 , 7, e32622	53
1981	High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. 2012 , 7, e43087	59
1980	The impact of hepatitis B knowledge and stigma on screening in Canadian Chinese persons. 2012 , 26, 597-602	45
1979	Association of paraoxonase activity and atherosclerosis in patients with chronic hepatitis B. 2012 , 12, 114-8	15
1978	Pretreatment viral DNA stratifies mortality risk in patients receiving antiviral therapy for severe acute exacerbation of chronic hepatitis B. 2013 , 18, 221-8	6
1977	Assessment of hepatic fibrosis and necroinflammation among inactive HBsAg carriers in Egypt. 2012 , 11, 464-470	7
1976	Prevention of hepatocellular carcinoma: a concise review of contemporary issues. 2012 , 11, 284-293	17
1975	Is there an association between the measurement of qualitative HBsAg and virologic response in chronic HBV infection?. 2012 , 11, 320-325	2
1974	Hepatitis B viral load and risk of HBV-related liver disease: from East to West?. 2012 , 11, 164-171	17
1973	Prevalence of hepatitis A, B and C serological markers in children from western Mexico. 2012 , 11, 194-201	20
1972	Hepatitis in the elderly: still a scourge. 2012 , 27, 472-81	2
1971	Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective. 2012 , 4, 227-35	3
1970	A case of Sweet's syndrome in a patient with liver cirrhosis caused by chronic hepatitis B. 2012 , 59, 441-4	5

1969	In vitro replication phenotype of a novel (-1G) hepatitis B virus variant associated with HIV co-infection. 2012 , 84, 1166-76	8
1968	Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation. 2012 , 18, 514-23	23
1967	Blockade of Tim-3 signaling restores the virus-specific CD8+ T-cell response in patients with chronic hepatitis B. 2012 , 42, 1180-91	118
1966	Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B. <i>Hepatology</i> , 2012 , 56, 474-83	11.2 17
1965	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. 2012 , 6, 531-61	768
1964	Chronic hepatitis. 2012 , 992-998.e1	
1963	Genotyping hepatitis B virus dual infections using population-based sequence data. 2012 , 93, 1899-1907	18
1962	Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B. 2012 , 57, 1358-65	16
1961	Use of nucleoside (tide) analogues in patients with hepatitis B-related acute liver failure. 2012 , 57, 1349-57	25
1960	Undertreatment of Asian chronic hepatitis B patients on the basis of standard guidelines: a community-based study. 2012 , 57, 1373-83	25
1959	Adherence with Use of Oral Agents in the Treatment of Chronic Hepatitis B. 2012 , 11, 70-74	2
1958	Partial Response to Entecavir and Tenofovir in Naïve Patients with Chronic Hepatitis B: Clinical Relevance and Management. 2012 , 11, 90-94	4
1957	Optimal Management of the Hepatitis B Patient Who Desires Pregnancy or Is Pregnant. 2012 , 11, 82-89	34
1956	Drugs in Development for the Treatment of Chronic Hepatitis B. 2012 , 11, 111-118	4
1955	Role of Resistance Testing During Oral Antiviral Therapy of Chronic Hepatitis B. 2012 , 11, 55-64	1
1954	The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. 2012 , 29, 1237-41	36
1953	Comparison of noninvasive models of fibrosis in chronic hepatitis B. 2012 , 6, 457-67	20
1952	Host genetic variants and hepatitis B virologic features in HBeAg-negative hepatitis B carriers with long-term biochemical remission. 2012 , 6, 598-605	1

1951	Hepatitis B virus infection and pregnancy: a practical approach. 2012 , 31, 43-54	17
1950	Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis. 2012 , 17, 290-3	7
1949	Ultrastructural and stereological study of the liver in chronic mixed HCV+HBV infection. 2012 , 152, 764-7	2
1948	Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B. 2012 , 32, 137-46	21
1947	Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. 2012 , 27, 306-12	36
1946	Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion. 2012 , 19, 138-46	30
1945	The tumour necrosis factor- β 38A allele increases the risk of chronic HBV infection in European populations. 2012 , 19, e11-7	20
1944	Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg-positive chronic hepatitis B. 2012 , 19, e41-7	8
1943	A review of chronic hepatitis B epidemiology and management issues in selected countries in the Middle East. 2012 , 19, 9-22	31
1942	Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. 2012 , 35, 458-68	34
1941	Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. 2012 , 35, 674-89	54
1940	Lo esencial en hepatitis B. Cuñdo derivar al hepatólogo. 2012 , 19, 143-148	
1939	Treatment of human immunodeficiency virus and hepatitis B virus infections. 2012 , 18 Suppl 4, 34-7	
1938	Treatment of chronic hepatitis B with nucleos(t)ide analogues. 2012 , 42, 219-25	11
1937	Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. 2012 , 42, 627-36	57
1936	Hepatitis B virus genotypes from European origin explains the high endemicity found in some areas from southern Brazil. 2012 , 12, 1295-304	36
1935	Use of anti-tumor necrosis factor- β therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan. 2012 , 39, 269-73	44
1934	Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. 2012 , 35, 1317-25	113

1933	Commentary: combination therapy with two nucleos(t)ide analogues in chronic hepatitis B. 2012 , 35, 1482		
1932	Letter: acute hepatitis B - to treat or not to treat?. 2012 , 36, 76-7		
1931	Safety and efficacy of two-step peginterferon α 2a treatment in patients of chronic hepatitis B with acute exacerbation. 2012 , 19, 161-72		13
1930	Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. 2012 , 19, 213-9		36
1929	Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection. 2012 , 19, 387-95		5
1928	Hepatocellular carcinoma screening practices and impact on survival among hepatitis B-infected Asian Americans. 2012 , 19, 594-600		34
1927	First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. 2012 , 19, 377-86		99
1926	Larger biopsies evaluation of transient elastography for detecting advanced fibrosis in patients with compensated chronic hepatitis B. 2012 , 27, 1219-26		18
1925	Assessment of chronic hepatitis B: the importance of hepatitis B virus DNA testing. 2012 , 42, 170-5		4
1924	Use of biological disease-modifying anti-rheumatic drugs in patients with concurrent rheumatic disease and hepatitis B. 2012 , 42, 523-31		
1923	A mutation in the interferon regulatory element of HBV may influence the response of interferon treatment in chronic hepatitis B patients. 2012 , 9, 10		8
1922	Report on a single-topic conference on "Chronic viral hepatitis--strategies to improve effectiveness of screening and treatment". <i>Hepatology</i> , 2012 , 55, 307-15	11.2	29
1921	Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B. 2012 , 84, 18-25		12
1920	Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy. 2012 , 84, 217-22		9
1919	Is there any value to hepatitis B virus genotype analysis?. 2012 , 14, 37-46		55
1918	Antiviral drug resistance testing in patients with chronic hepatitis B. 2012 , 57, 221-31		6
1917	High dose lamivudine in HBV-related cirrhotic patients with unsatisfactory response after adefovir add-on. 2012 , 57, 561-7		2
1916	Clinical significance of chronic hepatitis B virus infection in patients with primary Sjögren's syndrome. 2012 , 31, 309-15		9

1915	Hepatitis B serological changes following allogeneic bone marrow transplantation. 2013 , 15, 98-103	7
1914	Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study. 2013 , 10, 87	8
1913	FOXP3 gene polymorphism is associated with hepatitis B-related hepatocellular carcinoma in China. 2013 , 32, 39	27
1912	Prevalence, risk factors, and disease knowledge of chronic hepatitis B infection in Vietnamese Americans in California. 2013 , 28, 319-24	26
1911	Eradication of hepatitis B: a nationwide community coalition approach to improving vaccination, screening, and linkage to care. 2013 , 38, 799-804	21
1910	The level of knowledge of, attitude toward and emphasis given to HBV and HCV infections among healthcare professionals: data from a tertiary hospital in Turkey. 2013 , 26, 122-31	2
1909	De novo acute hepatitis B in myeloperoxidase-specific anti-neutrophil cytoplasmic autoantibody-related microscopic polyangiitis treated with corticosteroids. 2013 , 2, 28-33	
1908	AASLD clinical practice guidelines: a critical review of scientific evidence and evolving recommendations. <i>Hepatology</i> , 2013 , 58, 2142-52	11.2 43
1907	Chronic hepatitis B: what should be the goal for new therapies?. 2013 , 98, 27-34	95
1906	The efficacy and safety of entecavir in patients with advanced schistosomiasis co-infected with hepatitis B virus. 2013 , 17, e606-9	8
1905	Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil. 2013 , 20 Suppl 1, 40-5	8
1904	Viral hepatitis in solid organ transplantation. 2013 , 13 Suppl 4, 147-68	64
1903	Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection. 2013 , CD009004	14
1902	Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a real-world clinical practice setting in China. 2013 , 20, 811-20	14
1901	Chronic HBV carrier's acceptance of regular surveilling program in China. 2013 , 33, 288-292	4
1900	HBsAg, HBeAg and HBV DNA level changes and precore/basal core promoter mutations in the natural history of chronic hepatitis B in Indonesian patients. 2013 , 7, 969-80	8
1899	Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B. 2013 , 7, 356-68	20
1898	Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. 2013 , 7, 429-36	88

1897	Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. 2013 , 7, 88-97	117
1896	Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin. 2013 , 48, 1401-10	31
1895	Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential. 2013 , 48, 999-1005	19
1894	Entecavir and interferon- β sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B. 2013 , 48, 397-404	19
1893	Response Guided Treatment for Peginterferon in Chronic Hepatitis B. 2013 , 12, 88-95	
1892	Baseline and On-treatment Predictors of Chronic Hepatitis B Patients Receiving Pegylated Interferon Therapy in Asia. 2013 , 12, 165-173	
1891	Are physicians following guidelines? A survey of Hepatitis B management strategies. 2013 , 7, 451-9	4
1890	Immunizations in chronic liver disease: what should be done and what is the evidence. 2013 , 15, 300	38
1889	Nucleos(t)ide Analogues Therapy for Chronic Hepatitis B in Taiwan: Short-Term Versus Long-Term. 2013 , 12, 181-187	1
1888	Resistance is no Longer a Problem with Entecavir and Tenofovir. 2013 , 12, 96-104	
1887	Stopping Therapy in HBeAg Negative Disease. 2013 , 12, 105-111	1
1886	Hepatitis B Virus Genotypes: Clinical Relevance and Therapeutic Implications. 2013 , 12, 124-132	
1885	HBSAg loss is not an ideal indicator for discontinuing treatment of HBeAg-negative chronic hepatitis B: a case report. 2013 , 19, 1188-92	1
1884	A southern blot assay for detection of hepatitis B virus covalently closed circular DNA from cell cultures. 2013 , 1030, 151-61	79
1883	HBV treatment in a patient who will be receiving immunosuppressive therapy. 2013 , 2, 34-37	1
1882	The natural course of chronic hepatitis B virus infection and its management. 2013 , 67, 247-91	19
1881	Efficacy of combined antiviral therapy with lamivudine and tenofovir in a liver transplanted girl with de novo hepatitis B virus infection. 2013 , 15, E81-4	
1880	Comparative efficacy of oral nucleoside or nucleotide analog monotherapy used in chronic hepatitis B: a mixed-treatment comparison meta-analysis. 2013 , 33, 144-51	15

1879	Association between anthropometric parameters and measurements of liver stiffness by transient elastography. 2013 , 11, 295-302.e1-3	48
1878	Evolution of viral biomarkers in predicting outcomes of chronic hepatitis B patients: From DNA to surface antigen. 2013 , 25, 75-81	2
1877	Caspase-cleaved fragments of cytokeratin-18 as a marker of inflammatory activity in chronic hepatitis B virus infection. 2013 , 58, 641-6	17
1876	Hepatitis Outreach Network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities. 2013 , 58, 890-7	49
1875	Complexity and diversity of hepatitis B virus quasispecies: correlation with long-term entecavir antiviral efficacy. 2013 , 99, 312-7	9
1874	APACHE II score is superior to SOFA, CTP and MELD in predicting the short-term mortality in patients with acute-on-chronic liver failure (ACLF). 2013 , 14, 484-90	58
1873	c-Myc-mediated overexpression of miR-17-92 suppresses replication of hepatitis B virus in human hepatoma cells. 2013 , 85, 969-78	51
1872	Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. 2013 , 59, 814-29	149
1871	Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies: a randomized controlled trial. 2013 , 20, 801-10	53
1870	[Glucocorticoids and... infections, doping, surgery, sexuality]. 2013 , 34, 269-78	2
1869	Fibroscan can avoid liver biopsy in Indian patients with chronic hepatitis B. 2013 , 28, 1738-45	39
1868	Liver abnormalities in the immunosuppressed. 2013 , 27, 597-618	1
1867	Hepatitis B antivirals and resistance. 2013 , 3, 495-500	24
1866	Acute liver failure. 2013 , 27, 757-69	13
1865	Biomarkers of liver fibrosis. 2013 , 62, 33-122	5
1864	Cost-effectiveness of viral hepatitis B & C treatment. 2013 , 27, 973-85	11
1863	Hepatitis B in immunosuppressed cancer patients: pathogenesis, incidence and prophylaxis. 2013 , 87, 12-27	15
1862	Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative. 2013 , 13, 458	27

1861	Expression pattern of serum cytokines in hepatitis B virus infected patients with persistently normal alanine aminotransferase levels. 2013 , 33, 1240-9	20
1860	Chronic hepatitis B management based on standard guidelines in community primary care and specialty clinics. 2013 , 58, 3626-33	22
1859	Short hairpin RNA induces methylation of hepatitis B virus covalently closed circular DNA in human hepatoma cells. 2013 , 436, 152-5	9
1858	Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination. 2013 , 28, 1842-8	29
1857	Precore and core promoter mutants are associated with higher HBeAg seroconversion but low disease remission rates in HBV patients treated with nucleos(t)ide analogues. 2013 , 20, 322-7	6
1856	Sustained efficacy of adefovir add-on therapy in chronic hepatitis B patient with a poor virological response to peginterferon alfa. 2013 , 48, 213-7	5
1855	Treatment of lamivudine-resistant chronic hepatitis B infection: a multicenter retrospective study. 2013 , 48, 196-204	3
1854	Infectious and malignant complications of TNF inhibitor therapy in IBD. 2013 , 108, 1835-42, quiz 1843	79
1853	Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. 2013 , 31, 2765-72	245
1852	Tratamiento del VHB en pacientes que van a recibir terapia inmunosupresora. 2013 , 2, S28-S32	78
1851	Ipilimumab administration in patients with advanced melanoma and hepatitis B and C. 2013 , 31, e370-2	18
1850	Hepatitis B virus treatment: Which patients can have treatment deferred?. 2013 , 2, 15-17	6
1849	Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis. 2013 , 20 Suppl 1, 58-64	7
1848	Hepatitis B vaccines. 2013 , 205-234	13
1847	Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. 2013 , 48, 13-21	84
1846	Should lamivudine monotherapy be stopped or continued in patients infected with hepatitis B with favorable responses after more than 5 years of treatment?. 2013 , 85, 34-42	11
1845	Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy. 2013 , 85, 55-64	18
1844	Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir. 2013 , 28, 46-50	22

1843	Hepatitis B virus reactivation associated with anti-neoplastic therapy. 2013 , 28, 31-7	50
1842	Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. 2013 , 35, 1997-2006	16
1841	Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: an Indian perspective. 2013 , 100, 300-5	17
1840	Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen-negative patients with chronic hepatitis. 2013 , 11, 1493-1499.e2	17
1839	Increased viral quasispecies evolution in HBeAg seroconverter patients treated with oral nucleoside therapy. 2013 , 58, 217-24	26
1838	Acute exacerbation among chronic hepatitis C patients: tip of the iceberg that deserves more attention. 2013 , 11, 1181-2	1
1837	Awareness of hepatitis B virus reactivation among physicians authorized to prescribe chemotherapy. 2013 , 24, e90-2	7
1836	How to manage HBeAg-negative chronic HBV infection with normal alanine aminotransferase levels in clinical practice?. 2013 , 24, 100-3	7
1835	[Characteristics of patients with chronic hepatitis B virus infection. analysis of a series of 474 patients]. 2013 , 36, 243-53	8
1834	Impact of therapy on the long-term outcome of chronic hepatitis B. 2013 , 17, 413-23	34
1833	Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. 2013 , 58, 427-33	108
1832	Hepatitis B in HIV-infected patients. 2013 , 17, 489-501	21
1831	Treatment of patients with HBV-related decompensated cirrhosis and liver transplanted patients. 2013 , 17, 451-73	13
1830	Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers. 2013 , 208, 584-93	37
1829	Peripheral type I interferon receptor correlated with oxidative stress in chronic hepatitis B virus infection. 2013 , 33, 405-14	9
1828	Variability of the preC/C region of hepatitis B virus genotype A from a South African cohort predominantly infected with HIV. 2013 , 85, 1883-92	9
1827	Is HBsAg quantification ready, for prime time?. 2013 , 37, 559-63	9
1826	A Novel Estimation of the Impact of Treatment with Entecavir on Long-Term Mortality, Morbidity, and Health Care Costs of Chronic Hepatitis B in China. 2013 , 2, 48-56	10

1825	[Need to intensify the relationship with medicine from primary care to improve the control and treatment of patients infected by the virus of hepatitis B]. 2013 , 36, 492-3		
1824	Should treatment of hepatitis B patients be based solely on liver fibrosis?. 2013 , 11, 1500-2		2
1823	ECHS1 acts as a novel HBsAg-binding protein enhancing apoptosis through the mitochondrial pathway in HepG2 cells. 2013 , 330, 67-73		29
1822	Screening for Hepatitis B. 2013 , 9, 233-237		1
1821	Treatment eligibility of patients with chronic hepatitis B initially ineligible for therapy. 2013 , 11, 565-71		12
1820	Association of Interleukin-1 and Gene Polymorphisms with Liver Pathogenesis in Hepatitis B Virus Infection among Eastern Indian Population. 2013 , 3, 281-7		11
1819	Focus. 2013 , 58, 641-2		2
1818	The effect of HLA-DQB1 alleles on virologic breakthroughs during chronic hepatitis B treatment with genetically low barrier drugs. 2013 , 37, 359-64		5
1817	Real-world application of the roadmap model in chronic hepatitis B patients with telbivudine therapy. 2013 , 35, 1386-99		8
1816	Reduced Expression of DNA Damage Repair Genes High Mobility Group Box1 and Poly(ADP-ribose) Polymerase1 in Inactive Carriers of Hepatitis B Virus Infection-A Possible Stage of Viral Integration. 2013 , 3, 89-95		8
1815	Immunosuppression-mediated hepatitis B reactivation diagnosed following an investigation into suspected transfusion-transmitted hepatitis B. 2013 , 83, 244-6		3
1814	Regulation of B7-H1 expression on peripheral monocytes and IFN- β secretion in T lymphocytes by HBeAg. 2013 , 283, 25-30		10
1813	Performance of risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients. 2013 , 37, 243-51		12
1812	Precore and basal core promoter mutations in Asian American patients with hepatitis B e antigen-positive chronic hepatitis B. 2013 , 37, 464-72		8
1811	Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. <i>Hepatology</i> , 2013 , 58, 1537-47	11.2	321
1810	Detection of hepatitis B virus core antigen by phage display mediated TaqMan real-time immuno-PCR. 2013 , 187, 121-6		22
1809	Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. 2013 , 144, 933-44		136
1808	Who will have the best response to entecavir?. 2013 , 28, 5-7		5

1807	Risk stratification for hepatitis B virus related hepatocellular carcinoma. 2013 , 28, 10-7	71
1806	Early on-treatment change in liver stiffness predicts development of liver-related events in chronic hepatitis B patients receiving antiviral therapy. 2013 , 33, 180-9	24
1805	Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial. 2013 , 33, 244-54	18
1804	Management of HBV in immunocompromised patients. 2013 , 33 Suppl 1, 182-7	16
1803	Impact of therapy on the outcome of chronic hepatitis B. 2013 , 33 Suppl 1, 111-5	49
1802	Why do I treat HBeAg-positive chronic hepatitis B patients with a nucleoside analogue. 2013 , 33 Suppl 1, 133-6	6
1801	Treatment of HBV related cirrhosis. 2013 , 33 Suppl 1, 176-81	13
1800	Medical therapies for hepatocellular carcinoma: a critical view of the evidence. 2013 , 10, 34-42	243
1799	Overlapping structure of hepatitis B virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution. 2013 , 94, 143-149	24
1798	Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis. 2013 , 58, 730-5	95
1797	A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. 2013 , 153, 389-401	94
1796	Review article: prescribing medications in patients with cirrhosis - a practical guide. 2013 , 37, 1132-56	124
1795	Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis. 2013 , 57, 209-14	79
1794	Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. <i>Hepatology</i> , 2013 , 58, 1888-96	11.2 166
1793	Circulating chemokine (C-X-C Motif) receptor 5(+) CD4(+) T cells benefit hepatitis B e antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection. <i>Hepatology</i> , 2013 , 58, 1277-86	11.2 69
1792	Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. 2013 , 38, 98-106	105
1791	Influence of overlapping genes on the evolution of human hepatitis B virus. 2013 , 441, 40-8	21
1790	IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. <i>Hepatology</i> , 2013 , 57, 890-6 ^{11.2}	127

1789	Association of chronic liver disease with depression: a population-based study. 2013 , 54, 52-9	53
1788	Underestimation of liver-related mortality in the United States. 2013 , 145, 375-82.e1-2	195
1787	Clinical problem-solving. Waiting for the other foot to drop. 2013 , 368, 2220-5	2
1786	An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study. 2013 , 34, 909-18	9
1785	Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients. 2013 , 58, 1089-95	82
1784	Lamivudine versus telbivudine in the treatment of chronic hepatitis B: a systematic review and meta-analysis. 2013 , 32, 11-8	14
1783	Detection of TFPI2 methylation in the serum of hepatocellular carcinoma patients. 2013 , 58, 1010-5	39
1782	Hepatitis B viral factors and treatment responses in chronic hepatitis B. 2013 , 112, 302-11	32
1781	Hepatocellular carcinoma and hepatitis B virus: family matters. 2013 , 11, 1646-7	1
1780	Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. 2013 , 207, 1157-65	89
1779	Quantification of hepatitis B surface antigen and E antigen: correlation between Elecsys and architect assays. 2013 , 20, 422-9	9
1778	Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. <i>Hepatology</i> , 2013 , 57, 934-43	11.2 45
1777	WITHDRAWN: Noninvasive predictive models of liver fibrosis in patients with chronic hepatitis B. 2013 ,	
1776	Prescription pattern for antivirals in the treatment of chronic hepatitis B: the EUPTHEA Study. 2013 , 20, 174-179	2
1775	Hepatocellular carcinoma: high hepatitis B viral load and mortality in patients treated with transarterial chemoembolization. 2013 , 267, 638-47	24
1774	Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naïve patients with chronic hepatitis B. 2013 , 57, 1790-6	33
1773	Prevention of infection caused by immunosuppressive drugs in gastroenterology. 2013 , 4, 167-85	57
1772	Genome-wide association study of chronic hepatitis B virus infection reveals a novel candidate risk allele on 11q22.3. 2013 , 50, 725-32	20

1771	Circulating cytokines and histological liver damage in chronic hepatitis B infection. 2013 , 2013, 757246	7
1770	Efficacy and safety of a chinese herbal formula (invigorating kidney and strengthening spleen) in chronic hepatitis B virus carrier: results from a multicenter, randomized, double-blind, and placebo-controlled trial. 2013 , 2013, 961926	4
1769	Tenofovir as rescue therapy following clinical failure to Lamivudine in severe acute hepatitis B. 2013 , 5, e2013035	8
1768	Combining Oxymatrine or Matrine with Lamivudine Increased Its Antireplication Effect against the Hepatitis B Virus In Vitro. 2013 , 2013, 186573	33
1767	Virological Response and Muscular Adverse Events during Long-Term Clevudine Therapy in Chronic Hepatitis B Patients. 2013 , 13, e6056	4
1766	Influencing Factors on the Outcome and Prognosis of Patients With HBV Infction: Seven Years Follow-up. 2013 , 13, e8743	10
1765	Occult hepatitis B: clinical viewpoint and management. 2013 , 2013, 259148	16
1764	Lingmao Formula Combined with Entecavir for HBeAg-Positive Chronic Hepatitis B Patients with Mildly Elevated Alanine Aminotransferase: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. 2013 , 2013, 620230	3
1763	Modeling and simulating dynamics of complete- and poor-response chronic hepatitis B chinese patients for adefovir and traditional chinese medicine plus adefovir therapy. 2013 , 2013, 767290	3
1762	Endothelial Nitric Oxide Synthase (eNOS) Gene Polymorphism is Associated with Age Onset of Menarche in Sickle Cell Disease Females of India. 2013 , 5, e2013036	6
1761	Mutation analysis of hepatitis B virus reverse transcriptase region among untreated chronically infected patients in Ahvaz city (South-West of Iran). 2013 , 31, 360-5	6
1760	A pregnant patient with a positive hepatitis B surface antigen. 2013 , 4, 12-19	1
1759	Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. <i>Hepatology</i> , 2013 , 58, 538-45	11.2 59
1758	Diagnostic accuracy of hepatic venous pressure gradient measurement in the prediction of stage 1 compensated liver cirrhosis in patients with chronic hepatitis B. 2013 , 25, 1170-6	4
1757	Update in the management of chronic hepatitis B. 2013 , 29, 250-6	33
1756	Acute hepatitis B in an urban tertiary care hospital in the United States: a cohort evaluation. 2013 , 47, e87-90	5
1755	Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults. 2013 , 9, 2474-9	18
1754	Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection. 2013 , 57, 6325-32	13

1753	Increasing hepatitis B screening for hmong adults: results from a randomized controlled community-based study. 2013 , 22, 782-91		47
1752	Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir. <i>World Journal of Gastroenterology</i> , 2013 , 19, 7671-9	5.6	6
1751	Gastrointestinal Disorders. 2013 , 415-443		
1750	Adherence to hepatitis B screening and prophylactic lamivudine for prevention of rituximab-associated hepatitis B reactivation. 2013 , 19, 18-23		7
1749	Evaluation of the hepatitis C virus-infected patient: the initial encounter. 2013 , 56, 853-60		6
1748	Hepatitis B. 2013 , 6, 790-800		
1747	Partial virological response to adefovir add-on lamivudine rescue therapy in patients with lamivudine-resistant chronic hepatitis B. 2013 , 87, 196-203		2
1746	Hepatitis B virus reactivation after chemotherapy in an HIV-positive patient. 2013 , 47, 565-6		5
1745	Peginterferon- α combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study. 2013 , 25, 1165-9		7
1744	Case treated with triple therapy of lamivudine, interferon- β and prednisolone for acute exacerbation of chronic hepatitis B during pregnancy. 2013 , 43, 425-9		6
1743	Fibrosis score consisting of four serum markers successfully predicts pathological fibrotic stages of chronic hepatitis B. 2013 , 43, 596-604		6
1742	Liver fibrosis progression in chronic hepatitis B patients positive for hepatitis B e antigen: a prospective cohort study with paired transient elastography examination. 2013 , 28, 1762-9		19
1741	Death from Liver Failure despite Lamivudine Prophylaxis during R-CHOP Chemotherapy due to Rapid Emergence M204 Mutations. 2013 , 2013, 454897		9
1740	Serum proteomics analysis and comparisons using iTRAQ in the progression of hepatitis B. 2013 , 6, 1169-1176	8	
1739	Update of liver fibrosis and steatosis with transient elastography (Fibroscan). 2013 , 1, 19-26		70
1738	Correlation between hepatitis B surface antigen titers and HBV DNA levels. 2013 , 19, 252-7		22
1737	Costs of treatment, follow-up, and complications of chronic hepatitis B and hepatitis C infections. 2013 , 30, 375-81		5
1736	Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. 2013 , 68, 2332-8		16

1735	Hepatitis B virus treatment: Which patients should be treated with interferon?. 2013 , 2, 18-20	3
1734	Coinfection of hepatitis B and hepatitis delta virus in Belgium: a multicenter BASL study. Prospective epidemiology and comparison with HBV mono-infection. 2013 , 85, 1513-7	20
1733	Hepatitis B virus in pregnancy. 2013 , 2, 29-33	2
1732	Does prolidase indicate worsening of hepatitis B infection?. 2013 , 27, 398-401	6
1731	Tratamiento del virus de la hepatitis B: Cúles pacientes deberñ ser tratados con los anfbog de nucleŃ(t)idos. 2013 , 2, 83-86	
1730	Complementary laboratory indices for predicting the disease status of patients with hepatitis B virus infection. 2013 , 20, 566-74	2
1729	Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. 2013 , 20, e37-46	66
1728	Application of Molecular Biology to the Diagnosis of Viral Hepatitis. 2013 , 552-563	
1727	Hepatitis D virus in Victoria 2000-2009. 2013 , 43, 1081-7	14
1726	Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. 2013 , 20, e11-9	30
1725	Hypophosphatemic osteomalacia and renal Fanconi syndrome induced by low-dose adefovir dipivoxil: a case report and literature review suggesting ethnic predisposition. 2013 , 38, 321-6	23
1724	Letter: First-line monotherapies for chronic hepatitis B - indirect comparison between entecavir and tenofovir. 2013 , 37, 584-5	1
1723	Entecavir for the treatment of patients with hepatitis B virus-related decompensated cirrhosis. 2013 , 14, 1363-9	3
1722	Histological improvement of long-term antiviral therapy in chronic hepatitis B patients with persistently normal alanine aminotransferase levels. 2013 , 20, 328-35	10
1721	Long-term efficacy of the hepatitis B vaccine in a high-risk group. 2013 , 85, 1518-22	28
1720	Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. 2013 , 19, 594-601	73
1719	Imbalance between circulating CD4+ regulatory T and conventional T lymphocytes in patients with HBV-related acute-on-chronic liver failure. 2013 , 33, 1517-26	26
1718	Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study. 2013 , 20 Suppl 1, 52-7	6

1717	Viral hepatitis B coinfection with human immunodeficiency virus, hepatitis D virus, or hepatitis C virus. 2013 , 2, 45-48		1
1716	Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil. 2013 , 20 Suppl 1, 46-51		2
1715	Challenges in managing patients in Australia with chronic hepatitis B: the General Practitioners' perspective. 2013 , 37, 405-10		16
1714	The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. 2013 , 169, 1295-303		102
1713	Hepatitis B virus treatment: Which patients should be treated with nucleos(t)ide analogue?. 2013 , 2, 21-23		3
1712	Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases. 2013 , 65, 1504-14		39
1711	Use of quantitative hepatitis B surface antigen with hepatitis B virus DNA in clinical practice. 2013 , 2, 8-10		2
1710	A different look at the management of chronic hepatitis B in a resource-constrained country. 2013 , 20 Suppl 1, 1		1
1709	Two-step evolution of the hepatitis B drug-resistant mutations in a patient who developed primary entecavir resistance. 2013 , 33, 642-6		10
1708	Targeted case finding for hepatitis B using dry blood spot testing in the British-Chinese and South Asian populations of the North-East of England. 2013 , 20, 638-44		24
1707	Treatment of Acute Hepatitis, Severe Acute Hepatitis, and Acute Liver Failure. 2013 , 468-485		
1706	Demographic and serological characteristics of Asian Americans with hepatitis B infection diagnosed at community screenings. 2013 , 20, 575-81		20
1705	Uncovering the experiences and needs of patients with chronic hepatitis B infection at diagnosis: a qualitative study. 2013 , 25, 32-40		28
1704	An evaluation of hepatitis B virus diagnostic methods and responses to antiretroviral therapy among HIV-infected women in Thailand. 2013 , 12, 349-53		4
1703	Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. <i>Hepatology</i> , 2013 , 57, 441-50	11.2	183
1702	Impact of liver fibrosis on prognosis following liver resection for hepatitis B-associated hepatocellular carcinoma. 2013 , 109, 573-81		53
1701	Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. <i>Hepatology</i> , 2013 , 58, 872-80	11.2	163
1700	Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. 2013 , 31, 3647-55		191

1699	Infliximab and occult hepatitis B infection: to treat or not to treat?. 2013 , 16, 377-8		1
1698	Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice. 2013 , 28, 855-60		21
1697	Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional study. 2014 , 19, 235-43		7
1696	Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues. 2013 , 18, 979-86		10
1695	Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies. 2014 , 19, 245-57		19
1694	Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine. 2013 , 25, 814-9		14
1693	Low hepatitis B envelope antigen seroconversion rate in chronic hepatitis B patients on long-term entecavir 0.5 mg daily in routine clinical practice. 2013 , 25, 338-43		19
1692	Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort. 2013 , 27, 191-201		65
1691	Causes of death in patients with hepatitis B: a natural history cohort study in the United States. <i>Hepatology</i> , 2013 , 58, 21-30	11.2	32
1690	Glucocorticoids can increase the survival rate of patients with severe viral hepatitis B: a meta-analysis. 2013 , 25, 926-34		17
1689	Response to higher dose of entecavir 1.0 mg daily in patients with partial response to entecavir 0.5 mg daily. 2013 , 47, 461-5		9
1688	New insights into how HBV manipulates the innate immune response to establish acute and persistent infection. 2013 , 18, 1-15		35
1687	Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir. 2013 , 18, 691-8		15
1686	Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon- α and adefovir. 2013 , 18, 895-904		60
1685	Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir. 2014 , 19, 259-67		11
1684	Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B mono-infection. 2013 , 18, 945-8		61
1683	Tumor necrosis factor- α inhibitors and chronic hepatitis C: a comprehensive literature review. <i>World Journal of Gastroenterology</i> , 2013 , 19, 7867-73	5.6	78
1682	The safety of chemotherapy for breast cancer patients with hepatitis C virus infection. 2013 , 4, 519-23		12

1681	Transient elastography-based risk estimation of hepatitis B virus-related occurrence of hepatocellular carcinoma: development and validation of a predictive model. 2013 , 6, 1463-9	18
1680	[Efficacy of entecavir switching therapy in chronic hepatitis B patients with clevidine-induced myopathy]. 2013 , 61, 30-6	2
1679	Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. <i>World Journal of Gastroenterology</i> , 2013 , 19, 9377-82	5.6 66
1678	Viral hepatitis and HIV: update and management. 2013 , 18, 451-8	4
1677	Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine. 2013 , 18, 671-9	8
1676	Effects of nucleoside analogue on patients with chronic hepatitis B-associated liver failure: meta-analysis. 2013 , 8, e54773	21
1675	The efficacy and safety of Nucleos(t)ide analogues in patients with spontaneous acute exacerbation of chronic hepatitis B: a systematic review and meta-analysis. 2013 , 8, e65952	12
1674	Characterization of treatment-naive HIV/HBV co-infected patients attending ART clinic of a tertiary healthcare centre in eastern India. 2013 , 8, e73613	21
1673	CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot study. 2013 , 8, e76798	14
1672	Serum ceruloplasmin levels correlate negatively with liver fibrosis in males with chronic hepatitis B: a new noninvasive model for predicting liver fibrosis in HBV-related liver disease. 2013 , 8, e77942	17
1671	Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent normal ALT. 2013 , 8, e78672	33
1670	High endemicity and low molecular diversity of hepatitis B virus infections in pregnant women in a rural district of North Cameroon. 2013 , 8, e80346	32
1669	Advances in the management of acute liver failure. <i>World Journal of Gastroenterology</i> , 2013 , 19, 7069-775.6	52
1668	Clinical use of anti-TNF therapy and increased risk of infections. 2013 , 5, 79-99	147
1667	Hepatology highlights. 2013 , 12, 354-356	
1666	Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review. 2013 , 12, 380-391	42
1665	Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. 2013 , 12, 205-212	27
1664	The efficacy and safety of nucleos(t)ide analogues in the treatment of HBV-related acute-on-chronic liver failure: a meta-analysis. 2013 , 12, 364-372	36

1663	Efficient identification of low-income Asian American women at high risk for hepatitis B. 2013 , 24, 1701-16		1
1662	Successful Treatment of Plaque Psoriasis with Ustekinumab in a Patient with Chronic Hepatitis B and Latent Tuberculosis. 2013 , 19a, 80-83		
1661	Treatment of Rheumatoid Arthritis Patients with Chronic Hepatitis B: Analysis of Korean National Health Insurance Claims Data. 2013 , 20, 24		1
1660	Hepatic inflammation and progressive liver fibrosis in chronic liver disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 2515-32	5.6	213
1659	Assessment of hepatic fibrosis regression by transient elastography in patients with chronic hepatitis B treated with oral antiviral agents. 2014 , 29, 570-5		10
1658	Management of chronic hepatitis B in the Torres Strait Islands: an identified need for a comprehensive public health approach to chronic hepatitis B in remote Australian Indigenous communities. 2014 , 20, 273-7		3
1657	Enhanced HBsAg synthesis correlates with increased severity of fibrosis in chronic hepatitis B patients. 2014 , 9, e87344		10
1656	rtM204Q may serve as a novel lamivudine-resistance-associated mutation of hepatitis B virus. 2014 , 9, e89015		15
1655	Association of T-cell immunoglobulin and mucin domain-containing molecule 3 (Tim-3) polymorphisms with susceptibility and disease progression of HBV infection. 2014 , 9, e98280		11
1654	Abbott RealTime HBV assay is more sensitive in detection of low viral load and little impacted by drug resistant mutation in chronic hepatitis B patients under nucleot(s)ide analogues therapy. 2014 , 9, e101790		8
1653	Liver stiffness measurement-based scoring system for significant inflammation related to chronic hepatitis B. 2014 , 9, e111641		5
1652	Prevalence and correlates of HIV and hepatitis B virus coinfection in Northern Alberta. 2014 , 25, e8-e13		7
1651	One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation. 2014 , 28, 41-4		28
1650	Caesarean section to prevent transmission of hepatitis B: a meta-analysis. 2014 , 28, 439-44		19
1649	Non-invasive diagnosis of hepatitis B virus-related cirrhosis. <i>World Journal of Gastroenterology</i> , 2014 , 20, 445-59	5.6	22
1648	Does antiviral therapy reduce complications of cirrhosis?. <i>World Journal of Gastroenterology</i> , 2014 , 20, 7306-11	5.6	12
1647	Management of patients with hepatitis B and C before and after liver and kidney transplantation. 2014 , 6, 315-25		10
1646	Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review. <i>World Journal of Gastroenterology</i> , 2014 , 20, 14598-614	5.6	59

1645 Oral antiviral agents for treatment of chronic hepatitis B. **2014**, 57, 60

1644 Update on hepatitis B virus infection. *World Journal of Gastroenterology*, **2014**, 20, 13293-305 5.6 53

1643 The Rate of Conversion from Immune-tolerant Phase to Early Immune-clearance Phase in Children with Chronic Hepatitis B Virus Infection. **2014**, 17, 41-6 17

1642 Update on Hepatitis B Virus Infection: Focus on Treatment. **2014**, 2, 285-91 4

1641 [Is HBsAg loss an ideal end-point of oral antiviral therapy in chronic hepatitis B patients?]. **2014**, 63, 329-32

1640 Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir. *World Journal of Gastroenterology*, **2014**, 20, 7169-80 5.6 15

1639 Emerging antivirals for the treatment of hepatitis B. *World Journal of Gastroenterology*, **2014**, 20, 7707-13.6 34

1638 Antiviral Therapy of Liver Cirrhosis Related to Hepatitis B Virus Infection. **2014**, 2, 197-201 15

1637 Natural history of chronic hepatitis B: phases in a complex relationship. *World Journal of Gastroenterology*, **2014**, 20, 10395-404 5.6 64

1636 Hepatitis B reactivation in patients with multiple myeloma and isolated positive hepatitis B core antibody: a call for greater cognizance. **2014**, 13, 461-465 10

1635 Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice. **2014**, 13, 327-336 56

1634 Factors associated with spontaneous HBsAg clearance in chronic hepatitis B patients followed at a university hospital. **2014**, 13, 762-770 22

1633 HBsAg expression of liver correlates with histological activities and viral replication in chronic hepatitis B. **2014**, 13, 771-780 3

1632 Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma. *World Journal of Gastroenterology*, **2014**, 20, 6006-12 5.6 17

1631 Viral Hepatitis. **2014**, 112-128.e1

1630 Antiviral agents for hepatitis B virus-related cirrhosis. **2014**,

1629 Entecavir for chronic hepatitis B. **2014**, 6

1628 Chronic hepatitis B and liver schistosomiasis: a deleterious association. **2014**, 108, 159-64 12

1627	Hepatitis B inactive carriers: An overlooked population?. 2014 , 21, 241-249	6
1626	Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. 2014 , 63, 1648-57	129
1625	Nucleoside analogs. 2014 , 133-149	
1624	Current developments in nucleoside/nucleotide analogues for hepatitis B. 2014 , 8, 607-22	33
1623	The safety of chemotherapy for colorectal cancer patients with hepatitis C virus infection. 2014 , 31, 212	6
1622	HBV DNA level could predict significant liver fibrosis in HBeAg negative chronic hepatitis B patients with biopsy indication. 2014 , 14, 218	16
1621	Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B. 2014 , 3, 191-202	7
1620	A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B. 2014 , 59, 1714-23	71
1619	Therapy of acute and fulminant hepatitis B. 2014 , 57, 181-8	16
1618	Antiviral therapy of chronic hepatitis B. 2014 , 57, 171-80	11
1617	Hepatitis B in pregnancy. 2014 , 5, 111-117	11
1616	Partial virological response to three different nucleotide analogues in naive patients with chronic hepatitis B. 2014 , 13, 602-11	2
1615	Management and treatment of chronic hepatitis B in HIV-positive patients. 2014 , 46, 290-6	9
1614	Prognostic values of fluctuations in serum levels of alanine transaminase in inactive carrier state of HBV infection. 2014 , 14, e17537	5
1613	Chronic hepatitis B virus in young adults: the need for new approaches to management. 2014 , 12, 1045-53	6
1612	Tripartite Motif-Containing 22 Gene -364T/C Polymorphism Associated With Hepatitis B Virus Infection in Chinese Han Population. 2014 , 14, e12110	5
1611	Oral antiviral therapy for hepatitis B: the case of besifovir, a new kid on the block with a long way to go. 2014 , 63, 869-70	5
1610	Bortezomib induced hepatitis B reactivation. 2014 , 2014, 964082	15

1609	Viral hepatitis among drug users in methadone maintenance: associated factors, vaccination outcomes, and interventions. 2014 , 33, 322-31	9
1608	Entecavir versus Lamivudine therapy for patients with chronic hepatitis B-associated liver failure: a meta-analysis. 2014 , 14, e19164	7
1607	Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. 2014 , 15, 10578-604	48
1606	How can we make decision for patients with chronic hepatitis B according to hepatitis B virus (HBV) DNA level?. 2014 , 14, e15285	7
1605	Current status in the therapy of liver diseases. 2014 , 15, 7500-12	27
1604	Parameters associated with significant liver histological changes in patients with chronic hepatitis B. 2014 , 2014, 913890	7
1603	Quantitative Levels of Hepatitis B Virus DNA and Surface Antigen and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Receiving Long-Term Nucleos(t)ide Analogue Therapy. 2014 , 3, 41-52	37
1602	Perception of hepatitis B virus infection reactivation-related issues among specialists managing hematologic malignancies: result of an Italian survey. 2014 , 55, 2564-71	9
1601	Guarding the sleeping giant: hepatitis B screening and management in patients with hematological malignancy. 2014 , 55, 2426-7	2
1600	Managing hepatitis B to prevent liver cancer: recent advances. 2014 , 8, 409-15	3
1599	Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy. 2014 , 29, 1715-21	20
1598	Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients. 2014 , 20, O687-93	10
1597	Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis. 2014 , 29, 568-75	14
1596	A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study. 2014 , 20, O90-O100	25
1595	Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study. 2014 , 28, 153-9	27
1594	Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B. 2014 , 40, 811-8	16
1593	Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. 2014 , 32, 3736-43	223
1592	Oral antiviral therapy improves the diagnostic accuracy of alpha-fetoprotein levels in patients with chronic hepatitis B. 2014 , 29, 1699-705	21

1591	Long-term therapy of chronic delta hepatitis with peginterferon alfa. 2014 , 40, 93-104		61
1590	Exportin 4 gene expression and DNA promoter methylation status in chronic hepatitis B virus infection. 2014 , 21, 241-50		9
1589	Predictors associated with treatment initiation and switch in a real-world chronic hepatitis B population from five European countries. 2014 , 21, 662-70		2
1588	Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy. <i>Hepatology</i> , 2014 , 59, 1303-10	11.2	20
1587	Comparison of three luminescent immunoassays for hepatitis B virus surface antigen quantification during the natural history of chronic hepatitis B virus infection. 2014 , 21, 1521-7		3
1586	Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection. 2014 , 176, 102-11		8
1585	Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. 2014 , 21, 430-8		33
1584	Correlation of MR elastography with morphometric quantification of liver fibrosis (Fibro-C-Index) in chronic hepatitis B. 2014 , 72, 1123-9		30
1583	Prevention and management of viral hepatitis in pregnancy. 2014 , 41, 573-92		20
1582	MicroRNA-196A-2 polymorphisms and hepatocellular carcinoma in patients with chronic hepatitis B. 2014 , 86, 446-53		15
1581	Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. 2014 , 39, 197-208		47
1580	Treatment options beyond IFN and NUCs for chronic HBV infection: expectations for tomorrow. 2014 , 21, 753-61		7
1579	HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?. 2014 , 34 Suppl 1, 127-32		10
1578	Extended peginterferon alfa-2a (Pegasys) therapy in Chinese patients with HBeAg-negative chronic hepatitis B. 2014 , 86, 1705-13		21
1577	HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?. 2014 , 34 Suppl 1, 120-6		12
1576	HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?. 2014 , 34 Suppl 1, 112-9		37
1575	The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. <i>Hepatology</i> , 2014 , 59, 1283-92	11.2	62
1574	Methylation of serum insulin-like growth factor-binding protein 7 promoter in hepatitis B virus-associated hepatocellular carcinoma. 2014 , 53, 90-7		27

1573	Hepatitis B virus reactivation after ustekinumab treatment. 2014 , 170, 477-8	3
1572	Efficacy and safety of infliximab in treating patients with ulcerative colitis: experiences from a single medical center in southern China. 2014 , 15, 483-90	5
1571	Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis: the need for continued vigilance. 2014 , 55, 938-9	11
1570	HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?. 2014 , 34 Suppl 1, 108-11	17
1569	Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. 2014 , 39, 629-37	27
1568	Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides. 2014 , 40, 804-10	28
1567	Relationship between hepatitis B virus genotype B and C and response to interferon therapy in HBeAg positive chronic hepatitis B patients: A meta-analysis. 2014 , 29, 1387-95	8
1566	Reply: To PMID 24519364. <i>Hepatology</i> , 2014 , 60, 1797-8	11.2 1
1565	Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis B virus e antigen-positive, lamivudine-resistant chronic hepatitis B. 2014 , 29, 1485-93	4
1564	Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B--a prospective cohort study with paired transient elastography examinations. 2014 , 39, 883-93	79
1563	Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B: A meta-analysis. 2014 , 54, 959-67	1
1562	Lamivudine compared with newer antivirals for prophylaxis of hepatitis B core antibody positive livers: a cost-effectiveness analysis. 2014 , 14, 629-34	16
1561	Sequential analysis of amino acid substitutions with hepatitis B virus in association with nucleoside/nucleotide analog treatment detected by deep sequencing. 2014 , 44, 678-84	2
1560	Historic and current hepatitis B viral DNA and quantitative HBsAg level are not associated with cirrhosis in non-Asian women with chronic hepatitis B. 2014 , 29, 133-8	6
1559	Nucleos(t)ide analogue therapy for HBV-related HCC after hepatic resection: clinical benefits and unanswered questions. 2014 , 35, 12779-84	19
1558	A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy. 2014 , 24, 1-7	25
1557	Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice. 2014 , 15, 449	20
1556	Serum prolidase activity and oxidant-antioxidant status in children with chronic hepatitis B virus infection. 2014 , 40, 95	20

1555	Chronic hepatitis B and liver cancer risks among Asian immigrants in New York City: Results from a large, community-based screening, evaluation, and treatment program. 2014 , 23, 2229-39	32
1554	Monitoring and Care. 2014 , 478-493	
1553	Comparison of lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B. 2014 , 48, 889-95	8
1552	Transient elastography, APRI, and ultrasound have minimal utility in chronic low-replicative hepatitis B infection. 2014 , 26, 1010-4	4
1551	Risk assessment of liver-related events using transient elastography in patients with chronic hepatitis B receiving entecavir. 2014 , 48, 272-8	22
1550	Current treatment guidelines for chronic hepatitis B and their applications. 2014 , 48, 773-83	11
1549	Comparison of telbivudine efficacy in treatment-naïve patients with hepatitis B virus-related compensated and decompensated cirrhosis in 96 weeks. 2014 , 26, 396-403	5
1548	Clinical significance of hepatitis B virion and SVP productivity: relationships between intrahepatic and serum markers in chronic hepatitis B patients. 2014 , 2, 99-107	8
1547	Predictors of significant fibrosis in chronic hepatitis B patients with low viremia. 2014 , 48, e50-6	11
1546	First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment. 2014 , 26, 774-80	16
1545	Role of hepatitis B surface antigen (HBsAg) in identifying true inactive HBsAg carriers infected with genotype C hepatitis B virus. 2014 , 48, 166-71	9
1544	Clinical presentation of hepatitis D in Pakistani children. 2014 , 26, 1098-103	8
1543	Hepatobiliary manifestations of inflammatory bowel disease. 2014 , 20, 1655-67	17
1542	Telbivudine versus entecavir for nucleos(t)ide-naïve HBeAg-positive chronic hepatitis B: a meta-analysis. 2014 , 347, 131-8	10
1541	Liver and pancreatic cancer related to hepatitis B exposure: has the jury reached a verdict?. 2014 , 48, 655-6	1
1540	Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance. 2014 , 58, 1730-7	25
1539	Clinical implications of evolutionary patterns of homologous, full-length hepatitis B virus quasispecies in different hosts after perinatal infection. 2014 , 52, 1556-65	10
1538	Aberrant DNA methylation of G-protein-coupled bile acid receptor Gpbar1 (TGR5) is a potential biomarker for hepatitis B Virus associated hepatocellular carcinoma. 2014 , 11, 164-71	40

1537	Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations. 2014 , 57, 239-47	5
1536	The feasibility of discontinuing lamivudine in lamivudine-resistant chronic hepatitis B patients on lamivudine and adefovir combination therapy. 2014 , 57, 337-43	3
1535	SASLT practice guidelines for the management of hepatitis B virus. 2014 , 20, 5-25	21
1534	The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis. 2014 , 3, 21	4
1533	The appropriate use of vaccines in patients with inflammatory bowel disease. 2014 , 48, 395-401	8
1532	Do the epidemiology, physiological mechanisms and characteristics of hepatocellular carcinoma in HIV-infected patients justify specific screening policies?. 2014 , 28, 1379-91	21
1531	The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy. 2014 , 40, 1262-9	47
1530	JSH Guidelines for the Management of Hepatitis B Virus Infection. 2014 , 44 Suppl S1, 1-58	120
1529	Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-naïve Taiwanese patients with chronic hepatitis B. 2014 , 29, 185-92	8
1528	Metabolic syndrome association with fibrosis development in chronic hepatitis B virus inactive carriers. 2014 , 29, 173-8	21
1527	APRI and FIB-4 are good predictors of the stage of liver fibrosis in chronic hepatitis B: the Chronic Hepatitis Cohort Study (CHeCS). 2014 , 21, 917-20	71
1526	Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. 2014 , 146, 980-8	127
1525	[Patient with HBsAg negativization during treatment. Could it be considered a cure for hepatitis B?]. 2014 , 37, 324-6	
1524	Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon. 2014 , 102, 35-43	25
1523	Prevention of hepatocellular carcinoma resulting from hepatitis B: are we there yet?. 2014 , 12, 894-6	
1522	Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. 2014 , 60, 715-22	73
1521	Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. 2014 , 60, 339-45	173
1520	From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. 2014 , 70, 178-86	50

1519	Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections. 2014 , 159, 29-37	3
1518	Chemopreventive strategies in hepatocellular carcinoma. 2014 , 11, 45-54	218
1517	Application of deep sequence technology in hepatology. 2014 , 44, 141-8	2
1516	Similar response to entecavir 0.5 and 1.0 mg in treatment-naïve chronic hepatitis B patients: a case-control study. 2014 , 59, 168-73	7
1515	Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B. 2014 , 24, 70-8	130
1514	A rationalized approach to the treatment of patients infected with hepatitis B. 2014 , 18, 203-12	1
1513	Capsid proteins of enveloped viruses as antiviral drug targets. 2014 , 5, 63-71	35
1512	Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. 2014 , 39, 35-46	46
1511	Prophylaxis against hepatitis B reactivation among patients with lymphoma receiving rituximab. 2014 , 12, 151-4	5
1510	Does anti-HBV therapy benefit the prognosis of HBV-related hepatocellular carcinoma following hepatectomy?. 2014 , 21, 1010-5	12
1509	Dynamic comparison between Daan real-time PCR and Cobas TaqMan for quantification of HBV DNA levels in patients with CHB. 2014 , 14, 85	38
1508	Disease and treatment perceptions among Asian Americans diagnosed with chronic hepatitis B infection. 2014 , 29, 477-84	6
1507	Management of hepatitis B virus-related acute liver failure. 2014 , 7, 19-26	17
1506	Two rescue therapies in lamivudine-resistant patients with chronic hepatitis B in the central China: adefovir monotherapy and adefovir plus lamivudine. 2014 , 48, 32-7	5
1505	Loss of HBsAg and antiviral treatment: from basics to clinical significance. 2014 , 8, 39-54	6
1504	Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients. 2014 , 8, 72-82	11
1503	Ending vertical transmission of hepatitis B: the third trimester intervention. <i>Hepatology</i> , 2014 , 60, 448-511.2	17
1502	Hepatitis B reactivation and rituximab: a new boxed warning and considerations for solid organ transplantation. 2014 , 14, 788-96	26

1501	Effect of HLA-DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B e-antigen seropositive chronic hepatitis B patients. 2014 , 44, 1000-7	22
1500	A rapid and sensitive method based on magnetic beads for the detection of hepatitis B virus surface antigen in human serum. 2014 , 29, 591-7	9
1499	Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation. 2014 , 81, 478-84	21
1498	Maladies systémiques et biomédicaments : comprendre, apprécier et prévenir le risque de réactivation d'hépatite B. 2014 , 81, 374-380	
1497	HBV reactivation in immunosuppressed patients: prevention or containment?. <i>Hepatology</i> , 2014 , 59, 2062-4	11.2 5
1496	Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir. 2014 , 21, 590-6	24
1495	Traitement préemptif de la réactivation de l'hépatite virale B des patients sous chimiothérapie anticancéreuse. 2014 , 6, 47-53	
1494	Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle. 2014 , 106, 111-5	56
1493	Relationship between level of hepatitis B virus DNA and liver disease: a population-based study of hepatitis B e antigen-negative persons with hepatitis B. 2014 , 12, 701-6.e1-3	16
1492	Hepatitis B management in vulnerable populations: gaps in disease monitoring and opportunities for improved care. 2014 , 59, 46-56	30
1491	Chronic hepatitis B virus infection. 2014 , 98, 39-54	58
1490	A fusion DNA vaccine encoding middle version of HBV envelope protein fused to interleukin-21 did not enhance HBV-specific immune response in mice. 2014 , 27, 430-7	4
1489	No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. 2014 , 12, 2106-12.e1	33
1488	Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF. 2014 , 86, 1473-81	7
1487	Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: a randomized trial. 2014 , 61, 509-16	10
1486	Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B. 2014 , 21, 825-34	29
1485	New therapeutic perspectives in HBV: when to stop NAs. 2014 , 34 Suppl 1, 146-53	18
1484	Persistent viremia in human immunodeficiency virus/hepatitis B coinfecting patients undergoing long-term tenofovir: virological and clinical implications. <i>Hepatology</i> , 2014 , 60, 497-507	11.2 52

1483	De novo combination therapy adefovir plus lamivudine as a treatment for women of child-bearing age with HBeAg-positive chronic hepatitis B before pregnancy. 2014 , 86, 433-6	3
1482	Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. 2014 , 61, 1228-37	70
1481	Treating children with HBeAg-positive chronic hepatitis B: no small accomplishment. 2014 , 46, 1064-5	3
1480	Management of chronic hepatitis B in children: an unresolved issue. 2014 , 29, 912-9	29
1479	Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters. 2014 , 29, 1242-9	14
1478	Reducing the risk of infection in a 74-year-old man who is to receive prednisone. 2014 , 186, 1239-40	2
1477	Prevention of hepatitis B virus reinfection in liver transplant recipients. 2014 , 57, 196-201	20
1476	Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3). 2014 , 8, 1529-38	28
1475	Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy. 2014 , 21, 288-96	19
1474	Long-term efficacy of entecavir plus adefovir combination therapy versus entecavir monotherapy in adefovir refractory chronic hepatitis B patients with prior lamivudine resistance. 2014 , 57, 8-16	8
1473	Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≥ 40 IU/L and significant hepatic fibrosis. 2014 , 39, 349-58	59
1472	Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir. 2014 , 34, 1216-23	27
1471	Re-appraisal of old and new diagnostic tools in the current management of chronic hepatitis B. 2014 , 34, 991-1000	7
1470	No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. <i>Hepatology</i> , 2014 , 59, 434-42	11.2 181
1469	Antiviral efficacy analysis of telbivudine concurrent with the first cycle of chemotherapy in HBsAg-positive lymphoma patients. 2014 , 61, 199-203	5
1468	The Use of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase. 2014 , 147, 718-9	
1467	The interferon-gamma (IFN- γ)+874T allele reduces the risk of hepatitis B infection in an Asian population. 2014 , 21, 281-7	4
1466	Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China. <i>Hepatology</i> , 2014 , 60, 46-55	11.2 27

1465	Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: a randomized, clinical trial. 2014 , 29, 997-1004		20
1464	Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains. 2014 , 58, 6710-6		29
1463	Distinct seromarkers predict different milestones of chronic hepatitis B progression. <i>Hepatology</i> , 2014 , 60, 77-86	11.2	26
1462	HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. 2014 , 63, 1325-32		214
1461	The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene. 2014 , 88, 6805-18		27
1460	Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy. 2014 , 109, 1241-9		89
1459	CD8+ T cell responses specific for hepatitis B virus core protein in patients with chronic hepatitis B virus infection. 2014 , 61, 40-6		6
1458	Magnetic resonance elastography of liver. 2014 , 22, 433-46		109
1457	Management of patients with hepatitis B who require immunosuppressive therapy. 2014 , 11, 209-19		167
1456	A drug safety evaluation of rituximab and risk of hepatitis B. 2014 , 13, 977-87		11
1455	Poor adherence to AASLD guidelines for chronic hepatitis B Management and treatment in a large academic medical center. 2014 , 109, 867-75		40
1454	Neurotoxicity of commonly used hepatic drugs. 2014 , 120, 675-82		10
1453	Four homoisoflavonoids isolated from traditional Chinese medicine: "gan luo xin". 2014 , 16, 813-8		5
1452	Human immunodeficiency virus and coinfection with hepatitis B and C. 2014 , 28, 477-99		12
1451	Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. <i>Hepatology</i> , 2014 , 60, 468-76	11.2	137
1450	Hepatitis B virus reactivation in hepatitis B surface antigen seropositive patients with metastatic non-small cell lung cancer receiving cytotoxic chemotherapy: the efficacy of preemptive lamivudine and identification of risk factors. 2014 , 31, 119		15
1449	Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries. 2014 , 8, 382-94		9
1448	FibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis B. 2014 , 14, 118		6

1447	Alpha-fetoprotein level as a biomarker of liver fibrosis status: a cross-sectional study of 619 consecutive patients with chronic hepatitis B. 2014 , 14, 145	22
1446	Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs. 2014 , 14, 439	37
1445	Gateway to Care campaign: a public health initiative to reduce the burden of hepatitis B in Haimen City, China. 2014 , 14, 754	9
1444	Low treatment rates in patients meeting guideline criteria in diverse practice settings. 2014 , 59, 2091-9	25
1443	Hepatitis B virus treatment beyond the guidelines: special populations and consideration of treatment withdrawal. 2014 , 7, 148-55	19
1442	The relationship between IL-28B polymorphisms and the response to peginterferon alfa-2a monotherapy in anti-HBe-positive patients with chronic HBV infection. 2014 , 33, 2025-33	8
1441	Characteristics and management of patients with chronic hepatitis B in an integrated care setting. 2014 , 59, 2100-8	27
1440	Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. 2014 , 8, 223-40	60
1439	Immunotherapeutic interventions in chronic hepatitis B virus infection: a review. 2014 , 407, 1-8	22
1438	Performance of two real-time PCR assays for hepatitis B virus DNA detection and quantitation. 2014 , 201, 24-30	15
1437	Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. 2014 , 146, 1240-8	117
1436	Chinese medicine syndrome distribution of chronic hepatitis B virus carriers in immunotolerant phase. 2014 , 20, 94-100	5
1435	Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China. 2014 , 8, 135-44	36
1434	Can Nucleos(t)ide Analogue (NA) Therapy Ever be Stopped in HBeAg-Negative Chronic Hepatitis B?. 2014 , 13, 256-263	4
1433	Comparison of hepatitis B surface antigen and e antigen in predicting liver histology in hepatitis B e antigen-positive chronic hepatitis B patients. 2014 , 8, 216-23	7
1432	Management of the HBV reactivation in isolated HBCAb positive patients affected with Non Hodgkin Lymphoma. 2014 , 14, 31	21
1431	Tickling the TLR7 to cure viral hepatitis. 2014 , 12, 129	21
1430	Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. 2014 , 26, 78-88	119

1429	Evidence-based guidelines for laboratory screening for infectious diseases before initiation of systemic immunosuppressive agents in patients with autoimmune bullous dermatoses. 2014 , 171, 1307-17	15
1428	Hepatitis B and C in African Americans: current status and continued challenges. 2014 , 12, 738-48	32
1427	Current hepatitis B treatment guidelines and future research directions. 2014 , 8, 145-57	4
1426	Computerized physician order entry-based system to prevent HBV reactivation in patients treated with biologic agents: the PRESCRIB project. <i>Hepatology</i> , 2014 , 60, 106-13	11.2 21
1425	The role of von Willebrand factor as a biomarker of tumor development in hepatitis B virus-associated human hepatocellular carcinoma: a quantitative proteomic based study. 2014 , 106, 99-112	39
1424	Comparison of the Abbott RealTime HBV assay with the Roche Cobas AmpliPrep/Cobas TaqMan HBV assay for HBV DNA detection and quantification. 2014 , 60, 206-14	31
1423	Histologic changes in liver tissue from patients with chronic hepatitis B and minimal increases in levels of alanine aminotransferase: a meta-analysis and systematic review. 2014 , 12, 1262-6	20
1422	HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels. 2014 , 61, 730-7	19
1421	N-glycosylation mutations within hepatitis B virus surface major hydrophilic region contribute mostly to immune escape. 2014 , 60, 515-22	59
1420	Prevalence of diagnosed chronic hepatitis B infection among U.S. Medicaid enrollees, 2000-2007. 2014 , 24, 418-23	15
1419	Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. 2014 , 147, 152-61	105
1418	A possible role for NKT-like cells in patients with chronic hepatitis B during telbivudine treatment. 2014 , 160, 65-71	11
1417	Hepatitis B and C. 2014 , 30, 149-67	4
1416	Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. 2014 , 60, 1127-34	40
1415	Treatment of pediatric chronic viral hepatitis B and C. 2014 , 38, 415-8	
1414	Peginterferon in the treatment of chronic hepatitis B. 2014 , 14, 995-1006	13
1413	Current recommendations of managing HBV infection in preconception or pregnancy. 2014 , 8, 158-65	10
1412	Hepatitis B virus infection. 2014 , 384, 2053-63	930

1411	Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model. 2014 , 88, 10421-31		59
1410	Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). 2014 , 61, 777-84		152
1409	Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study. 2014 , 15, 1-5		3
1408	Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients. 2014 , 113, 786-93		7
1407	Management of hepatitis B: our practice and how it relates to the guidelines. 2014 , 12, 16-26		75
1406	Efficacy of early treatment on 52 patients with preneoplastic hepatitis B virus-associated hepatocellular carcinoma by compound Phyllanthus Urinaria L. 2014 , 20, 263-71		10
1405	Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients. 2014 , 19, 551-8		10
1404	Treatment of pegylated interferon- α in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation. 2015 , 20, 217-24		1
1403	Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B. 2014 , 19, 543-50		11
1402	Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. <i>World Journal of Gastroenterology</i> , 2014 , 20, 6262-78	5.6	94
1401	Vaccines for viral hepatitis. 2014 , 219-228		
1400	On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy. 2015 , 20, 369-75		46
1399	Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection. 2015 , 20, 141-7		15
1398	[Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline]. 2014 , 155 Suppl, 25-36		1
1397	The influences of antiviral therapy on T-cell function in adult patients with chronic hepatitis B. 2014 , 9, 913-920		
1396	The Microbiota in Inflammatory Bowel Disease. 2014 , 187-203		
1395	Approach and management of patients with chronic hepatitis B and C during the course of inflammatory bowel disease. 2014 , 20, 2142-50		4
1394	Preventing hepatocellular carcinoma: the crucial role of chronic hepatitis B monitoring and antiviral treatment. 2014 , 1, 255-257		0

- 1393 Toxicity of targeted therapeutic agents in lymphoma and management: part 1: monoclonal antibodies and radioimmunotherapy. **2014**, 3, 41-51
- 1392 Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin. **2015**, 99, 1321-34 45
- 1391 Studies on the epidemiology of hepatitis B and C virus infections are still needed. **2015**, 62, 1225-7 7
- 1390 Defining and grading HBV reactivation. **2015**, 5, 35-38 16
- 1389 Management strategies for hepatitis B-infected patients undergoing immunomodulatory therapy: Is lamivudine enough?. **2015**, 5, 43-46 1
- 1388 Hepatitis B reactivation from immunosuppressive drug therapy: A global menace. **2015**, 5, 39-42 7
- 1387 Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. **2015**, 42, 243-57 83
- 1386 Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis. **2015**, 42, 1182-91 34
- 1385 Smartphone-Imaged HIV-1 Reverse-Transcription Loop-Mediated Isothermal Amplification (RT-LAMP) on a Chip from Whole Blood. **2015**, 1, 324-335 62
- 1384 Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy. *Scientific Reports*, **2015**, 5, 17123 4.9 13
- 1383 Characterisation of peripheral blood mononuclear cell microRNA in hepatitis B-related acute-on-chronic liver failure. *Scientific Reports*, **2015**, 5, 13098 4.9 18
- 1382 Androgen receptor in hepatocarcinogenesis: Recent developments and perspectives. **2015**, 9, 1983-1988 21
- 1381 HBV carrying drug-resistance mutations in chronically infected treatment-naive patients. **2015**, 20, 387-95 27
- 1380 [In Process Citation]. **2015**, 156 Suppl 1, 25-35
- 1379 Automated biphasic morphological assessment of hepatitis B-related liver fibrosis using second harmonic generation microscopy. *Scientific Reports*, **2015**, 5, 12962 4.9 27
- 1378 Circulating cell death biomarker: good candidates of prognostic indicator for patients with hepatitis B virus related acute-on-chronic liver failure. *Scientific Reports*, **2015**, 5, 14240 4.9 20
- 1377 Management of patients with hepatitis B in special populations. *World Journal of Gastroenterology*, **2015**, 21, 1738-48 5.6 36
- 1376 Efficacy of tenofovir disoproxil fumarate to prevent vertical transmission in mothers with lamivudine-resistant HBV. **2015**, 20, 681-7 19

1375	Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B. 2015 , 32, 727-41			16
1374	Langzeittherapie der HBV-Infektion mit oralen Polymeraseinhibitoren. 2015 , 10, 268-283			
1373	Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors. 2015 , 15, 999			4
1372	Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection. 2015 , 12, 225			8
1371	Nephrotoxicity caused by oral antiviral agents in patients with chronic hepatitis B treated in a hospital for tropical diseases in Thailand. 2015 , 16, 38			4
1370	Expansion of Access to HBV Treatment. 2015 , 14, 195-202			
1369	Reactivation of hepatitis B (reverse seroconversion) after melphalan/dexamethasone therapy for primary amyloidosis: a case report. 2015 , 9, 122			2
1368	Present and future therapies of hepatitis B: From discovery to cure. <i>Hepatology</i> , 2015 , 62, 1893-908	11.2	211	
1367	Rethinking the pathogenesis of hepatitis B virus (HBV) infection. 2015 , 87, 1989-99			19
1366	Tenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir. 2015 , 22, 675-81			15
1365	Clonal evolution of multidrug resistant hepatitis B virus during entecavir rescue therapy. 2015 , 35, 2370-83			2
1364	Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients. 2016 , 16, 14			11
1363	A model with combined viral and metabolic factors effectively predicts HBeAg status under long term entecavir therapy: a prospective cohort study. 2015 , 12, 179			2
1362	Promoter methylation status and expression of PPAR- γ gene are associated with prognosis of acute-on-chronic hepatitis B liver failure. 2015 , 7, 115			27
1361	Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. 2015 , 9, 164			79
1360	Outcomes of the implementation of the computer-assisted HBView system for the prevention of hepatitis B virus reactivation in chemotherapy patients: a retrospective analysis. 2015 , 1, 29			7
1359	Renal Function in Chronic Hepatitis B Patients Treated With Tenofovir Disoproxil Fumarate or Entecavir Monotherapy: A Matched Case-Cohort Study. 2015 , 49, 873-7			19
1358	Diabetes and prediabetes in patients with hepatitis B residing in North America. <i>Hepatology</i> , 2015 , 62, 1364-74	11.2	19	

1357	The interferon receptor-1 promoter polymorphisms affect the outcome of Caucasians with HBeAg-negative chronic HBV infection. 2015 , 35, 2506-13		8
1356	Long-term follow-up and suboptimal treatment rates of treatment-eligible chronic hepatitis B patients in diverse practice settings: a gap in linkage to care. 2015 , 2, e000060		10
1355	Selected Cytokines Serve as Potential Biomarkers for Predicting Liver Inflammation and Fibrosis in Chronic Hepatitis B Patients With Normal to Mildly Elevated Aminotransferases. <i>Medicine (United States)</i> , 2015 , 94, e2003	1.8	26
1354	Hepatitis B: encouraging the use of interferon. 2015 , 28, 557-62		4
1353	Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. <i>Hepatology</i> , 2015 , 62, 40-6	11.2	60
1352	Prevention of acute exacerbation of chronic hepatitis B infection in cancer patients receiving chemotherapy in a hepatitis B virus endemic area. <i>Hepatology</i> , 2015 , 62, 387-96	11.2	16
1351	Current treatment of hepatitis B virus infections. 2015 , 25, 354-65		11
1350	Forns index predicts recurrence and death in patients with hepatitis B-related hepatocellular carcinoma after curative resection. 2015 , 35, 1992-2000		12
1349	Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation. 2015 , 35, 2530-6		18
1348	Association of Inducible T Cell Costimulator Polymorphisms with Susceptibility and Outcome of Hepatitis B Virus Infection in a Chinese Han Population. 2015 , 82, 275-81		6
1347	Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B. <i>Medicine (United States)</i> , 2015 , 94, e1341	1.8	17
1346	Aberrant GSTP1 promoter methylation predicts short-term prognosis in acute-on-chronic hepatitis B liver failure. 2015 , 42, 319-29		17
1345	Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis: 2 years of entecavir treatment. 2015 , 30, 1775-81		12
1344	An intrahepatic transcriptional signature of enhanced immune activity predicts response to peginterferon in chronic hepatitis B. 2015 , 35, 1824-32		13
1343	Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus. 2015 , 35, 2265-74		2
1342	Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects. <i>Hepatology</i> , 2015 , 62, 684-93	11.2	60
1341	Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy. <i>Hepatology</i> , 2015 , 62, 1757-66	11.2	73
1340	Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures. 2015 , 87, 1013-21		4

1339	HBeAg-negative chronic hepatitis patients should be monitored more strictly: a cross-sectional retrospective study on antiviral treatment-naïve patients. 2015 , 87, 1682-8		4
1338	Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate. 2015 , 22, 1079-87		16
1337	Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. <i>Hepatology</i> , 2015 , 62, 694-701	11.2	75
1336	Osteomalacia and Fanconi's syndrome caused by long-term low-dose adefovir dipivoxil. 2015 , 40, 345-8		13
1335	Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir. 2015 , 30, 1514-21		11
1334	Increased Pygo2 expression in liver of patients with hepatitis B virus-related fibrosis. 2015 , 35, 2522-9		2
1333	iTRAQ-based proteomic analysis of hepatic tissues from patients with hepatitis B virus-induced acute-on-chronic liver failure. 2015 , 10, 1732-1742		3
1332	Serum Biomarkers Predictive of Significant Fibrosis and Cirrhosis in Chronic Hepatitis B. 2015 , 49, 705-13		30
1331	Can Serum ST2 Levels Be Used as a Marker of Fibrosis in Chronic Hepatitis B Infection?. <i>Medicine (United States)</i> , 2015 , 94, e1889	1.8	13
1330	A new model combining the liver/spleen volume ratio and classification of varices predicts HVP in hepatitis B patients with cirrhosis. 2015 , 27, 335-43		14
1329	Tenofovir monotherapy after achieving complete viral suppression on entecavir plus tenofovir combination therapy. 2015 , 27, 871-6		6
1328	Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks. 2015 , 29, 1173-82		13
1327	Performance of several simple, noninvasive models for assessing significant liver fibrosis in patients with chronic hepatitis B. 2015 , 56, 272-9		15
1326	Evaluation of a Rapid One-step Real-time PCR Method as a High-throughput Screening for Quantification of Hepatitis B Virus DNA in a Resource-limited Setting. 2015 , 5, 11-15		2
1325	IL28B is associated with outcomes of chronic HBV infection. 2015 , 56, 625-33		8
1324	Hepatitis B virus therapy: What's the future holding for us?. <i>World Journal of Gastroenterology</i> , 2015 , 21, 12558-75	5.6	29
1323	Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation. 2015 , 16, 28126-45		13
1322	Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. 2015 , 7, 344-61		56

1321	Hepatocellular Carcinoma Risk of Compensated Cirrhosis Patients with Elevated HBV DNA Levels according to Serum Aminotransferase Levels. 2015 , 30, 1618-24		7
1320	Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy. 2015 , 12, 416-22		4
1319	Genotypic resistance profiles in Chinese patients with chronic hepatitis B virus infection and the efficacy of nucleoside analog rescue therapy. 2015 , 11, 417-23		
1318	Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis. <i>World Journal of Gastroenterology</i> , 2015 , 21, 7869-76	5.6	18
1317	A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis. 2015 , 12, 10039-55		14
1316	Hepatitis prevention project in the Korean American community in Killeen, Texas. 2015 , 28, 435-7		1
1315	Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon. 2015 , 5, 218-26		40
1314	The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder system. 2015 , 10, e0116978		22
1313	Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinoma. 2015 , 10, e0122041		22
1312	High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid Leukemia. 2015 , 10, e0126037		17
1311	The Efficacy and Safety of Entecavir and Interferon Combination Therapy for Chronic Hepatitis B Virus Infection: A Meta-Analysis. 2015 , 10, e0132219		12
1310	Seroclearance of Hbsag in Chronic Hepatitis B Virus Patients on Lamivudine Therapy: A 10 Year Experience. 2015 , 7, 101-7		4
1309	miR-106a Is Downregulated in Peripheral Blood Mononuclear Cells of Chronic Hepatitis B and Associated with Enhanced Levels of Interleukin-8. 2015 , 2015, 629862		7
1308	Prospective study of hepatitis B virus reactivation in patients with hematological malignancies. 2015 , 14, 168-174		12
1307	Viral Hepatitis. 2015 , 1439-1468.e7		4
1306	Determination of the upper cut-off values of serum alanine aminotransferase and aspartate aminotransferase in Chinese. <i>World Journal of Gastroenterology</i> , 2015 , 21, 2419-24	5.6	12
1305	Reactivation of Hepatitis B Virus in Patients with Rheumatologic Disease Treated with Biologic Disease Modifying Anti-rheumatic Drugs: Screening and Treatment. 2015 , 22, 282		2
1304	The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: a meta-analysis. 2015 , 14, 150-160		13

1303	Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues. 2015 , 7, 1064-73		32
1302	Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. <i>World Journal of Gastroenterology</i> , 2015 , 21, 4644-51	5.6	18
1301	Chronic Hepatitis B Viral Infection. 2015 , 1916-1938		
1300	Association of serum gamma-glutamyl transferase with treatment outcome in chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , 2015 , 21, 9957-65	5.6	5
1299	Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries. 2015 , 1, 103-110		21
1298	EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. 2015 , 63, 237-64		1082
1297	Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study. 2015 , 17, 136		11
1296	Chronic HBV-infected subjects older than 35 years with persistently normal ALT and ultrasound, despite high viral load do not have significant fibrosis. 2015 , 34, 341-2		1
1295	Comprehensive DNA methylation analysis of hepatitis B virus genome in infected liver tissues. <i>Scientific Reports</i> , 2015 , 5, 10478	4.9	26
1294	Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?. 2015 , 63, 722-32		76
1293	Clinical management of chronic hepatitis B infection: results from a registry at a German tertiary referral center. 2015 , 43, 153-62		3
1292	Oral antiviral therapy for HBeAg negative chronic hepatitis B: better stop or continue?. 2015 , 64, 526-8		13
1291	Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes. 2015 , 63, 586-92		70
1290	Real life adherence of chronic hepatitis B patients to entecavir treatment. 2015 , 47, 577-83		15
1289	Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination. 2015 , 37, 1433-42		7
1288	Can serum level of HBsAg differentiate HBeAg-negative chronic hepatitis B from inactive carrier state?. 2015 , 82, 114-9		9
1287	Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients. 2015 , 8, e21444		7
1286	Efficacy of tenofovir disoproxil fumarate therapy in Chinese chronic hepatitis B patients after multiple antiviral failures. 2015 , 45, E43-52		1

1285	Does Nucleos(t)ide (NUC) Analogs Therapy in Hepatitis B Impact the Incidence of Liver Cancer?. 2015 , 14, 279-283		
1284	Prolonged entecavir therapy is not effective for HBeAg seroconversion in treatment-naive chronic hepatitis B patients with a partial virological response. 2015 , 59, 5348-56		7
1283	Increased A20 mRNA Level in Peripheral Blood Mononuclear Cells is Associated With Immune Phases of Patients With Chronic Hepatitis B. <i>Medicine (United States)</i> , 2015 , 94, e2428	1.8	5
1282	HBSAg Level as Predictor of Liver Fibrosis in HBeAg Positive Patients With Chronic Hepatitis B Virus Infection. 2015 , 5, 213-20		9
1281	An Analysis of Immunoreactive Signatures in Early Stage Hepatocellular Carcinoma. 2015 , 2, 438-46		20
1280	Recent Advances in the Management of Chronic Hepatitis B Including Suppression of Hepatocellular Carcinoma by Entecavir and Interferon. 2015 , 89 Suppl 2, 60-9		5
1279	C-reactive protein is a biomarker of AFP-negative HBV-related hepatocellular carcinoma. 2015 , 47, 543-54		26
1278	Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma?. 2015 , 14, 439-51		3
1277	Letter: safe and effective cessation of long-term nucleos(t)ide analogue therapy in noncirrhotic patients with HBeAg-negative chronic hepatitis B. 2015 , 41, 236-7		1
1276	Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?. 2015 , 35 Suppl 1, 107-13		19
1275	Low level of hepatitis B virus screening among patients receiving chemotherapy. 2015 , 13, 970-5; quiz e51		20
1274	Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end?. 2015 , 204, 121-9		20
1273	Reappraisal of serum alpha-foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment. 2015 , 35, 232-9		29
1272	Cost-effectiveness analysis of antiviral therapies for hepatitis B e antigen-positive chronic hepatitis B patients in China. 2015 , 35, 197-209		9
1271	Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. 2015 , 62, 956-67		285
1270	The use of novel agents in multiple myeloma patients with hepatic impairment. 2015 , 11, 501-10		11
1269	What can we learn from hepatitis B virus clinical cohorts?. 2015 , 35 Suppl 1, 91-9		10
1268	Perioperative antiviral therapy improves safety in patients with hepatitis B related HCC following hepatectomy. 2015 , 15, 1-5		11

1267	Clinical course of chronic hepatitis B (CHB) presented with normal ALT in Asian American patients. 2015 , 22, 809-16		5
1266	Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?. <i>Hepatology</i> , 2015 , 61, 703-11	11.2	156
1265	Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. <i>Hepatology</i> , 2015 , 61, 1809-20	11.2	95
1264	The effect of therapeutic vaccination for the treatment of chronic hepatitis B virus infection. 2015 , 87, 575-82		12
1263	Incidence of natural resistance mutations in naïve chronic hepatitis B patients: a systematic review and meta-analysis. 2015 , 30, 252-61		23
1262	Vaccinating the inflammatory bowel disease patient. 2015 , 9, 91-102		13
1261	Probability-based interpretation of liver stiffness measurement in untreated chronic hepatitis B patients. 2015 , 60, 1448-56		16
1260	Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. 2015 , 64, 1289-95		146
1259	Safety and efficacy of entecavir in adefovir-experienced patients. 2015 , 30, 43-50		7
1258	Diagnostic values of alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma. 2015 , 32, 59		43
1257	Viral hepatitis: past and future of HBV and HDV. 2015 , 5, a021345		28
1256	Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. 2015 , 64, 667-72		148
1255	Immunosuppressive treatment combined with nucleoside analog is superior to nucleoside analog only in the treatment of severe thrombocytopenia in patients with cirrhosis associated with hepatitis B in China: A multicenter, observational study. 2015 , 26, 672-9		4
1254	Elevated TGF- β /IL-31 Pathway Is Associated with the Disease Severity of Hepatitis B Virus-Related Liver Cirrhosis. 2015 , 28, 209-16		26
1253	HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients. 2015 , 35 Suppl 1, 82-90		49
1252	Serum wnt5a is a predictor for the prognosis of acute on chronic hepatitis B liver failure. 2015 , 20, 26-34		3
1251	Influence of Hepatic Inflammation on FibroScan Findings in Diagnosing Fibrosis in Patients with Chronic Hepatitis B. 2015 , 41, 1538-44		23
1250	Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection. 2015 , 50, 785-94		24

1249	Hepatitis B virus infection in children. 2015 , 13, 427-50	6
1248	Molecular biology of hepatitis B virus infection. 2015 , 479-480, 672-86	466
1247	Assessment of HBV preventive services in a medically underserved Asian and Pacific Islander population using provider and patient data. 2015 , 30, 68-74	15
1246	A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. 2015 , 16, 804-15	194
1245	Care of Adult Refugees with Chronic Conditions. 2015 , 99, 1039-58	13
1244	Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. 2015 , 121, 97-108	105
1243	Antiviral Therapy in Hepatitis B Virus-Associated Liver Cirrhosis. 2015 , 33, 608-12	5
1242	Feasibility, acceptability and safety of a nurse led hepatitis B clinic based in the community. 2015 , 22, 233-40	1
1241	Performance of HBsAg point-of-care tests for detection of diagnostic escape-variants in clinical samples. 2015 , 69, 33-5	8
1240	Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis. 2015 , 34, 286-91	25
1239	Serum sphingomyelin has potential to reflect hepatic injury in chronic hepatitis B virus infection. 2015 , 33, 149-55	16
1238	Prevention of Post-transplant HBV. 2015 , 14, 153-163	
1237	Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis. 2015 , 9, 543-57	3
1236	Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment. 2015 , 59, 4121-8	39
1235	Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection. 2015 , 49, 1015-30	12
1234	The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study. 2015 , 63, 1118-25	56
1233	Treatment of severe non-infectious uveitis in high-risk conditions (Part 2): systemic infections; management and safety issues. 2015 , 14, 1353-71	5
1232	Chronic hepatitis B: Are we close to a cure?. 2015 , 47, 836-41	13

1231	Optimal management of hepatitis B virus infection - EASL Special Conference. 2015 , 63, 1238-53	81
1230	Vibration-controlled transient elastography: a practical approach to the noninvasive assessment of liver fibrosis. 2015 , 31, 192-8	12
1229	Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study). <i>Hepatology</i> , 2015 , 61, 1512-22	11.2 124
1228	Chronic hepatitis B: A wave of new therapies on the horizon. 2015 , 121, 69-81	53
1227	Emerging challenges in managing hepatitis B in HIV patients. 2015 , 12, 344-52	19
1226	Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. 2015 , 15, 1167-1174	158
1225	Clinical Applications of Quantitative Real-Time PCR in Virology. 2015 , 42, 161-197	1
1224	A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update. 2015 , 13, 2071-87.e16	75
1223	Up-regulation of IL-12 expression in patients with chronic hepatitis B is mediated by the PI3K/Akt pathway. 2015 , 407, 135-42	9
1222	Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities. 2015 , 121, 47-58	175
1221	Management of chronic hepatitis B in patients from special populations. 2015 , 5,	2
1220	Intracellular levels of hepatitis B virus DNA and mutational patterns of the polymerase gene of hepatitis B virus in peripheral blood mononuclear cells of patients with lamivudine or telbivudine resistance. 2015 , 9, 885-890	0
1219	Correlation between two chemiluminescence based assays for quantification of hepatitis B surface antigen in patients with chronic hepatitis B infection. 2015 , 33, 96-100	3
1218	Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance. 2015 , 62, 1092-9	82
1217	[Is it possible to stop treatment with nucleos(t)ide analogs in patients with e-antigen negative chronic hepatitis B? Experience and new expectations]. 2015 , 38, 305-12	
1216	Clinical events after cessation of lamivudine therapy in patients recovered from hepatitis B flare with hepatic decompensation. 2015 , 13, 979-86	24
1215	Universal hepatitis B virus screening in patients receiving immunosuppressive therapy: a small step for the oncologists, a major advance for prevention of hepatitis B virus reactivation. 2015 , 13, 976-8	2
1214	Transplantation for Hepatitis A and B. 2015 , 105-119	

1213	Pretransplantation Evaluation: Infectious Disease. 2015 , 441-449	
1212	Late Complications and Recurrence of Disease After Transplantation. 2015 , 1051-1060	
1211	von Willebrand factor as a novel noninvasive predictor of portal hypertension and esophageal varices in hepatitis B patients with cirrhosis. 2015 , 50, 1160-9	14
1210	Long-term prognosis of patients with hepatitis B infection: causes of death and utility of nucleos(t)ide analogue therapy. 2015 , 50, 795-804	6
1209	Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centers. 2015 , 92, 193-213	28
1208	Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy. 2015 , 9, 224-30	15
1207	Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. 2015 , 62, S76-86	148
1206	Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon- β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection. 2015 , 35, 613-20	5
1205	Unveiling the roles of HBV polymerase for new antiviral strategies. 2015 , 10, 283-295	26
1204	Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation. 2015 , 59, 3168-73	21
1203	Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity. 2015 , 59, 1070-9	62
1202	Tenofovir discontinuation after long-term viral suppression in HBeAg negative chronic hepatitis B. Can HBsAg levels be useful?. 2015 , 68, 61-8	13
1201	Epidemiology of Acute Hepatitis B in the United States From Population-Based Surveillance, 2006-2011. 2015 , 61, 584-92	33
1200	Hepatitis B virus epidemiology. 2015 , 5, a021410	137
1199	Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B. 2015 , 41, 1190-9	7
1198	Hepatitis B virus genotypes and variants. 2015 , 5, a021436	132
1197	Residual amount of HBV DNA in serum is related to relapse in chronic hepatitis B patients after cessation of nucleos(t)ide analogs. 2015 , 49, 323-8	17
1196	Therapeutic management of chronic hepatitis B in clinical practice: a region-wide survey. 2015 , 49, 228-34	4

1195	Prophylaxis for Infections Following Allogeneic Hematopoietic Stem Cell Transplantation. 2015 , 23, 7-12		1
1194	Giving rituximab in patients with occult or resolved hepatitis B virus infection: are the current guidelines good enough?. 2015 , 14, 865-75		5
1193	Hepatitis B reverse seroconversion in a patient with well controlled HIV infection: a case report and a review of the literature. 2015 , 29, 246-8		
1192	Nationwide large survey on hepatitis B surface antigen quantification use in real-life clinical practice. 2015 , 27, 557-60		2
1191	Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. 2015 , 9, 243-50		46
1190	Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities. 2015 , 27, 46-54		4
1189	Serum Golgi protein 73 (GP73) is a diagnostic and prognostic marker of chronic HBV liver disease. <i>Medicine (United States)</i> , 2015 , 94, e659	1.8	32
1188	Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management. 2015 , 15, 1162-72		152
1187	Monotherapy for hepatitis B infection: a review of treatment options. 2015 , 13, 1457-68		3
1186	Renal proximal tubular dysfunction due to tenofovir in a patient with chronic hepatitis B mono-infection. 2015 , 39, e67-9		3
1185	Low serum hyaluronic acid levels associated with spontaneous HBsAg clearance. 2015 , 34, 2183-9		2
1184	Predicting clinical outcomes in patients with HBsAg-positive chronic hepatitis. 2015 , 9, 567-77		2
1183	A novel dendritic-cell-targeting DNA vaccine for hepatitis B induces T cell and humoral immune responses and potentiates the antiviral activity in HBV transgenic mice. 2015 , 168, 293-9		11
1182	Overcoming drug resistance in HSV, CMV, HBV and HCV infection. 2015 , 10, 1759-66		4
1181	An albumin, collagen IV, and longitudinal diameter of spleen scoring system superior to APRI for assessing liver fibrosis in chronic hepatitis B patients. 2015 , 31, 18-22		6
1180	Efficacy and safety of tenofovir in nucleos(t)ide-naïve patients with genotype C chronic hepatitis B in real-life practice. 2015 , 37, 1228-34		8
1179	High Prevalence of Hepatitis B Virus Infection in Young Adults in Ternate, Eastern Indonesia. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015 , 93, 1349-55	3.2	10
1178	Therapy of Delta Hepatitis. 2015 , 5,		8

1177	Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. 2015 , 41, 199-208	41
1176	Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B. 2015 , 41, 867-76	78
1175	HBV infection is associated with greater mortality in hospitalised patients compared to HCV infection or alcoholic liver disease. 2015 , 41, 928-38	9
1174	Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection. 2015 , 41, 949-60	41
1173	Australian Liver Association (ALA) expert consensus recommendations for the use of transient elastography in chronic viral hepatitis. 2015 , 30, 453-62	20
1172	Aberrant DNA methylation of G-protein-coupled bile acid receptor Gpbar1 predicts prognosis of acute-on-chronic hepatitis B liver failure. 2015 , 22, 112-9	6
1171	Where we are with point-of-care testing. 2015 , 22, 362-5	13
1170	Long-term outcome in Caucasian patients with chronic hepatitis B virus infection after HBsAg seroclearance. 2015 , 35, 140-7	27
1169	Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data. 2015 , 35, 860-9	9
1168	Loss of hepatitis B surface antigen in a real-life clinical cohort of patients with chronic hepatitis B virus infection. 2015 , 35, 130-9	25
1167	Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?. 2015 , 35 Suppl 1, 100-6	11
1166	On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. 2015 , 35, 1540-8	24
1165	Effect of Peg-interferon α 2a combined with Adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA. 2015 , 35, 1692-9	14
1164	Hepatitis B virus hijacks CTHRC1 to evade host immunity and maintain replication. 2015 , 7, 543-56	18
1163	Stopping Preemptive Antiviral Therapy for Hepatitis B Virus Can Be Considered for Patients with Favorable Predictors. 2015 , 60, 3794-800	1
1162	Simple organ failure count versus CANONIC grading system for predicting mortality in acute-on-chronic liver failure. 2015 , 30, 575-81	31
1161	Current Management of Chronic Hepatitis B and C in Chronic Kidney Disease. 2015 , 22, 352-60	5
1160	Hepatitis B: Working Towards a Cure. 2015 , 17, 35	

1159	Controversial Issues in Current Treatment of Chronic HBV Infection. 2015 , 14, 164-170	
1158	B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use. 2015 , 17, 65	11
1157	Future therapy for hepatitis B virus infection. 2015 , 8, 167-71	1
1156	Low adherence of HIV providers to practice guidelines for hepatocellular carcinoma screening in HIV/hepatitis B coinfection. 2015 , 61, 1742-8	9
1155	Hepatitis delta virus: From biological and medical aspects to current and investigational therapeutic options. 2015 , 122, 112-29	30
1154	Perspectives and control of hepatitis B virus infection in Taiwan. 2015 , 114, 901-9	52
1153	Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study. 2015 , 8, 978-88	14
1152	Overexpression of serum sST2 is associated with poor prognosis in acute-on-chronic hepatitis B liver failure. 2015 , 39, 315-23	7
1151	Editorial Commentary: Another Call to Cure Hepatitis B. 2015 , 61, 1307-9	16
1150	Hepatitis B Virus Inactive Carriers: Which Follow-up Strategy?. 2015 , 22, 47-51	3
1149	Microarray-based genotyping and detection of drug-resistant HBV mutations from 620 Chinese patients with chronic HBV infection. 2015 , 19, 291-5	8
1148	The use of Chinese herbal medicines associated with reduced mortality in chronic hepatitis B patients receiving lamivudine treatment. 2015 , 174, 161-7	13
1147	Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients. 2015 , 21, 1123.e1-9	13
1146	Cluster-Randomized Trial to Increase Hepatitis B Testing among Koreans in Los Angeles. 2015 , 24, 1341-9	27
1145	Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice. 2015 , 35, 805-15	41
1144	Antiviral therapy for chronic hepatitis B in China. 2015 , 204, 115-20	23
1143	[Hepatitis B virus infection in pregnancy and the immunosuppressed patient]. 2015 , 38, 31-9	
1142	Postpartum care for mothers diagnosed with hepatitis B during pregnancy. 2015 , 212, 365.e1-7	15

1141	Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting. 2015 , 22, 504-10	54
1140	Efficacy of entecavir treatment for up to 96 weeks in nucleoside-naïve HBeAg-positive chronic hepatitis B patients with high viral load. 2015 , 39, 366-72	7
1139	Baseline interpatient hepatitis B viral diversity differentiates HBsAg outcomes in patients treated with tenofovir disoproxil fumarate. 2015 , 62, 1033-9	10
1138	[Hepatitis B virus reactivation in rituximab-treated patients: incidence and risk factors]. 2015 , 38, 1-6	5
1137	Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B. 2015 , 30, 372-8	27
1136	Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. 2015 , 62, 56-63	50
1135	Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. 2015 , 62, 41-7	54
1134	Comparison of acoustic radiation force impulse imaging and transient elastography for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B. 2015 , 41, 7-14	26
1133	Cost effectiveness of response-guided therapy with peginterferon in the treatment of chronic hepatitis B. 2015 , 13, 377-385.e5	6
1132	Liver disease after hematopoietic cell transplantation in adults. 2015 , 29, 8-15	15
1131	Levels of interleukin-35 and its relationship with regulatory T-cells in chronic hepatitis B patients. 2015 , 28, 93-100	13
1130	Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN. 2015 , 64, 139-47	76
1129	Outcomes of patients with chronic hepatitis B who do not meet criteria for antiviral treatment at presentation. 2015 , 13, 193-201.e1	14
1128	Treating Immune-tolerant Hepatitis B. 2015 , 22, 77-84	30
1127	Role of CYP27B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon. 2015 , 22, 318-27	19
1126	Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B. 2015 , 59, 972-8	18
1125	Type 2 diabetes: a risk factor for liver mortality and complications in hepatitis B cirrhosis patients. 2015 , 30, 591-9	42
1124	The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil. 2015 , 22, 328-34	22

1123	HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients. 2015 , 114, 308-13		8
1122	Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. 2015 , 64, 292-302		82
1121	Prevalence and presentation of hepatitis B and C virus (HBV and HCV) infection in Vietnamese Americans via serial community serologic testing. 2015 , 17, 13-20		12
1120	Viral factors and predicting disease outcomes in chronic hepatitis B. 2015 , 64, 191-3		5
1119	Defective natural killer cell anti-viral capacity in paediatric HBV infection. 2015 , 179, 466-76		13
1118	American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. 2015 , 148, 221-244.e3		335
1117	Recent advances in micro/nanotechnologies for global control of hepatitis B infection. 2015 , 33, 178-190		33
1116	A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection. 2015 , 55, 288-97		16
1115	Contemporary assessment of hepatic fibrosis. 2015 , 19, 123-34		22
1114	Chronic liver disease in the human immunodeficiency virus patient. 2015 , 19, 1-22		13
1113	Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. <i>Hepatology</i> , 2015 , 61, 66-76	11.2	141
1112	The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets. 2015 , 235, 355-67		93
1111	Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling. 2015 , 60, 566-72		34
1110	Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases. 2015 , 22, 346-52		36
1109	Serum microRNA-124 is a novel biomarker for liver necroinflammation in patients with chronic hepatitis B virus infection. 2015 , 22, 128-36		22
1108	Noninvasive assessments of liver fibrosis with transient elastography and Hui index predict survival in patients with chronic hepatitis B. 2015 , 30, 582-90		10
1107	Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production. 2015 , 148, 403-14.e7		35
1106	Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab. 2015 , 56, 1611-8		9

1105	Characterization of chronic hepatitis B cases among foreign-born persons in six population-based surveillance sites, United States 2001-2010. 2015 , 17, 7-12		9
1104	Response to hepatitis B vaccination among HIV-infected adults in Vietnam. 2016 , 2, 102-106		6
1103	Treatment with lamivudine and entecavir in severe acute hepatitis B. 2016 , 34, 166-72		10
1102	Quantitative Molecular Methods. 2016 , 145-166		
1101	Hepatitis B Virus. 2016 , 713-770		
1100	Comparison of efficacy and renal safety of telbivudine and entecavir in treatment-naive elderly patients with chronic hepatitis B. 2016 , 28, 193-8		3
1099	Function and Regulation of MicroRNAs and Their Potential as Biomarkers in Paediatric Liver Disease. 2016 , 17,		21
1098	Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , 2016 , 22, 8314-8321	5.6	35
1097	PREVALENCE OF OCCULT HEPATITIS B INFECTION IN IRANIAN CANCER PATIENTS BEFORE CHEMOTHERAPY TREATMENT. 2016 , 53, 175-9		4
1096	Adefovir dipivoxil is less expensive than lamivudine and associated with similar prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after radical resection. 2016 , 9, 6897-6907		6
1095	KASL clinical practice guidelines: management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2016 , 22, 18-75	6.9	141
1094	Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations. 2016 , 8, 385-94		51
1093	The Author's Response: Anti-Viral Therapy for Compensated Liver Cirrhosis Patients with Normal Alanine Aminotransferase. 2016 , 31, 825-6		1
1092	Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma. 2016 , 10, 939-947		12
1091	HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b. 2016 , 129, 2212-9		12
1090	Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. <i>World Journal of Gastroenterology</i> , 2016 , 22, 6484-500	5.6	58
1089	Impact of weight reduction program on serum alanine aminotransferase activity and immunologic response in obese hepatitis B patients. 2016 , 16, 128-34		0
1088	Hepatitis B virus and its sexually transmitted infection - an update. 2016 , 3, 420-437		55

1087	Hepatitis B Serology in Patients with Rheumatic Diseases. 2016 , 10, 39-48		13
1086	Prevention of Hepatitis B reactivation in the setting of immunosuppression. <i>Clinical and Molecular Hepatology</i> , 2016 , 22, 219-37	6.9	73
1085	Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNA. 2016 , 2016, 6725073		10
1084	Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016 , 22, 262-74	5.6	80
1083	Simple models based on gamma-glutamyl transpeptidase and platelets for predicting survival in hepatitis B-associated hepatocellular carcinoma. 2016 , 9, 2099-109		17
1082	Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients. 2016 , 10, 897-910		5
1081	The Honolulu Liver Disease Cluster at the Medical Center: Its Mysteries and Challenges. 2016 , 17, 476		24
1080	The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy. 2016 , 11, e0164210		6
1079	Dry Blood Spots a Reliable Method for Measurement of Hepatitis B Viral Load in Resource-Limited Settings. 2016 , 11, e0166201		17
1078	Hepatitis B surface antigen escape mutations: Indications for initiation of antiviral therapy revisited. 2016 , 4, 71-5		11
1077	The mystery of the Hawaii liver disease cluster in summer 2013: A pragmatic and clinical approach to solve the problem. 2016 , 15, 91-109		29
1076	Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-Screened. 2016 , 16, e35810		25
1075	Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2016 , 22, 152-9	6.9	
1074	Treatment Outcomes With First-line Therapies With Entecavir and Tenofovir in Treatment-Naive Chronic Hepatitis B Patients in a Routine Clinical Practice. 2016 , 50, 169-74		18
1073	Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy. 2016 , 50, 338-44		2
1072	Postpartum Laboratory Follow-up in Women With Hepatitis B in Massachusetts From 2007 to 2012. 2016 , 50, e60-4		8
1071	Histologic Disease in Chinese Chronic Hepatitis B Patients With Low Viral Loads and Persistently Normal Alanine Aminotransferase Levels. 2016 , 50, 790-6		14
1070	Serum Interleukin (IL)-9 and IL-10, but not T-Helper 9 (Th9) Cells, are Associated With Survival of Patients With Acute-on-Chronic Hepatitis B Liver Failure. <i>Medicine (United States)</i> , 2016 , 95, e3405	1.8	16

1069	Transient Elastography is Superior to FIB-4 in Assessing the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. <i>Medicine (United States)</i> , 2016 , 95, e3434	1.8	10
1068	The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B. 2016 , 71, 281-6		17
1067	Antiviral effects of Stichopus japonicus acid mucopolysaccharide on hepatitis B virus transgenic mice. 2016 , 15, 719-725		2
1066	Pretransplant Hepatitis B Viral Infection Increases Risk of Death After Kidney Transplantation: A Multicenter Cohort Study in Korea. <i>Medicine (United States)</i> , 2016 , 95, e3671	1.8	16
1065	Measuring spleen stiffness to predict varices in chronic hepatitis B cirrhotic patients with or without receiving non-selective beta-blockers. 2016 , 17, 538-546		25
1064	Effect of prior hepatitis B virus exposure on long-term risk of liver-related events after liver transplantation. 2016 , 30, 579-88		3
1063	Comparative efficacy of antiviral therapy in preventing vertical transmission of hepatitis B: a network meta-analysis. 2016 , 36, 634-41		15
1062	Cost-effectiveness of quantitative hepatitis B virus surface antigen testing in pregnancy in predicting vertical transmission risk. 2016 , 36, 1604-1610		10
1061	Efficacy and safety of tenofovir, entecavir, and telbivudine for chronic hepatitis B in heart transplant recipients. 2016 , 18, 319-25		4
1060	Relationship Between Hepatic Steatosis and the Elevation of Aminotransferases in HBV-Infected Patients With HBe-Antigen Negativity and a Low Viral Load. <i>Medicine (United States)</i> , 2016 , 95, e3565	1.8	12
1059	Tenofovir monotherapy for hepatitis B after 1 year does not produce renal dysfunction, but is associated with hyperparathyroidism not related to vitamin D. 2016 , 28, 64-9		7
1058	Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B. <i>Hepatology</i> , 2016 , 63, 377-87	11.2	59
1057	Quality of care metrics in chronic hepatitis B. <i>Hepatology</i> , 2016 , 63, 1755-8	11.2	2
1056	Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis. 2016 , 88, 1576-86		5
1055	Identification of FDA-approved drugs that target hepatitis B virus transcription. 2016 , 23, 191-201		15
1054	Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study. 2016 , 36, 1108-15		18
1053	High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma. 2016 , 88, 1010-7		38
1052	Nested case-control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance. 2016 , 43, 1197-207		16

1051	Care delivery and outcomes among US veterans with hepatitis B: A national cohort study. <i>Hepatology</i> , 2016 , 63, 1774-82	11.2	23
1050	Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. <i>Hepatology</i> , 2016 , 63, 1481-92	11.2	153
1049	Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations. 2016 , 50, 286-94		36
1048	Long-term follow up of peginterferon- α 2a treatment of hepatitis B e-antigen (HBeAg) positive and HBeAg negative chronic hepatitis B patients in phase II and III studies. 2016 , 46, 992-1001		4
1047	Prediction model for sustained hepatitis B e antigen seroconversion to peginterferon alfa-2a in chronic hepatitis B. 2016 , 31, 1963-1970		8
1046	Fluctuation of Viremia in Hepatitis B Virus-Infected Healthcare Workers Performing Exposure-Prone Procedures in the Netherlands. 2016 , 37, 655-60		3
1045	Prediction of virologic response to tenofovir mono-rescue therapy for multidrug resistant chronic hepatitis B. 2016 , 88, 1027-34		8
1044	Flares during long-term entecavir therapy in chronic hepatitis B. 2016 , 31, 1882-1887		7
1043	Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents' era. 2016 , 95, 1465-72		9
1042	Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression. <i>Hepatology</i> , 2016 , 64, 381-9	11.2	76
1041	Reply. 2016 , 68, 725-6		1
1040	Comparison of clinical efficacy and renal safety of telbivudine and entecavir in chronic hepatitis B patients receiving cytotoxic chemotherapy. 2016 , 17, 325-33		2
1039	Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance. 2016 , 43, 1253-61		47
1038	Alanine aminotransferase course, serum hepatitis B virus DNA, and liver stiffness measurement for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B. 2016 , 46, 1347-1357		5
1037	Long-term efficacy of Peg-Interferon/Ribavirin with and without Lamivudine therapy for HBeAg-positive hepatitis B and C dual infection. 2016 , 31, 835-41		6
1036	A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response. 2016 , 23, 427-38		24
1035	Up-regulation of A20 gene expression in peripheral blood mononuclear cells is associated with acute-on-chronic hepatitis B liver failure. 2016 , 23, 180-90		5
1034	Clinical impact of five large-scale screening projects for chronic hepatitis B in Chinese migrants in the Netherlands. 2016 , 36, 1425-32		9

1033	Factors associated with HBV virological breakthrough. 2017 , 22, 53-60		9
1032	Testing and Linking Foreign-Born People with Chronic Hepatitis B Virus Infection to Care at Nine U.S. Programs, 2012-2014. 2016 , 131 Suppl 2, 20-8		14
1031	Bibliometric analysis of the top-cited gastroenterology and hepatology articles. 2016 , 6, e009889		29
1030	Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon- α : 1 year follow-up of the OSST study. 2016 , 21, 337-44		32
1029	VIRUSES. 2016 , 275-346		
1028	Cost-effectiveness analysis of hepatocellular carcinoma screening by combinations of ultrasound and alpha-fetoprotein among Alaska Native people, 1983-2012. 2016 , 75, 31115		10
1027	Gamma-glutamyl transpeptidase to platelet ratio index is a good noninvasive biomarker for predicting liver fibrosis in Chinese chronic hepatitis B patients. 2016 , 44, 1302-1313		21
1026	UGT2B28 genomic variation is associated with hepatitis B e-antigen seroconversion in response to antiviral therapy. <i>Scientific Reports</i> , 2016 , 6, 34088	4.9	3
1025	Chronic Hepatitis B, C, and D. 2016 , 4,		0
1024	Pluripotent Stem Cell-Derived Hepatocyte-like Cells: A Tool to Study Infectious Disease. 2016 , 4, 147-156		8
1023	Prevalence of hepatitis B and clinical outcomes in inflammatory bowel disease patients in a viral-endemic region. 2016 , 16, 100		4
1022	Comparative transcriptome analysis of peripheral blood mononuclear cells in hepatitis B-related acute-on-chronic liver failure. <i>Scientific Reports</i> , 2016 , 6, 20759	4.9	6
1021	World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015. 2016 , 50, 691-703		8
1020	Assessment of State Perinatal Hepatitis B Prevention Laws. 2016 , 51, e179-e185		3
1019	Prevention of hepatitis B virus-associated liver diseases by antiviral therapy. 2016 , 10, 574-93		15
1018	Tfh cell-mediated humoral immune response and HBsAg level can predict HBeAg seroconversion in chronic hepatitis B patients receiving peginterferon- α therapy. 2016 , 73, 37-45		8
1017	Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. <i>Hepatology</i> , 2016 , 63, 284-306	11.2	281
1016	Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study. 2016 , 65, 674-682		27

1015	A Novel Collaborative Community-Based Hepatitis B Screening and Linkage to Care Program for African Immigrants. 2016 , 62 Suppl 4, S289-97		26
1014	Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure. 2016 , 10, 779-88		17
1013	AASLD guidelines for treatment of chronic hepatitis B. <i>Hepatology</i> , 2016 , 63, 261-83	11.2	1293
1012	Chronic hepatitis B and C infection in the United States: a review of current guidelines, disease burden and cost effectiveness of screening. 2016 , 14, 511-21		14
1011	Knowledge of Hepatitis B Transmission Risks Among Health Workers in Tanzania. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016 , 94, 1100-2	3.2	14
1010	Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg. 2016 , 111, 1286-94		49
1009	Hepatitis B and elders: An underestimated issue. 2016 , 46, 22-8		11
1008	The effect of long-term entecavir therapy on liver histopathology in patients with chronic viral hepatitis B. 2016 , 71, 244-9		4
1007	Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders. 2016 , 16, 917-26		28
1006	Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir. 2016 , 131, 148-55		11
1005	Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy. 2016 , 11, 117-123		2
1004	Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). 2016 , 16, 606-617		89
1003	Hepatitis B and C in Children. 2016 , 83, 1303-1310		2
1002	Serum hepatocyte apoptosis biomarker predicts the presence of significant histological lesion in chronic hepatitis B virus infection. 2016 , 48, 1463-1470		8
1001	Chemotherapy-induced fatal hepatitis B virus reactivation in a small-cell lung cancer patient. 2016 , 5, 382-384		6
1000	Missed treatment in an Italian HBV infected patients cohort: HBV RER. 2016 , 48, 1346-1350		1
999	Hepatobiliary Infections After Solid Organ or Hematopoietic Cell Transplantation. 2016 , 653-673		3
998	Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection. 2016 , 10, 1373-1383		10

997	Chronic Hepatitis B and D. 2016 , 473-479	
996	Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy. 2016 , 12, 421-429	4
995	Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients. 2016 , 23, 905-911	34
994	Viral Hepatitis. 2016 , 121-134	
993	Gastrointestinal and Hepatic Complications. 2016 , 1140-1160	4
992	Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis. 2016 , 38, 1035-43	17
991	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. 2016 , 68, 1-25	717
990	Is there a relationship between hepatitis B surface antibody status and diabetes?. 2016 , 8, 36-7	
989	Serum interferon-inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B. 2016 , 43, 145-53	19
988	Clinical course of 161 untreated and tenofovir-treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region. 2016 , 23, 15-22	41
987	HBV: Do I treat my immunotolerant patients?. 2016 , 36 Suppl 1, 93-9	15
986	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. 2016 , 68, 1-26	1274
985	Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study. 2016 , 43, 134-44	49
984	Hepatitis B virus: new therapeutic perspectives. 2016 , 36 Suppl 1, 85-92	35
983	Bringing to an end mother-to-child transmission of hepatitis B: A role for quantitative hepatitis B surface antigen?. <i>Hepatology</i> , 2016 , 64, 1408-1410	11.2 1
982	Editorial Commentary: Sliding Down the Cascade of Care for Chronic Hepatitis B Virus Infection. 2016 , 63, 1209-1211	3
981	Fibromyalgia incidence among patients with hepatitis B infection. 2016 , 19, 637-43	7
980	Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection. 2016 , 44, 653-61	22

979	Treatment of Hepatitis B: A Concise Review. 2016 , 7, e190		19
978	Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature. 2016 , 23, 545-59		35
977	CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 21-2016. A 32-Year-Old Man in an Unresponsive State. 2016 , 375, 163-71		2
976	Delayed HBV reactivation in rituximab-containing chemotherapy: How long should we continue anti-virus prophylaxis or monitoring HBV-DNA?. 2016 , 50, 46-49		31
975	Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis. 2016 , 164, 30-40		101
974	Factors associated with significant liver necroinflammation in chronic hepatitis B patients with cirrhosis. <i>Scientific Reports</i> , 2016 , 6, 33093	4.9	3
973	Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. 2016 , 27, 2172-2184		43
972	The Cascade of Care in Chronic Hepatitis B. 2016 , 15, 209-219		9
971	Chronic hepatitis B which converting to HBs antigen negativity and HBs antibody positivity during Peg-IFN α treatment after surgery for hepatocellular carcinoma: a case report. 2016 , 57, 666-673		
970	Identification and clinical significance of an elevated level of serum aminoacylase-1 autoantibody in patients with hepatitis B virus-related liver cirrhosis. 2016 , 14, 4255-4262		9
969	Early Identification and Linkage to Care of Foreign-Born People with Chronic Hepatitis B Virus Infection, Multnomah County, Oregon, 2012-2014. 2016 , 131 Suppl 2, 105-11		6
968	Impact of the Hepatitis Testing and Linkage to Care (HepTLC) Initiative on Linkage to Care for Minnesota Refugees with Hepatitis B, 2012-2014. 2016 , 131 Suppl 2, 112-8		4
967	An evaluation of entecavir treatment among nucleos(t)ide-naïve Moroccan patients with chronic hepatitis B. 2016 , 3, e000081		
966	Hepatitis B virus infection in Chinese patients with hepatitis C virus infection: prevalence, clinical characteristics, viral interactions and host genotypes: a nationwide cross-sectional study. 2016 , 6, e012016		10
965	HBsAg and HBeAg in the prediction of a clinical response to peginterferon α 2b therapy in Chinese HBeAg-positive patients. 2016 , 13, 180		4
964	HBV-associated intrahepatic cholangiocarcinoma with high serum alpha-fetoprotein: a case report with review of literature. 2016 , 16, 295		3
963	Vitamin D serum level is associated with Child-Pugh score and metabolic enzyme imbalances, but not viral load in chronic hepatitis B patients. <i>Medicine (United States)</i> , 2016 , 95, e3926	1.8	26
962	Protective effect of an improved immunization practice of mother-to-infant transmission of hepatitis B virus and risk factors associated with immunoprophylaxis failure. <i>Medicine (United States)</i> , 2016 , 95, e4390	1.8	22

961	On-treatment and off-treatment efficacy of entecavir in a real-life cohort of chronic hepatitis B patients. 2016 , 28, 1179-87		8
960	Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis. <i>Medicine (United States)</i> , 2016 , 95, e4433	1.8	25
959	Poor adherence and low persistency rates for hepatocellular carcinoma surveillance in patients with chronic hepatitis B. <i>Medicine (United States)</i> , 2016 , 95, e4744	1.8	24
958	The distribution of hepatitis B virus exposure and infection in a population-based sample of U.S. Hispanic adults. <i>Hepatology</i> , 2016 , 63, 445-52	11.2	6
957	Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA . 2016 , 72, 39-45		18
956	Clinical implication of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level on hepatitis B e-antigen loss or seroconversion in hepatitis B e-antigen positive patients. 2016 , 46, 1065-1073		10
955	Screening rate for hepatitis B virus infection in patients undergoing chemotherapy in Japan. 2016 , 21, 1162-1166		10
954	Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China. 2016 , 10, 924-936		8
953	Analysis of baseline hepatitis B virus DNA levels in chronic hepatitis B patients with non-hematological malignancies prior to the initiation of cancer chemotherapy. 2016 , 5, 165-170		
952	Long-term follow-up of HBsAg-positive patients in Germany. 2016 , 28, 48-56		5
951	Impact of HBeAg on the maturation and function of dendritic cells. 2016 , 46, 42-8		12
950	Effects of nucleos(t)ide analogs on body composition in HBV-infected men: An age- and BMI-matched, cross-sectional study. 2016 , 32, 1206-10		4
949	Quantification of Transfusion Recipients at Risk of Receiving Hepatitis B Virus-Contaminated Blood Components: A Korean Study. 2016 , 32, 312-9		
948	HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics. 2016 , 65, 48-56		88
947	Mutations in the S gene and in the overlapping reverse transcriptase region in chronic hepatitis B Chinese patients with coexistence of HBsAg and anti-HBs. 2016 , 20, 1-7		12
946	Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B. 2016 , 16, 38		12
945	A community- based hepatitis B linkage-to-care program: a case study on Asian Americans chronically infected with hepatitis B virus. 2016 , 1, 6		4
944	Sci-B-Vac TM Vs ENGERIX-B Vaccines for Hepatitis B Virus in Patients with Inflammatory Bowel Diseases: A Randomised Controlled Trial. 2016 , 10, 905-12		9

943	Hepatitis B knowledge among key stakeholders in Haimen City, China: Implications for addressing chronic HBV infection. 2016 , 1, 4	4
942	Fatigue in Patients with Chronic Hepatitis B Living in North America: Results from the Hepatitis B Research Network (HBRN). 2016 , 61, 1186-96	17
941	Association between hepatitis B virus infection and risk of multiple myeloma: a systematic review and meta-analysis. 2016 , 46, 307-14	8
940	Discontinuity of care for mothers with chronic hepatitis B diagnosed during pregnancy. 2016 , 23, 561-8	9
939	Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B. 2016 , 14, 1647-1656.e6	29
938	Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. 2016 , 65, 852-60	62
937	Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience. 2016 , 22, 95.e1-95.e7	40
936	Oral oxymatrine preparation for chronic hepatitis B: A systematic review of randomized controlled trials. 2016 , 22, 141-9	8
935	Prevention of HBV reactivation in patients treated with biologic agents. 2016 , 9, 579-589	8
934	Hepatitis B: treatment choice and monitoring for response and resistance. 2016 , 10, 697-707	10
933	New therapeutic agents for chronic hepatitis B. 2016 , 16, e10-21	49
932	Clinical Virology: Diagnosis and Virologic Monitoring. 2016 , 205-216	
931	The Lumipulse G HBsAg-Quant assay for screening and quantification of the hepatitis B surface antigen. 2016 , 228, 39-47	16
930	Prevention and management of hepatitis B virus reactivation in cancer patients. 2016 , 10, 407-14	16
929	A novel method for nucleos(t)ide analogues susceptibility assay of hepatitis B virus by viral polymerase transcomplementation. 2016 , 126, 99-107	1
928	Resultados en la práctica clínica del tratamiento de la hepatitis crónica por virus B con tenofovir y entecavir. 2016 , 20, 123-129	
927	Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis. 2016 , 14, 461-468.e2	18
926	Infection and Cancer: The Case of Hepatitis B. 2016 , 34, 83-90	105

925	Efficacy of tenofovir-based rescue therapy in patients with lamivudine-resistant hepatitis B virus: A systematic review and meta-analysis. 2016 , 40, 447-56		4
924	Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B. 2016 , 213, 966-74		44
923	Mutation Changes in the preC/Core Promoter in HBeAg-Positive Patients With Chronic Hepatitis B During Interferon Therapy. <i>Medicine (United States)</i> , 2016 , 95, e2657	1.8	4
922	A Retrospective Study on the Significance of Liver Biopsy and Hepatitis B Surface Antigen in Chronic Hepatitis B Infection. <i>Medicine (United States)</i> , 2016 , 95, e2503	1.8	11
921	Gastroenterologists Have Suboptimal Hepatitis B Virus Screening Rates in Patients Receiving Immunosuppressive Therapy. 2016 , 61, 2236-2241		9
920	Vaccinations for rheumatoid arthritis. 2016 , 28, 330-6		15
919	Utility of Prediction Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues. 2016 , 90, 199-208		7
918	Efficacy of interferon for chronic hepatitis B in patients with nucleoside and nucleotide combination therapy failure. 2016 , 31, 248-55		2
917	The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients. 2016 , 31, 546-52		15
916	Hepatitis B: 50 years after the discovery of Australia antigen. 2016 , 23, 5-14		21
915	Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. <i>Hepatology</i> , 2016 , 63, 319-33	11.2	209
914	The prognosis and management of inactive HBV carriers. 2016 , 36 Suppl 1, 100-4		39
913	Development of an in-House TaqMan Real-Time PCR-Based Method to Detect Residual Host Cell DNA in HBV Vaccine. 2016 , 179, 375-82		10
912	Long-Term Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleos(t)ide-Experienced Chronic Hepatitis B Patients. 2016 , 36, 471-8		2
911	Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: A Thai nationwide cohort study. 2016 , 31, 1874-1881		9
910	Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up. 2016 , 14, 1481-1489.e5		36
909	Management of mother-to-child transmission of hepatitis B virus: Propositions and challenges. 2016 , 77, 32-9		53
908	Combination of Pegylated Interferon and Tenofovir for Hepatitis B Treatment: Screening and Counseling of Patients are Warranted. 2016 , 150, 32-4		1

907	Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma. 2016 , 57, 1355-62	31
906	Coinfection with Hepatitis B or C in People Living with HIV Undergoing Immunosuppressive Therapy. 2016 , 227-234	
905	Intérêt du FibroScan [®] et des marqueurs biologiques de la fibrose hépatique, chez des sénégalais porteurs chroniques du virus de l'hépatite B faiblement répliquatifs. 2016 , 10, 14-20	
904	Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France. 2016 , 61, 3072-3083	53
903	Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies. 2016 , 51, 999-1010	28
902	How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma?. 2016 , 17, 911-9	9
901	Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation. 2016 , 18, 4	5
900	Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose. 2016 , 214, 16-22	148
899	Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia. 2016 , 30, 201-11	20
898	Multiple Hepatitis B Virus (HBV) Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients With Acute Hepatitis B. 2016 , 213, 1897-905	33
897	Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients. 2016 , 32, 10-5	1
896	Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study. 2016 , 43, 869-74	37
895	Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. 2016 , 150, 684-695.e5	126
894	Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. 2016 , 51, 830-9	61
893	Rates of Treatment Eligibility in Follow-Up of Patients with Chronic Hepatitis B (CHB) Across Various Clinical Settings Who Were Initially Ineligible at Presentation. 2016 , 61, 618-25	11
892	Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). 2016 , 64, 1011-1019	61
891	Lymphoproliferative Disease and Hepatitis B Reactivation: Challenges in the Era of Rapidly Evolving Targeted Therapy. 2016 , 16, 5-11	11
890	Hepatitis B and cancer: A practical guide for the oncologist. 2016 , 98, 137-46	23

889	Reactivation of Hepatitis B Virus Due to Cancer Chemotherapy and Other Immunosuppressive Drug Therapy. 2016 , 399-431	
888	A label-free electrochemical immunosensor for hepatitis B based on hyaluronic acid-carbon nanotube hybrid film. 2016 , 148, 209-15	42
887	An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults. 2016 , 10, 177-86	7
886	Acute hepatitis B virus infection or acute exacerbation of chronic hepatitis B infection: the differential serological diagnosis. 2016 , 35, 29-40	13
885	Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. 2016 , 64, 773-80	169
884	Management of hepatitis B during pregnancy. 2016 , 17, 301-10	6
883	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. 2016 , 10, 1-98	1288
882	Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result. 2016 , 16, 429-36	47
881	Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia. 2016 , 65, 2007-2016	83
880	Combination of Tenofovir Disoproxil Fumarate and Peginterferon α 2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. 2016 , 150, 134-144.e10	219
879	Screening for viral hepatitis prior to rituximab chemotherapy. 2016 , 95, 27-33	7
878	Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan. 2016 , 10, 294-301	2
877	#38: Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission. 2016 , 214, 6-14	161
876	Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders. 2016 , 65, 340-50	52
875	Identification of the transcriptional regulators by expression profiling infected with hepatitis B virus. 2016 , 40, 57-72	1
874	Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. 2016 , 65, 313-20	85
873	Extended duration versus standard duration of peginterferon alfa-2a in treatment of chronic hepatitis B: A systematic review and meta-analysis. 2016 , 40, 195-202	3
872	Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014. 2016 , 10, 139-46	7

871	Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues. 2016 , 213, 224-32		102
870	Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. 2016 , 65, 1042-51		69
869	The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection. 2016 , 65, 1347-58		33
868	HBV reactivation risk factors in patients with chronic HBV infection with low replicative state and resolved HBV infection undergoing hematopoietic stem cell transplantation in Korea. 2017 , 11, 87-95		5
867	Reply to Letter: "Adjuvant Antiviral Therapy With Nucleos(t)ide Analogs in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma". 2017 , 265, e47-e48		
866	Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic. 2017 , 32, 451-458		14
865	Nucleos(t)ide analogs improve long-term prognosis in patients with chronic hepatitis B-associated liver failure. 2017 , 47, 347-358		3
864	The LAW index as an accurate indicator of the initiation of antiviral treatment in patients with chronic hepatitis B. 2017 , 32, 208-214		2
863	The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. <i>Hepatology</i> , 2017 , 65, 1840-1850	11.2	51
862	Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients. 2017 , 49, 530-534		6
861	Hypermethylation of the galectin-3 promoter is associated with poor prognosis of acute-on-chronic hepatitis B liver failure. 2017 , 49, 664-671		5
860	Hepatitis B virus reactivation after cessation of prophylaxis with entecavir in a patient with Burkitt type acute lymphoblastic leukaemia treated with rituximab. 2017 , 40, 470-471		0
859	Characteristics and course of chronic hepatitis B e antigen-negative infection. 2017 , 40, 59-69		5
858	Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. 2017 , 23, 581-587		12
857	Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy. 2017 , 24, 599-607		31
856	Antiviral therapies for managing viral hepatitis in lymphoma patients. 2017 , 18, 363-376		9
855	Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. 2017 , 31, 1853-1859		24
854	Characterization of contrasting features between hepatitis B virus genotype A and genotype D in small envelope protein expression and surface antigen secretion. 2017 , 503, 52-61		11

853	Impact of universal infant hepatitis B vaccination in the US-affiliated Pacific Islands, 1985-2015. 2017 , 35, 997-1000	5
852	Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management. 2017 , 24, 561-572	15
851	Dynamic Changes in Liver Stiffness Measured by Transient Elastography Predict Clinical Outcomes Among Patients With Chronic Hepatitis B. 2017 , 36, 261-268	36
850	Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis. <i>Hepatology</i> , 2017 , 66, 379-388	11.2 95
849	Hepatitis B reactivation in patients receiving immunosuppressive therapy: a hidden menace. 2017 , 11, 31-33	4
848	A novel noninvasive algorithm for the assessment of liver fibrosis in patients with chronic hepatitis B virus infection. 2017 , 24, 589-598	18
847	A noninvasive diagnostic model to assess nonalcoholic hepatic steatosis in patients with chronic hepatitis B. 2017 , 10, 207-217	35
846	Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. 2017 , 152, 1297-1309	297
845	Are non-invasive fibrosis markers for chronic hepatitis B reliable in sub-Saharan Africa?. 2017 , 37, 1461-1467	27
844	Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy. 2017 , 15, 479-490	7
843	Significance of anti-HBc alone serological status in clinical practice. 2017 , 2, 123-134	28
842	Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomized controlled trial. 2017 , 9, 177-183	59
841	Platelet counts modulate the quantitative relationship between hepatitis B viral DNA and surface antigen concentrations: a cross-sectional study of hematological, histological and viral factors. 2017 , 17, 9	1
840	Hepatocellular carcinoma suppressor 1 promoter hypermethylation in serum. A diagnostic and prognostic study in hepatitis B. 2017 , 41, 171-180	16
839	Gastrointestinal and Hepatic Complications in Cancer Patients. 2017 , 1-16	
838	Chronic hepatitis: Epidemiology, clinical features, and management. 2017 , 1058-1064.e2	
837	Hepatic Issues and Complications Associated With Inflammatory Bowel Disease: A Clinical Report From the NASPGHAN Inflammatory Bowel Disease and Hepatology Committees. 2017 , 64, 639-652	18
836	Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir. 2017 , 37, 1788-1795	31

835	Hepatitis B reactivation in patients receiving targeted therapies. 2017 , 22, 592-598		13
834	Predictors of HBeAg seroconversion after long-term nucleos(t)ide analogues treatment for chronic hepatitis B: a multicenter study in real clinical setting. 2017 , 21, 213-218		1
833	Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. 2017 , 10, 707-716		21
832	Characterization of Cerebral Edema in Acute-on-Chronic Liver Failure. 2017 , 7, 190-197		12
831	Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review. 2017 , 123, 751-758		40
830	Epidemiology of hepatitis B and the role of vaccination. 2017 , 31, 239-247		30
829	Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG. <i>Scientific Reports</i> , 2017 , 7, 1957	4.9	3
828	Biosensing of hepatitis B antigen with poly(acrylic acid) hydrogel immobilized with antigens and antibodies. 2017 , 252, 409-417		16
827	Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON). 2017 , 215, 1085-1093		33
826	Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B. 2017 , 29, 946-950		4
825	Novel therapies and potential therapeutic targets in the management of chronic hepatitis B. 2017 , 29, 987-993		4
824	Hepatitis B serological markers and plasma DNA concentrations. 2017 , 31, 1109-1117		8
823	HBV Therapy and the Problem of Drug Resistance. 2017 , 3-20		1
822	Using health-system-wide data to understand hepatitis B virus prophylaxis and reactivation outcomes in patients receiving rituximab. <i>Medicine (United States)</i> , 2017 , 96, e6528	1.8	8
821	Characteristics and course of chronic hepatitis B e antigen-negative infection. 2017 , 40, 59-69		2
820	Prevalence of Human Immunodeficiency Virus, Hepatitis C Virus, and Hepatitis B Virus Among Homeless and Nonhomeless United States Veterans. 2017 , 65, 252-258		36
819	Comparison of the long-term efficacy between entecavir and tenofovir in treatment-naïve chronic hepatitis B patients. 2017 , 17, 39		27
818	Discontinuation of lamivudine treatment in HBeAg-negative chronic hepatitis B: a pilot study with long-term follow-up. 2017 , 22, 559-570		5

817	Widespread geographical disparities in chronic hepatitis B virus infection in Algeria. 2017 , 162, 1641-1648		5
816	Assessing the clinical and economic impact of increasing treatment uptake in chronic hepatitis B infection using a Markov model. 2017 , 32, 1370-1377		2
815	Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. <i>Hepatology</i> , 2017 , 65, 804-812	11.2	160
814	Lamivudine therapy during the second vs the third trimester for preventing transmission of chronic hepatitis B. 2017 , 24, 246-252		24
813	Seroprevalence of Hepatitis B Infection Among Immigrants in a Primary Care Clinic: A Case for Granular Ethnicity and Language Data Collection. 2017 , 19, 987-990		3
812	Antiviral Therapy Inhibits Viral Reactivation and Improves Survival after Repeat Hepatectomy for Hepatitis B Virus-Related Recurrent Hepatocellular Carcinoma. 2017 , 224, 283-293.e4		15
811	Determination of hepatitis B phenotype using biochemical and serological markers. 2017 , 24, 320-329		34
810	Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. 2017 , 66, 897-909		83
809	Core I97L mutation in conjunction with P79Q is associated with persistent low HBV DNA and HBs antigen clearance in patients with chronic hepatitis B. 2017 , 23, 407.e1-407.e7		2
808	ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. 2017 , 112, 18-35		384
807	Stability of Chronic Hepatitis-Related Parameters in Serum Samples After Long-Term Storage. 2017 , 15, 211-219		3
806	Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients. <i>Scientific Reports</i> , 2017 , 7, 14352	4.9	19
805	Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody-A Review of New Issues. 2017 , 112, 1780-1788		16
804	Elevated serum prostaglandin E2 predicts the risk of infection in hepatitis B virus-related acute-on-chronic liver failure patients. 2017 , 10, 916-920		1
803	Screening, prophylaxis and counselling before the start of biological therapies: A practical approach focused on IBD patients. 2017 , 49, 1289-1297		15
802	Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection. 2017 , 147, 75-85		8
801	Comparison of the efficacy of Gd-EOB-DTPA-enhanced magnetic resonance imaging and magnetic resonance elastography in the detection and staging of hepatic fibrosis. <i>Medicine (United States)</i> , 2017 , 96, e8339	1.8	7
800	Factors associated with the decrease in hepatitis B surface antigen titers following interferon therapy in patients with chronic hepatitis B: Is interferon and adefovir combination therapy effective?. 2017 , 7, 257-262		3

799	Anti-Rheumatic Therapy and Comorbidity. 2017 , 345-380		
798	Is serum high-mobility group box 1 (HMGB-1) level correlated with liver fibrosis in chronic hepatitis B?. <i>Medicine (United States)</i> , 2017 , 96, e7547	1.8	7
797	Predictors for efficacy of combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B. 2017 , 37, 547-555		4
796	Performance of simple noninvasive scoring systems for the prediction of advanced fibrosis in patients with chronic hepatitis B. 2017 , 29, 1235-1240		3
795	Clinical Course of Partial Virologic Response with Prolonged Tenofovir Therapy in Nucleos(t)ides-Naïve Patients with Chronic Hepatitis B. 2017 , 62, 2908-2914		6
794	Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. 2017 , 67, 918-924		146
793	Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine. <i>Medicine (United States)</i> , 2017 , 96, e7021	1.8	31
792	Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial. 2017 , 2, 576-584		28
791	Viral minority variants in the core promoter and precore region identified by deep sequencing are associated with response to peginterferon and adefovir in HBeAg negative chronic hepatitis B patients. 2017 , 145, 87-95		12
790	Hepatitis B virus reactivation after cessation of prophylaxis with entecavir in a patient with Burkitt type acute lymphoblastic leukaemia treated with rituximab. 2017 , 40, 470-471		
789	Role of quantitative hepatitis B surface antigen in predicting inactive carriers and HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients. <i>Medicine (United States)</i> , 2017 , 96, e6554	1.8	12
788	Provider, Patient, and Practice Factors Shape Hepatitis B Prevention and Management by Primary Care Providers. 2017 , 51, 626-631		23
787	Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience. 2017 , 29, 56-60		4
786	Comparison of the Efficacy of Tenofovir Versus Tenofovir plus Entecavir in the Treatment of Chronic Hepatitis B in Patients With Poor Efficacy of Entecavir: A Systematic Review and Meta-analysis. 2017 , 39, 1870-1880		9
785	A robust cell culture system supporting the complete life cycle of hepatitis B virus. <i>Scientific Reports</i> , 2017 , 7, 16616	4.9	37
784	Telbivudine therapy for gravidas with chronic hepatitis B infection and patients at risk of renal impairment. 2017 , 24 Suppl 1, 6-11		1
783	Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy. 2017 , 24 Suppl 1, 21-28		1
782	Association of the S267F variant on NTCP gene and treatment response to pegylated interferon in patients with chronic hepatitis B: a multicentre study. 2018 , 23, 67-75		3

781	Chronic hepatitis B: correlation of abnormal features on T2-weighted imaging and dynamic contrast-enhanced imaging with hepatic histopathology. 2017 , 122, 807-813	2
780	Incidence of Low Seroimmunity to Hepatitis B Virus in Children With Inflammatory Bowel Disease. 2017 , 65, 551-554	10
779	Current Condition of Chronic Hepatitis B Virus Infection in Cuban Adults. 2017 , 85, 15-19	4
778	Identifying Patient and Provider-specific Gaps in Care Among Patients With Hepatitis B. 2017 , 51, 900-906	4
777	Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial. 2017 , 17, 15	10
776	Prevalence and clinical outcomes of hepatitis B virus infection in patients with aplastic anemia. 2017 , 106, 484-489	2
775	Drugs in Development for Hepatitis B. 2017 , 77, 1263-1280	21
774	Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: a systematic review. 2017 , 23, 916-923	26
773	Impact of Hepatic and Extrahepatic Insults on the Outcome of Acute-on-Chronic Liver Failure. 2017 , 7, 9-15	11
772	Hepatitis B Reactivation in Rheumatic Diseases: Screening and Prevention. 2017 , 43, 133-149	29
771	Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers. 2017 , 6, 350-362	58
770	High risk of occult hepatitis B virus infection in leukemia patients from China. 2017 , 162, 349-357	7
769	Efficacy and safety of tenofovir disoproxil fumarate rescue therapy for chronic hepatitis B patients who failed other nucleos(t)ide analogs. 2017 , 47, 1032-1041	8
768	Genotypic profiles of hepatitis B in African immigrants and their clinical relevance. 2017 , 89, 1000-1007	7
767	Antiviral response is not sustained after cessation of lamivudine treatment in chronic hepatitis B patients: A 10-year follow-up study. 2017 , 89, 849-856	8
766	Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance. 2017 , 24, 141-147	22
765	Vaccines and Disease-Modifying Antirheumatic Drugs: Practical Implications for the Rheumatologist. 2017 , 43, 1-13	44
764	Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon- α . 2017 , 47, 747-754	17

763	Clinical Manifestations of Acute and Chronic Hepatitis. 2017 , 363-374.e4	
762	Infections Associated with Immunobiologics. 2017 , 796-804.e2	
761	Improvements in hepatitis B virus screening before rituximab therapy: A community-based, safety-net hospital experience. 2017 , 123, 650-656	4
760	High promoter methylation levels of glutathione-S-transferase M3 predict poor prognosis of acute-on-chronic hepatitis B liver failure. 2017 , 47, 566-573	5
759	Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B. 2017 , 33, 495-504	12
758	A combination of different diagnostic tools allows identification of inactive hepatitis B virus carriers at a single time point evaluation. 2017 , 37, 362-368	12
757	Estimation of Upper Limit of Normal for Serum Alanine Transaminase in Healthy South Indian Population. 2017 , 32, 337-342	3
756	The Liver in Pregnancy. 2017 , 244-267	
755	Racial/ethnic disparities in the prevalence and awareness of Hepatitis B virus infection and immunity in the United States. 2017 , 24, 1052-1066	33
754	Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). 2017 , 5, 297-318	136
753	Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience. 2017 , 9, 48-56	19
752	Efficacy of Real-world Entecavir Therapy in Treatment-naïve Chronic Hepatitis B Patients. 2017 , 130, 2190-2197	6
751	New Antiretrovirals for HIV and Antivirals for HBV. 2017 , 628-664	
750	Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks. 2017 , 9,	35
749	Comparison of the QIAGEN artus HBV QS-RGQ Assay With the Roche COBAS AmpliPrep/COBAS TaqMan HBV Assay for Quantifying Viral DNA in Sera of Chronic Hepatitis B Patients. 2017 , 37, 248-253	7
748	Modulation of Tim-3 Expression by Antigen-Dependent and -Independent Factors on T Cells from Patients with Chronic Hepatitis B Virus Infection. 2017 , 7, 98	7
747	Add-on Pegylated Interferon Alpha-2a Therapy in Chronic Hepatitis B Japanese Patients Treated with Entecavir. 2017 , 2017, 2093847	2
746	Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. 2017 , 12, e0184550	32

745	Addition of nucleoside analogues to peg-IFN α enhances virological response in chronic hepatitis B patients without early response to peg-IFN α : a randomized controlled trial. 2017 , 17, 102		4
744	Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy. 2017 , 17, 154		5
743	Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?. 2017 , 17, 168		12
742	Severe de novo Hepatitis B Recovered from Late-Onset Liver Insufficiency with Prolonged Ascites and Hypoalbuminemia due to Hepatitis B Virus Genotype Bj with Precore Mutation. 2016 , 10, 553-559		2
741	Pediatric hepatitis B treatment. 2017 , 5, 37		12
740	Management of Antiviral Resistance in Chronic Hepatitis B. 2017 , 11, 189-195		29
739	Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response. 2017 , 32, 636-646		10
738	Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B. 2017 , 10, 201-207		12
737	Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management. 2017 , 7, 35-40		7
736	Hepatitis B in patients with hematological diseases: An update. 2017 , 9, 1043-1053		14
735	An Inexpensive Digital Image Analysis Technique for Liver Fibrosis Quantification in Chronic Hepatitis B Patients. 2017 , 16, 881-887		7
734	Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma. 2017 , 16, 198-206		9
733	Value of gamma-glutamyltranspeptidase-to-platelet ratio in diagnosis of hepatic fibrosis in patients with chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2017 , 23, 7425-7432	5.6	25
732	Comparison between tenofovir disoproxil fumarate and entecavir treatment in real-world clinical practice. 2017 , 4, 87-93		
731	Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients. <i>Clinical and Molecular Hepatology</i> , 2017 , 23, 66-73	6.9	9
730	Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir. <i>Clinical and Molecular Hepatology</i> , 2017 , 23, 230-238	6.9	11
729	A novel predictive model using routinely clinical parameters to predict liver fibrosis in patients with chronic hepatitis B. 2017 , 8, 59257-59267		15
728	Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy. 2018 , 33, 1766-1772		4

727	Circulating cell-free DNA of methylated insulin-like growth factor-binding protein 7 predicts a poor prognosis in hepatitis B virus-associated hepatocellular carcinoma after hepatectomy. 2018 , 52, 455-464	15
726	Antiviral Therapy Reduces Hepatocellular Carcinoma Recurrence in Patients With Low HBV-DNA Levels: A Randomized Controlled Trial. 2018 , 268, 943-954	54
725	Utilisation of hepatocellular carcinoma screening in Australians at risk of hepatitis B virus-related carcinoma and prescribed anti-viral therapy. 2018 , 27, 2673-2683	1
724	RFX1 participates in doxorubicin-induced hepatitis B virus reactivation. 2018 , 7, 2021-2033	9
723	Chronic Liver Failure and Hepatic Cirrhosis. 2018 , 21-39	0
722	Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study. 2018 , 52, 201-209	17
721	Systematic review with meta-analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance. 2018 , 47, 1340-1348	27
720	Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. 2018 , 25, 1026-1037	15
719	Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT. 2018 , 46, 385-393	23
718	Cost-effectiveness of antiviral treatment after resection in hepatitis B virus-related hepatocellular carcinoma patients with compensated cirrhosis. <i>Hepatology</i> , 2018 , 68, 1476-1486	11.2 12
717	Clinical connection between rheumatoid arthritis and liver damage. 2018 , 38, 715-724	23
716	Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation. 2018 , 154, 26-34	11
715	Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis. 2018 , 37, 3201-3214	1
714	Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. <i>Hepatology</i> , 2018 , 67, 1560-1599	11.2 1460
713	Performance of the cobas Hepatitis B virus (HBV) test using the cobas 4800 system and comparison of HBV DNA quantification ability between the COBAS AmpliPrep/COBAS TaqMan HBV test version 2.0 and cobas HBV test. 2018 , 101, 47-51	5
712	Hepatitis B and Hepatitis D Viruses. 2018 , 1107-1114.e4	
711	Management of Chronic Hepatitis B: Knowledge and Practices of Physicians in Pakistan. 2018 , 8, 342-351	1
710	Treatment of HCV, HDV, or HIV Coinfection. 2018 , 239-262	2

709	Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic Response Evaluation in Hepatocellular Carcinoma. 2018 , 24, 2203-2213	59
708	Nucleos(t)ide Therapy and Long-Term Outcomes. 2018 , 193-217	1
707	Liver sampling: a vital window into HBV pathogenesis on the path to functional cure. 2018 , 67, 767-775	24
706	Risk of Hepatitis B Virus Reactivation Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection. 2018 , 52, 908-912	8
705	Management of chronic viral hepatitis in the hematological patient. 2018 , 16, 227-241	9
704	Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. 2018 , 93, 545-559	88
703	Safety of biologic agents for psoriasis in patients with viral hepatitis. 2018 , 29, 553-556	7
702	Changes of FibroScan, APRI, and FIB-4 in chronic hepatitis B patients with significant liver histological changes receiving 3-year entecavir therapy. 2018 , 18, 273-282	9
701	Factors associated with non-adherence to HBV antiviral therapy. 2018 , 23, 425-433	6
700	Prophylactic effect of lamivudine on chemotherapy-induced hepatitis B virus reactivation in patients with solid tumour: A meta-analysis. 2018 , 27, e12799	6
699	Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon- α treatment in HBeAg-positive chronic hepatitis B patients. 2018 , 90, 721-729	7
698	Molecular Virology and Life Cycle. 2018 , 1-23	1
697	Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals. 2018 , 25, 707-717	15
696	Microsuspension of fatty acid esters of entecavir for parenteral sustained delivery. 2018 , 543, 52-59	13
695	Increasing co-morbidities in chronic hepatitis B patients: experience in primary care and referral practices during 2000-2015. 2018 , 9, 141	20
694	Neutrophil gelatinase-associated lipocalin accurately predicts renal tubular injury in patients with chronic hepatitis B treated with nucleos(t)ide analogs. 2018 , 48, 144-152	0
693	Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naïve chronic hepatitis B patients. 2018 , 48, 59-68	41
692	Enhanced liver fibrosis test using ELISA assay accurately discriminates advanced stage of liver fibrosis as determined by transient elastography fibroscan in treatment naïve chronic HCV patients. 2018 , 18, 45-50	7

691	Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study. 2018 , 27, 66-75		7
690	Aberrant GSTP1 promoter methylation predicts poor prognosis of acute-on-chronic hepatitis B pre-liver failure. 2018 , 18, 51-62		7
689	The Role of Primary Health Care in Hepatitis B Testing and Management: A Case Study. 2018 , 43, 38-47		5
688	A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma. <i>Hepatology</i> , 2018 , 67, 662-675	11.2	152
687	Liver tissue trace element levels in HepB patients and the relationship of these elements with histological injury in the liver and with clinical parameters. 2018 , 45, 70-77		9
686	Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B. 2018 , 48, E213-E221		14
685	Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. 2018 , 67, 2181-2191		117
684	Role of Age and Race in the Risk of Hepatocellular Carcinoma in Veterans With Hepatitis B Virus Infection. 2018 , 16, 252-259		31
683	Combined detection of insulin-like growth factor-binding protein 7 promoter methylation improves the diagnostic efficacy of AFP in hepatitis B virus-associated hepatocellular carcinoma. 2018 , 214, 144-150		2
682	Increased BATF expression is associated with the severity of liver damage in patients with chronic hepatitis B. 2018 , 18, 263-272		4
681	Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network. 2018 , 63, 61-71		8
680	Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance. 2018 , 90, 497-502		5
679	Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B. 2018 , 50, 163-167		7
678	Pain and Rash in a Stem Cell Transplant Recipient. 2018 , 177-181		
677	Antiviral therapy improves survival in patients with HBV infection and intrahepatic cholangiocarcinoma undergoing liver resection. 2018 , 68, 655-662		19
676	A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia. 2018 , 11, 57-70		23
675	A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients. 2018 , 42, 40-47		10
674	HBsAg-Negative, Anti-HBc-Negative Patients Still Have a Risk of Hepatitis B Virus-Related Hepatitis after Autologous Stem Cell Transplantation for Multiple Myeloma or Malignant Lymphoma. 2018 , 50, 1121-1129		2

673	Screening for Hepatitis B Virus Infection: Are We Asking the Right Questions?. 2018 , 36, 935-936		1
672	Common viral infections in kidney transplant recipients. 2018 , 37, 323-337		36
671	Epidemiology of Hepatitis B viral infection among students and non-teaching (casual) staff of Nile University of Nigeria: A 2017 study. 2018 , 10, 77-86		3
670	Role of the PI3K-AKT-mTOR pathway in hepatitis B virus infection and replication. 2018 , 17, 4713-4719		11
669	Different interventional criteria for chronic hepatitis B pregnant women with HBeAg(+) or HBeAg(-): Epidemiological data from Shaanxi, China. <i>Medicine (United States)</i> , 2018 , 97, e11406	1.8	7
668	Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naïve chronic hepatitis B: A case report and review of the literature. <i>World Journal of Gastroenterology</i> , 2018 , 24, 1919-1924	5.6	17
667	Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status. 2018 , 19, 561-571		13
666	Assessment of histopathological alterations in patients with chronic hepatitis B infection following long-term oral antiviral therapy. 2018 , 39, 999-1005		
665	Risk factors associated with nonalcohol fatty liver disease and fibrosis among patients with type 2 diabetes mellitus. <i>Medicine (United States)</i> , 2018 , 97, e12356	1.8	12
664	HIV and the Liver. 2018 , 536-555.e7		1
663	Adverse events in IBD therapy: the 2018 update. 2018 , 12, 1183-1191		32
662	Serum sphingolipid levels associate with upcoming virologic events and HBV genotype D in a cohort of patients with HBeAg-negative HBV infection. 2018 , 13, e0207293		5
661	Insights into the Interplay between KIR Gene Frequencies and Chronic HBV Infection in Burkina Faso. 2018 , 10, e2018060		4
660	Entecavir-based combination therapies for chronic hepatitis B: A meta-analysis. <i>Medicine (United States)</i> , 2018 , 97, e13596	1.8	1
659	Serum cytoskeleton-associated protein 4 as a biomarker for the diagnosis of hepatocellular carcinoma. 2019 , 12, 359-364		6
658	Silencing TRIP13 inhibits cell growth and metastasis of hepatocellular carcinoma by activating of TGF- β /smad3. 2018 , 18, 208		30
657	Management of chronic hepatitis B during pregnancy. 2018 , 6, 257-262		11
656	Management of anti-HBc-positive patients with rheumatic diseases treated with disease-modifying antirheumatic drugs-a single-center analysis of 2054 patients. 2018 , 37, 2963-2970		13

655	Improvements in the management of chronic hepatitis B virus infection. 2018 , 12, 1153-1166		6
654	Molecular Microbiology. 2018 , 87-124		
653	Evaluation of reliability and performance of hepatitis B virus-e-antigen assays in tertiary care setting. 2018 , 39, 622-635		
652	Decreased Methylation of IFNAR Gene Promoter from Peripheral Blood Mononuclear Cells Is Associated with Oxidative Stress in Chronic Hepatitis B. 2018 , 38, 480-490		1
651	Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study. 2018 , 20, 246		15
650	Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation. <i>Scientific Reports</i> , 2018 , 8, 15629	4.9	9
649	Predictors of Therapeutic Outcome to Nucleotide Reverse Transcriptase Inhibitor in Hepatitis B Patients. 2018 , 31, 632-638		2
648	Evaluation of performance characteristics of hepatitis B e antigen serologic assays. 2018 , 109, 22-28		0
647	Molecular Monitoring of Viral Infections. 2018 , 1, 65-80		
646	Robust Human and Murine Hepatocyte Culture Models of Hepatitis B Virus Infection and Replication. 2018 , 92,		10
645	Disease Characteristics and Change in Arthritis Activity according to Treatment in Hepatitis B Surface Antigen-positive Rheumatoid Arthritis Patients: a Retrospective Chart Review Study. 2018 , 33, e168		
644	Hepatitis B Virus Surface Antigen Enhances the Sensitivity of Hepatocytes to Fas-Mediated Apoptosis via Suppression of AKT Phosphorylation. 2018 , 201, 2303-2314		14
643	Frangulosid as a novel hepatitis B virus DNA polymerase inhibitor: a virtual screening study. 2018 , 6, 10		3
642	Persistently Increased Resting Energy Expenditure Predicts Short-Term Mortality in Patients with Acute-on-Chronic Liver Failure. 2018 , 73, 2-9		0
641	Durability of Telbivudine-Associated Improvement of Renal Function Following Withdrawal or Switching of Antivirals in Chronic Hepatitis B Patients. 2018 , 5, ofx271		3
640	Hepatitis. 2018 , 181-191		
639	48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse. 2018 , 2018, 1817680		9
638	Design and in vivo evaluation of entecavir-3-palmitate microcrystals for subcutaneous sustained delivery. 2018 , 130, 143-151		7

637	Hepatitis B Virus Testing and Care among Pregnant Women Using Commercial Claims Data, United States, 2011-2014. 2018 , 2018, 4107329	8
636	The human C-type lectin 18 is a potential biomarker in patients with chronic hepatitis B virus infection. 2018 , 25, 59	4
635	Fibrosis-4 Model Influences Results of Patients with Hepatocellular Carcinoma Undergoing Hepatectomy. 2018 , 2018, 4305408	2
634	Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)- α on the Liver. 2018 , 19,	35
633	Viral Hepatitis. 2018 , 372-415	3
632	Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence. 2018 , 11, 1756284818786108	15
631	Entecavir versus other oral antiviral drugs for chronic hepatitis B. 2018 ,	78
630	Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B. 2018 , 33, e11	4
629	When Hepatitis B Virus Meets Interferons. 2018 , 9, 1611	38
628	Synthesis and Physicochemical Evaluation of Entecavir-Fatty Acid Conjugates in Reducing Food Effect on Intestinal Absorption. 2018 , 23,	7
627	Modeling the dynamics of hepatitis B infection, immunity, and drug therapy. 2018 , 285, 38-54	22
626	Evaluation of IgG4 levels as a fibrosis marker on disease activity in the course of hepatitis B infection. 2018 , 13, 385-390	1
625	Risk of renal events during tenofovir disoproxil fumarate and entecavir antiviral prophylaxis in HBsAg-positive cancer patients undergoing chemotherapy. 2018 , 25, 1599-1607	4
624	Investigation of the values of CT perfusion imaging and ultrasound elastography in the diagnosis of liver fibrosis. 2018 , 16, 896-900	4
623	Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians. 2018 , 18, 212-218	18
622	Hepatitis B. 2018 , 211-221	
621	Hepatitis B. 2018 , 395-420	
620	Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy: A multicenter study. 2018 , 90, 1593-1603	4

619	Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients. 2018 , 13, e0190581		3
618	Hepatitis B Vaccines. 2018 , 342-374.e17		9
617	A novel risk score for hepatocellular carcinoma in Asian cirrhotic patients: a multicentre prospective cohort study. <i>Scientific Reports</i> , 2018 , 8, 8608	4.9	3
616	Changes in Liver Tissue Trace Element Concentrations During Hepatitis B Viral Infection Treatment. 2019 , 188, 245-250		5
615	Aberrant DNA methylation profile of hepatitis B virus infection. 2019 , 91, 81-92		3
614	Expression Analysis of MicroRNA-21 and MicroRNA-122 in Hepatocellular Carcinoma. 2019 , 9, 294-301		12
613	Investigation of hepatitis B virus (HBV) rtS78T/sC69* mutation in a large cohort of chronic HBV-infected patients with nucleoside/nucleotide analogue treatment. 2019 , 170, 104579		4
612	KASL clinical practice guidelines for management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2019 , 25, 93-159	6.9	87
611	Association between abdominal obesity and liver steatosis and fibrosis among patients with chronic hepatitis B measured by Fibroscan. 2019 , 18, 1891-1898		1
610	Community-Based Strategies to Improve Screening, Diagnosis and Linkage to Care for Patients with Chronic Hepatitis B. 2019 , 18, 342-356		
609	Vaccination in Organ Transplant Patients. 2019 , 1095-1109		1
608	Prediction and clinical implications of HBV reactivation in lymphoma patients with resolved HBV infection: focus on anti-HBs and anti-HBc antibody titers. 2019 , 13, 407-415		8
607	Identification of hepadnavirus in the sera of cats. <i>Scientific Reports</i> , 2019 , 9, 10668	4.9	11
606	Fatigue in chronic hepatitis B patients is significant and associates with autonomic dysfunction. 2019 , 17, 130		1
605	Risk factors associated with fatigue in chronic hepatitis B patients. 2019 , 13, 1065-1072		2
604	Liver Disease in Human Immunodeficiency Virus Infection. 2019 , 23, 309-329		2
603	HBV/HCV Coinfection in the Era of HCV-DAA. 2019 , 23, 463-472		10
602	Hepatic Complications of Inflammatory Bowel Disease. 2019 , 23, 191-208		11

601	Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies. 2019 , 39, 1190-1203	20
600	Tumor necrosis factor- β -induced protein 8-like 2 mRNA in peripheral blood mononuclear cells is associated with the disease progression of chronic hepatitis B virus infection. 2019 , 16, 120	3
599	A Novel Online Calculator Based on Serum Biomarkers to Detect Hepatocellular Carcinoma among Patients with Hepatitis B. 2019 , 65, 1543-1553	24
598	Genotypic Resistance Remains A Concern In Chronic Hepatitis B Patients With High Viral Load After Lamivudine And Adefovir Combination Therapy. 2019 , 12, 297-303	
597	Identification of key genes and pathways associated with different immune statuses of hepatitis B virus infection. 2019 , 23, 7474-7489	4
596	Hepatitis B virus reactivation during belatacept treatment after kidney transplantation. 2019 , 21, e13170	3
595	Prevalence of Hepatitis B Virus Infection in Shenzhen, China, 2015-2018. <i>Scientific Reports</i> , 2019 , 9, 13948.9	11
594	Diagnostic value of NKG2D promoter methylation in hepatitis B virus-associated hepatocellular carcinoma. 2019 , 13, 1093-1105	3
593	A Large-Scale Multicenter Study Validates Aldo-Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma. <i>Hepatology</i> , 2019 , 69, 2489-2501	11.2 35
592	Peripartum Maternal Hepatitis B Care in a US Nationwide Data Set. 2019 , 53, e424-e430	2
591	Update upon the infection risk in patients receiving TNF alpha inhibitors. 2019 , 18, 219-229	22
590	Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B. 2019 , 12, 845-854	18
589	Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. 2019 , 20, 829-845	16
588	Bayesian Network Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B Drugs. 2019 , 39, 835-846	2
587	Efficacy and safety of telbivudine and tenofovir disoproxil fumarate in preventing hepatitis B vertical transmission: A real-life practice. 2019 , 26, 1170-1177	8
586	Relationship Between Chronic Hepatitis B Virus Infection and Nature Killer Cells. 2019 , 32, 263-268	1
585	Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a. 2019 , 16, 61	9
584	Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement. 2019 , 210, 462-468	10

583	Receptor-Interacting Protein Kinase 3 (RIPK3) mRNA Levels Are Elevated in Blood Mononuclear Cells of Patients with Poor Prognosis of Acute-on-Chronic Hepatitis B Liver Failure. 2019 , 247, 237-245	4
582	Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China. 2019 , 19, 65	3
581	Resource Utilization and Outcomes of Medicare Recipients With Chronic Hepatitis B in the United States. 2019 , 53, e341-e347	
580	Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice. 2019 , 8, 354-365	12
579	Interpretation and management of positive anti-hepatitis B core antibody tests in immunocompromised pediatric patients. 2019 , 21, e13074	0
578	Durability of Antibody Response Against the Hepatitis B Virus in Kidney Transplant Recipients: A Proposed Immunization Guideline From a 3-Year Follow-up Clinical Study. 2019 , 6, ofy342	2
577	Antiviral therapy predicts the outcomes following resection of hepatocellular carcinoma in patients negative for HBV DNA: a propensity score matching analysis. 2019 , 17, 45	7
576	Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. 2019 , 26, 856-865	11
575	Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. 2019 , 17, 2541-2551.e2	15
574	Development and Validation of a Novel Model to Predict Liver Histopathology in Patients with Chronic Hepatitis B. 2019 , 2019, 1621627	1
573	Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load. 2019 , 1, 9-16	17
572	Prevalence of the entecavir-resistance-inducing mutation rtA186T in a large cohort of Chinese hepatitis B virus patients. 2019 , 164, 131-138	7
571	Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection. 2019 , 17, 1850-1859.e4	26
570	Tim-3 regulates inflammatory cytokine expression and Th17 cell response induced by monocytes from patients with chronic hepatitis B. 2019 , 89, e12755	4
569	The different effects of adefovir dipivoxil and telbivudine on the prognosis of hepatitis b virus-related hepatocellular carcinoma patients after curative resection. <i>Medicine (United States)</i> , 2019 , 98, e14386	1.8 3
568	Immunomodulatory Effects of Combination Therapy with Bushen Formula plus Entecavir for Chronic Hepatitis B Patients. 2019 , 2019, 8983903	2
567	Risk of Liver Fibrosis in Hepatitis B Virus and HIV Coinfected Youths Receiving Tenofovir-Containing Antiretroviral Regimen. 2019 , 18, 2325958218823259	2
566	Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B. 2019 , 91, 1288-1294	7

565	Improved Drug Loading and Sustained Release of Entecavir-loaded PLGA Microsphere Prepared by Spray Drying Technique. 2019 , 40, 306-312		5
564	Towards Genotype-Specific Care for Chronic Hepatitis B: The First 6 Years Follow Up From the CHARM Cohort Study. 2019 , 6, ofz469		3
563	Genotype and Serotype Identification of Hepatitis B Virus in Chronic Hepatitis B Patients Treated with Telbivudine. 2019 , 1374, 012025		
562	Emerging tools in the changing landscape of chronic hepatitis B management. 2019 , 17, 943-955		2
561	[Natural History and Treatment Indications of Chronic Hepatitis B]. 2019 , 74, 245-250		2
560	Decreased liver stiffness by transient elastography indicates lower incidence of hepatocellular carcinoma in patients with chronic hepatitis B. <i>Medicine (United States)</i> , 2019 , 98, e13929	1.8	2
559	Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections. 2019 , 31, 845-852		2
558	Phenotypes of Chronic Hepatitis B in Children From a Large North American Cohort. 2019 , 69, 588-594		8
557	Artificial Liver Support System Improves Short-Term Outcomes of Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Propensity Score Analysis. 2019 , 2019, 3757149		12
556	[Prophylaxis of infections post-allogeneic transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. 2019 , 106, S23-S34		5
555	Risk factors associated with hepatic osteopathy in HBV related cirrhosis measured by liver stiffness: An Observational study. <i>Medicine (United States)</i> , 2019 , 98, e16628	1.8	3
554	Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection. 2019 , 8,		3
553	Expression of IL-17 and its gene promoter methylation status are associated with the progression of chronic hepatitis B virus infection. <i>Medicine (United States)</i> , 2019 , 98, e15924	1.8	7
552	Spleen thickness can predict significant liver pathology in patients with chronic hepatitis B with persistently normal alanine aminotransferase or minimally raised alanine aminotransferase: a retrospective study. 2019 , 47, 122-132		3
551	Epidemiology and Management of Hepatocellular Carcinoma. 2019 , 156, 477-491.e1		595
550	Discovery of Half-life of Circulating Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B Infection Using Heavy Water Labeling. 2019 , 69, 542-545		10
549	Taiwan consensus statement on the management of chronic hepatitis B. 2019 , 118, 7-38		25
548	HBV Polymerase as a Target for Development of Anti-HBV Drugs. 2019 , 237-270		1

547	Prophylactic Use of Entecavir for Lymphoma Patients With Past Hepatitis B Virus Infection: A Randomized Controlled Trial. 2019 , 19, 103-108	10
546	Updates on vaccinating the inflammatory bowel disease patient. 2019 , 13, 229-239	5
545	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. 2019 , 4, 135-184	216
544	Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection. 2019 , 17, 1348-1355.e2	10
543	Risk factors of hepatitis B virus surface antigen carriage and serological profile of HBsAg carriers in Lomé, Togo, 2016. 2019 , 19, 32	
542	Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis. 2019 , 11, 321-333	19
541	Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. 2019 , 133, 137-146	59
540	Combination of Entecavir/Peginterferon Alfa-2a in Children With Hepatitis B e Antigen-Positive Immune Tolerant Chronic Hepatitis B Virus Infection. <i>Hepatology</i> , 2019 , 69, 2326-2337	11.2 20
539	Poor Adherence to Guidelines for Treatment of Chronic Hepatitis B Virus Infection at Primary Care and Referral Practices. 2019 , 17, 957-967.e7	11
538	Minority Report: ENUMERATING Treatment of Chronic HBV Infection Among Asian-American Communities. 2019 , 64, 289-291	
537	A Comparison Between Community and Academic Practices in the USA in the Management of Chronic Hepatitis B Patients Receiving Entecavir: Results of the ENUMERATE Study. 2019 , 64, 358-366	4
536	Monitoring the Progression of Chronic Liver Damage in Rats Using [F]PBR06. 2019 , 21, 669-675	3
535	Evaluation of Hepatitis B Virus Screening, Vaccination, and Linkage to Care Among Newly Arrived Refugees in Four States, 2009-2011. 2019 , 21, 39-46	11
534	Novel predictive models using serum ceruloplasmin levels for hepatic steatosis in patients with chronic hepatitis B infection. 2020 , 44, 57-65	3
533	Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection. 2020 , 119, 335-344	5
532	Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir. 2020 , 92, 302-308	2
531	Should Level of HBV RNA be Used to Determine When Patients Should Stop Treatment With Nucleos(t)ide Analogues. 2020 , 18, 551-552	3
530	Influence of PON1 gene polymorphisms (rs662 and rs854560) on the chronicity of HBV infection. 2020 , 23, 100618	1

529	Cost-Effectiveness Analysis of Screening for Hepatitis B Virus Infection in Patients With Solid Tumors Before Initiating Chemotherapy. 2020 , 18, 1600-1608.e4		4
528	Comparing the frequency of osteoporosis and osteopenia in chronic hepatitis B patients with and without Tenofovir treatment. 2020 , 8, 428-431		1
527	RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. <i>Hepatology</i> , 2020 , 72, 19-31	11.2	47
526	Patients with suboptimal hepatitis B virus diagnostic characterization are at risk of liver fibrosis progression. 2020 , 32, 426-432		0
525	48 weeks outcome after cessation of nucleos(t)ide analogue therapy in chronic hepatitis B patients. 2020 , 19, 329-334		2
524	Risk factors and prognostic analysis of acute-on-chronic liver failure of chronic hepatitis B after cessation of nucleos(t)ide analogs. 2020 , 32, 265-275		3
523	Liver safety assessment in clinical trials of new agents for chronic hepatitis B. 2020 , 27, 96-109		3
522	Knowledge and Perceptions of Hepatitis B and Hepatocellular Carcinoma Screening Guidelines Among Trainees: A Tale of Three Centers. 2020 , 65, 2551-2561		2
521	Chronic Hepatitis B Infection in Children and Its Relation to Pulmonary Function Tests: A Case-control Study. 2020 , 39, 192-196		0
520	Expanded circulating follicular dendritic cells facilitate immune responses in chronic HBV infection. 2020 , 18, 417		2
519	Screening and Evaluation of Novel Compounds against Hepatitis B Virus Polymerase Using Highly Purified Reverse Transcriptase Domain. 2020 , 12,		3
518	Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks. 2020 , 99, 171-178		7
517	Clinical Profile and Efficacy of Antivirals in Hepatitis B Virus Reactivation, in Patients With Cancer Receiving Chemotherapy. 2020 , 10, 590-598		1
516	COLD-PCR Method for Early Detection of Antiviral Drug-Resistance Mutations in Treatment-Naive Children with Chronic Hepatitis B. <i>Diagnostics</i> , 2020 , 10,	3.8	4
515	Management of Hepatitis B Surface Antigen and Hepatitis C Antibody-Positive Patients by Departments Not Specializing in Hepatology at a Suburban University Hospital in Japan: A Single-Center Observational Study. 2020 , 13, 743-750		1
514	Role of Nucleic Acid Polymers and Entry Inhibitors in Functional Cure Strategies for HBV. 2020 , 19, 370-381		
513	Hepatitis B virus persistence and reactivation. 2020 , 370, m2200		30
512	Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. 2020 , 2, 100152		8

511	Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections. 2020 , 20, 931		0
510	Effects of nucleo(s)tide analogs therapy on chronic hepatitis B as evaluated by hepatosplenic radionuclide angiography. 2020 , 41, 314-319		
509	Consolidation period of 18 months no better at promoting off-treatment durability in HBeAg-positive chronic hepatitis B patients with tenofovir disoproxil fumarate treatment than a 12-month period: A prospective randomized cohort study. <i>Medicine (United States)</i> , 2020 , 99, e19907	1.8	1
508	Prognostic value of non-invasive fibrosis indices post-curative resection in hepatitis-B-associated hepatocellular carcinoma patients. 2020 , 245, 703-710		3
507	HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis B. 2020 , 27, 1061-1070		4
506	The Different Effects of Nucleotide and Nucleoside Analogues on the Prognosis of HBV-Related HCC After Curative Resection. 2021 , 25, 1419-1429		2
505	Care quality and outcomes among US veterans with chronic hepatitis B in the hepatitis C direct-acting antiviral era. 2020 , 27, 1082-1092		2
504	Game-Theoretical Model of Retroactive Hepatitis B Vaccination in China. 2020 , 82, 80		8
503	Global dynamics of a model of hepatitis B virus infection in a sub-Saharan African rural area. 2020 , 13, 2050054		0
502	Maternal knowledge of the risk of vertical transmission and offspring acquisition of hepatitis B. 2020 , 19, 388-395		2
501	Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans. 2020 , 12,		4
500	Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B. 2020 , 14, 243-251		4
499	Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review. 2020 , 55, 496-514		14
498	Case reports of latent HBV hepatitis in patients after neurosurgical treatment for hypothalamic and pituitary tumors. 2020 , 20, 230		2
497	Low but Long-lasting Risk of Reversal of Seroconversion in Patients With Rheumatoid Arthritis Receiving Immunosuppressive Therapy. 2020 , 18, 2573-2581.e1		7
496	Entecavir-resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization. 2020 , 40, 1564-1577		2
495	Hepatitis B virus mutation pattern rtA181S+T184I+M204I may contribute to multidrug resistance in clinical practice: Analysis of a large cohort of Chinese patients. 2020 , 180, 104852		3
494	Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment. 2020 , 27, 731-738		1

493	Prevention of hepatitis B virus reactivation in patients with hematological malignancies and resolved hepatitis B virus infection: a systematic review and meta-analysis. 2020 , 21, 160-169		0
492	Hepatitis B core antibody and liver stiffness measurements predict HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with minimally elevated alanine aminotransferase (ALT) levels. 2020 , 20, 241-248		2
491	Predictive factors for risk of hepatocellular carcinoma in immune inactive chronic hepatitis B. 2020 , 44, 711-717		2
490	Gadobenate dimeglumine-enhanced magnetic resonance imaging can accurately predict the severity of esophageal varices and portal vein pressure in patients with hepatitis B cirrhosis. 2020 , 21, 104-111		2
489	Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update. 2020 , 50, 892-923		27
488	Fluorescence-based biochemical analysis of human hepatitis B virus reverse transcriptase activity. 2020 , 597, 113642		2
487	Insulin resistance is related with liver fibrosis in type 2 diabetic patients with non-alcoholic fatty liver disease proven biopsy and Mediterranean diet pattern as a protective factor. 2020 , 68, 557-563		15
486	Association between Hepatitis B Virus Infection and Metabolic Syndrome in Southwest China: A Cross-sectional Study. <i>Scientific Reports</i> , 2020 , 10, 6738	4.9	1
485	The association between vitamin D-related gene polymorphisms and hepatitis B virus-related liver cirrhosis. 2020 , 48, 300060520910906		1
484	The USP18 cysteine protease promotes HBV production independent of its protease activity. 2020 , 17, 47		2
483	Real-world prevalence of hepatitis B virus reactivation in cancer patients in Taiwan. 2021 , 27, 63-70		1
482	Tenofovir is Superior to Entecavir in Patients with Treatment-naïve Hepatitis B e-Antigen-Positive Chronic Hepatitis B. 2021 , 11, 37-44		0
481	Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. 2021 , 44, 133-165		4
480	Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. 2021 , 36, 637-645		9
479	Hepatocellular carcinoma in patients with chronic renal disease: Challenges of interventional treatment. 2021 , 36, 42-50		4
478	Liver transplantation in acute liver failure due to Hepatitis B. Two clinical cases. 2021 , 21, 100107		1
477	Epidemiology and Natural History of Hepatitis B Virus Infection: Time-Dependent Driving Factors of Chronic Hepatitis B Progression. 2021 , 143-167		
476	Antimicrobial Resistance and Antimicrobial Nanomaterials. 2021 , 1-28		1

475	Serum N-glycan fingerprint nomogram predicts liver fibrosis: a multicenter study. 2021 , 59, 1087-1097	
474	Hepatitis. 2021 , 155-181	
473	Prevalence of Hepatitis B Virus among Febrile Patient in General Hospital Okigwe, Imo State, Nigeria. 2021 , 09, 12-19	
472	PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF. 2022 , 71, 163-175	7
471	Substantial Gaps in Evaluation and Treatment of Hepatitis B Patients in the US: A Nationwide Study of 14,693 Patients.	
470	A systematic study of Tupaia as a model for human acute hepatitis B infection. 2021 , 83, 1004-1011	1
469	Hepatitis B prevalence association with sexually transmitted infections: a systematic review and meta-analysis. 2021 , 18, 269-279	1
468	Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors. 2021 , 44, 132-139	9
467	Maintaining Antiviral Efficacy after Switching to Generic Entecavir 1 mg for Antiviral-resistant Chronic Hepatitis B. 2021 , 77, 22-29	1
466	A longitudinal observational study in two cats naturally-infected with hepadnavirus. 2021 , 254, 108999	2
465	A qualitative exploration of enablers for hepatitis B clinical management among ethnic Chinese in Australia. 2021 , 28, 925-933	
464	Initial Evaluation, Long-Term Monitoring, and Hepatocellular Carcinoma Surveillance of Chronic Hepatitis B in Routine Practice: A Nationwide US Study. 2021 , 116, 1885-1895	2
463	Entecavir resistance in a patient with treatment-naïve HBV: A case report. 2021 , 14, 113	5
462	Everolimus Related Fulminant Hepatitis in Pancreatic Neuroendocrine Tumor With Liver Metastases: A Case Report and Literature Review. 2021 , 12, 639967	1
461	Discovery of Novel Pyrimidine-Based Capsid Assembly Modulators as Potent Anti-HBV Agents. 2021 , 64, 5500-5518	1
460	A Retrospective Evaluation of Patients Hospitalized in the Internal Medicine Department at the Turkey Recep Tayyip Erdogan Somalia Mogadishu Training and Research Hospital.	
459	Multilocus drug resistance mutation analysis in 148 HBV patients in northern Henan Province of China.	1
458	Outcome after kidney transplantation in hepatitis B surface antigen-positive patients. <i>Scientific Reports</i> , 2021 , 11, 11744	4.9 1

457	Emerging Hepatotropic Viruses in Cats: A Brief Review. 2021 , 13,	1
456	Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease. 2021 , 80, 1393-1399	3
455	Progress in hepatitis B virus-related acute-on-chronic liver failure treatment in China: A large, multicenter, retrospective cohort study using a propensity score matching analysis. 2021 ,	3
454	The Study of Clinical and Biochemical Parameters in Assessing the Response to the Antiviral Therapy in the Chronic Viral Hepatitis B. 2021 , 57,	0
453	HBV Reactivation During the Treatment of Non-Hodgkin Lymphoma and Management Strategies. 2021 , 11, 685706	4
452	Effect of Low-Dose Corticosteroid Use on HBV Reactivation in HBsAg-positive Rheumatoid Arthritis Patients. 2021 , 15, 39-44	0
451	Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update. 2021 ,	3
450	The trend of direct medical costs and associated factors in patients with chronic hepatitis B in Guangzhou, China: an eight-year retrospective cohort study. 2021 , 21, 71	2
449	Polymorphisms Predict the Efficacy of Peginterferon Alpha in Patients With Chronic Hepatitis B: A Meta-Analysis. 2021 , 8, 691365	2
448	Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy. 2021 , 9, 5769-5781	3
447	Predictive Nomograms for Clinical Outcomes in Hepatitis B-Related Cirrhosis Patients Receiving Antiviral Therapy. 2021 , 14, 2707-2719	0
446	High Risk of Viral Reactivation in Hepatitis B Patients with Systemic Lupus Erythematosus. 2021 , 22,	0
445	Prospective clinical trial of hepatitis B vaccination for children with hematological malignancies: a study on the safety and immunogenicity efficacy. 2021 , 1-9	
444	Substantial gaps in evaluation and treatment of patients with hepatitis B in the US. 2021 ,	3
443	Evaluation and comparison of the seroprevalence of hepatitis B and hepatitis C virus infection in patients admitted to clinics at the Recep Tayyip Erdogan Training and Research Hospital, Turkey.	
442	Fast and Sensitive Real-Time PCR Detection of Major Antiviral-Drug Resistance Mutations in Chronic Hepatitis B Patients by Use of a Predesigned Panel of Locked-Nucleic-Acid TaqMan Probes. 2021 , 59, e0093621	0
441	Cryptolepine and Nibima inhibit hepatitis B virus replication. 2021 , 13, e00942	0
440	The Impact of Nucleos(t)ide Analogs Off-Therapy Among Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. 2021 , 9, 709220	0

439	Chronic Hepatitis Is Common and Often Untreated Among Children with Hepatitis B Infection in the United States and Canada. 2021 , 237, 24-33.e12	0
438	Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor β Therapy for Inflammatory Bowel Disease. 2021 ,	0
437	Interpretation of HBV Serologies. 2021 , 25, 689-709	
436	Controversies in Treating Chronic Hepatitis B Virus Infection: Discordant Serologic Results. 2021 , 25, 805-816	
435	Gastrointestinal disorders. 2022 , 409-435	
434	Fulminant hepatitis B: A case report. 2021 , 26, 148-161	
433	Nucleos(t)ide Therapy and Long-Term Outcomes. 2021 , 287-318	
432	Treatment of Hepatitis B. 188-202	1
431	Epidemiology of Hepatocellular Carcinoma. 2020 , 758-772	19
430	Gastrointestinal Manifestations of Systemic Lupus Erythematosus. 2012 , 153-168	1
429	Natural History of HBV Infection in the Community. 2016 , 249-276	2
428	Cancer Screening Among Asian Americans. 2016 , 81-105	1
427	Epidemiology and Natural History of Chronic Hepatitis B Virus Infection. 2018 , 63-89	3
426	Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate. 2012 , 22, 470-3	12
425	Viral Hepatitis. 2010 , 203-229	1
424	Chronic viral hepatitis. 2012 , 53-69	1
423	Hepatitis B Virus and Hepatitis Delta Virus. 2015 , 1815-1839.e7	4
422	Targeted therapies for autoimmune/idiopathic nonmalignant diseases: risk and management of opportunistic infections. 2020 , 19, 817-842	12

4 ²¹	Evaluation of Serum GDF15, AFP, and PIVKA-II as Diagnostic Markers for HBV-Associated Hepatocellular Carcinoma. 2021 , 52, 381-389	2
4 ²⁰	Oxethazaine inhibits hepatitis B virus capsid assembly by blocking the cytosolic calcium-signalling pathway. 2016 , 97, 1198-1209	8
4 ¹⁹	Tri-typing of hepatitis B-related acute-on-chronic liver failure defined by the World Gastroenterology Organization. 2021 , 36, 208-216	7
4 ¹⁸	Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study. 2017 , 24, 1089-1097	11
4 ¹⁷	Retrospective observational study of temporal trends and outcomes of hepatitis B screening in patients receiving rituximab. 2020 , 10, e043672	3
4 ¹⁶	Absence of Hepatitis B Resistance Mutants before Introduction of Oral Antiviral Therapy. 2013 , 2013, 130384	2
4 ¹⁵	Entecavir as specific antiviral therapy in selected cases of severe acute hepatitis B. 2012 , 2, 18-22	8
4 ¹⁴	Optimal liver stiffness measurement values for the diagnosis of significant fibrosis and cirrhosis in chronic liver disease in Singapore. 2019 , 60, 532-537	5
4 ¹³	Different Mechanisms May Exist for HBsAg Synthesis and Secretion During Various Phases of Chronic Hepatitis B Virus Infection. 2017 , 23, 1385-1393	5
4 ¹²	A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. 2011 , 6, e23077	61
4 ¹¹	Factors associated with elevated ALT in an international HIV/HBV co-infected cohort on long-term HAART. 2011 , 6, e26482	9
4 ¹⁰	Post-arrival health screening in Karen refugees in Australia. 2012 , 7, e38194	41
4 ⁰⁹	Upper limits of normal for serum alanine aminotransferase levels in Chinese Han population. 2012 , 7, e43736	22
4 ⁰⁸	Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. 2012 , 7, e44930	202
4 ⁰⁷	Mathematical modeling of triphasic viral dynamics in patients with HBeAg-positive chronic hepatitis B showing response to 24-week clevudine therapy. 2012 , 7, e50377	9
4 ⁰⁶	IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B. 2013 , 8, e58071	23
4 ⁰⁵	Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients. 2013 , 8, e68568	20
4 ⁰⁴	TCR(+)CD4(-)CD8(-) T cells suppress the CD8(+) T-cell response to hepatitis B virus peptides, and are associated with viral control in chronic hepatitis B. 2014 , 9, e88475	8

403	Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings. 2014 , 9, e89789	18
402	Mutation profiling of the hepatitis B virus strains circulating in North Indian population. 2014 , 9, e91150	17
401	Molecular epidemiology and genotyping of hepatitis B virus of HBsAg-positive patients in Oman. 2014 , 9, e97759	23
400	A serum microRNA signature is associated with the immune control of chronic hepatitis B virus infection. 2014 , 9, e110782	29
399	Lower mutation frequency of BCP/precore regions in e antigen-negative chronic HBV-infected children instead of adults patients. 2015 , 10, e0120733	4
398	Age as a predictor of significant fibrosis features in HBeAg-negative chronic hepatitis B virus infection with persistently normal alanine aminotransferase. 2015 , 10, e0123452	17
397	Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients. 2015 , 10, e0130392	7
396	Risk of Severe Acute Exacerbation of Chronic HBV Infection Cancer Patients Who Underwent Chemotherapy and Did Not Receive Anti-Viral Prophylaxis. 2015 , 10, e0132426	20
395	A Mechanistic Assessment of the Discordance between Normal Serum Alanine Aminotransferase Levels and Altered Liver Histology in Chronic Hepatitis B. 2015 , 10, e0134532	10
394	Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China. 2015 , 10, e0139876	18
393	Study on Post-Treatment Relapse in HBeAg Positive CHB Patients. 2015 , 10, e0141072	1
392	Prediction of Clinical Outcomes in Hepatitis B E Antigen Negative Chronic Hepatitis B Patients with Elevated Hepatitis B Virus DNA Levels. 2015 , 10, e0144777	5
391	Genetic Evidence for Genotoxic Effect of Entecavir, an Anti-Hepatitis B Virus Nucleotide Analog. 2016 , 11, e0147440	8
390	Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study. 2016 , 11, e0153227	47
389	Does Pay-For-Performance Program Increase Providers Adherence to Guidelines for Managing Hepatitis B and Hepatitis C Virus Infection in Taiwan?. 2016 , 11, e0161002	7
388	Application of Bayesian Approach to Cost-Effectiveness Analysis of Antiviral Treatments in Chronic Hepatitis B. 2016 , 11, e0161936	4
387	Comparison of the Efficacies and Safety of Combined Therapy between Telbivudine Plus Adefovir and Lamivudine Plus Adefovir in Patients with Hepatitis B Virus Infection in Real-World Practice. 2016 , 11, e0165416	3
386	On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B. 2017 , 12, e0174046	4

385	Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis. 2017 , 12, e0179680	15
384	Insights into the genetic diversity, recombination, and systemic infections with evidence of intracellular maturation of hepadnavirus in cats. 2020 , 15, e0241212	8
383	Hepatitis B and Hepatitis C Reactivation in the Biologic Era. 2014 , 2, 240-6	10
382	Hepatitis B Reactivation with Novel Agents in Non-Hodgkin's Lymphoma and Prevention Strategies. 2016 , 4, 143-50	9
381	[Interdisciplinary aspects of and new drugs for chronic hepatitis B]. 2013 , 154, 1142-50	1
380	Characteristics of an outpatient chronic hepatitis B virus infection cohort. 2015 , 13, 189-95	2
379	HBsAg seroclearance or seroconversion induced by peg-interferon alpha and lamivudine or adefovir combination therapy in chronic hepatitis B treatment: a meta-analysis and systematic review. 2016 , 108, 263-70	6
378	Altered expression of A20 gene in peripheral blood mononuclear cells is associated with the progression of chronic hepatitis B virus infection. 2016 , 7, 68821-68832	6
377	Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma. 2017 , 8, 15047-15056	12
376	Perioperative entecavir for patients with HBV-related hepatocellular carcinoma and low levels of viral DNA: analysis using propensity score matching. 2017 , 8, 51810-51816	5
375	Identification of CD14 as a potential biomarker of hepatocellular carcinoma using iTRAQ quantitative proteomics. 2017 , 8, 62011-62028	15
374	Development and validation of a model for staging hepatic fibrosis for chronic hepatitis B patients with E antigen-positive. 2017 , 8, 98812-98822	2
373	Optimizing antiviral agents for hepatitis B management in malignant lymphomas. 2017 , 5, 39	3
372	Plasma miR-146a predicts serological conversion of hepatitis B e-antigen (HBeAg) in chronic hepatitis B patients treated with nucleotide analogs. 2019 , 7, 449	1
371	Molecular and epidemiological characteristics of hepatitis B virus in conditions of mass vaccine prophylaxis. 2019 , 10-39	5
370	Risk prediction models for hepatocellular carcinoma in different populations. 2016 , 28, 150-60	5
369	Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma. 2017 , 56, 1967-1971	8
368	Introduction of an automated system for the diagnosis and quantification of hepatitis B and hepatitis C viruses. 2012 , 6, 122-34	7

367	Natural History of Chronic Hepatitis B Virus Infection in Ahvaz City, Iran. 2018 , 19, 2125-2129		3
366	KIDNEY DISEASE IN THE SETTING OF HIV INFECTION: CONCLUSIONS FROM A KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES (KDIGO) CONTROVERSIES CONFERENCE. 2018 , 22, 84-100		2
365	Hepatitis B prevalence in Denmark - an estimate based on nationwide registers and a national screening programme, as on 31 December 2007. 2013 , 18,		25
364	A validation of the use of names to screen for risk of chronic hepatitis B in Victoria, Australia, 2001 to 2010. 2013 , 18,		2
363	Guidelines for the management of hepatitis B virus infection. 2013 , 54, 402-472		3
362	A case of resolved hepatitis B who was observed HBV viremia transiently during HSV hepatitis immediately after steroid pulse therapy. 2014 , 55, 51-56		1
361	Conservative treatment of lamivudine-induced rhabdomyolysis in a patient with acute exacerbation of chronic hepatitis B. 2015 , 56, 341-347		1
360	Hepatitis B Virus: From Diagnosis to Treatment. 2020 , 69, 391-399		3
359	KASL Clinical Practice Guidelines: Management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2012 , 18, 109-62	6.9	129
358	Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2013 , 19, 29-35	6.9	12
357	A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience. <i>Clinical and Molecular Hepatology</i> , 2013 , 19, 51-9	6.9	22
356	Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade. <i>Clinical and Molecular Hepatology</i> , 2013 , 19, 195-209	6.9	23
355	HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data. <i>Clinical and Molecular Hepatology</i> , 2013 , 19, 409-16	6.9	5
354	Prediction of fibrosis progression in chronic viral hepatitis. <i>Clinical and Molecular Hepatology</i> , 2014 , 20, 228-36	6.9	35
353	Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adeфовir combination therapy in patients with lamivudine-resistant chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2014 , 20, 274-82	6.9	2
352	The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adeфовir combination therapy. <i>Clinical and Molecular Hepatology</i> , 2016 , 22, 241-9	6.9	4
351	Personalized treatment of hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2015 , 21, 1-6	6.9	20
350	Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir. <i>Clinical and Molecular Hepatology</i> , 2015 , 21, 24-31	6.9	16

349	Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment. <i>Clinical and Molecular Hepatology</i> , 2016 , 22, 350-358	6.9	1
348	Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study). <i>Clinical and Molecular Hepatology</i> , 2016 , 22, 443-449	6.9	7
347	Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2016 , 22, 382-389	6.9	17
346	Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience. <i>Clinical and Molecular Hepatology</i> , 2017 , 23, 323-330	6.9	6
345	Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. <i>Clinical and Molecular Hepatology</i> , 2020 , 26, 411-429	6.9	22
344	Chronic hepatitis B in pregnancy: unique challenges and opportunities. 2011 , 17, 1-8		11
343	Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfecting with hepatitis B virus. 2011 , 17, 199-205		21
342	Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B. 2011 , 17, 268-73		7
341	Recent advances in managing hepatitis B. 2010 , 2,		4
340	Hepatitis B virus infection and renal transplantation. <i>World Journal of Gastroenterology</i> , 2010 , 16, 3878-876		16
339	Predictors of loss of hepatitis B surface antigen in HIV-infected patients. <i>World Journal of Gastroenterology</i> , 2010 , 16, 1093-6	5.6	13
338	Management of occult hepatitis B virus infection: an update for the clinician. <i>World Journal of Gastroenterology</i> , 2011 , 17, 1563-8	5.6	34
337	Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , 2011 , 17, 2945-52	5.6	5
336	Hepatitis B virus and hepatocellular carcinoma at the miRNA level. <i>World Journal of Gastroenterology</i> , 2011 , 17, 3353-8	5.6	57
335	Quantification of HBsAg: basic virology for clinical practice. <i>World Journal of Gastroenterology</i> , 2011 , 17, 283-9	5.6	25
334	Management of chronic hepatitis B in pregnancy. <i>World Journal of Gastroenterology</i> , 2012 , 18, 4517-21	5.6	21
333	Hepatitis B in pregnancy. <i>World Journal of Gastroenterology</i> , 2012 , 18, 4677-83	5.6	144
332	Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adeфовir combination treatment. <i>World Journal of Gastroenterology</i> , 2012 , 18, 6437-46; discussion p.6445	5.6	5

331	Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2012 , 18, 6943-50	5.6	5
330	Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2012 , 18, 6987-95	5.6	4
329	Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. <i>World Journal of Gastroenterology</i> , 2012 , 18, 6996-7002	5.6	23
328	Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues. <i>World Journal of Gastroenterology</i> , 2012 , 18, 7149-57	5.6	18
327	Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis. <i>World Journal of Gastroenterology</i> , 2013 , 19, 3481-6	5.6	8
326	Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis. <i>World Journal of Gastroenterology</i> , 2013 , 19, 6849-56	5.6	15
325	Liver diseases in pregnancy: diseases not unique to pregnancy. <i>World Journal of Gastroenterology</i> , 2013 , 19, 7630-8	5.6	16
324	Antiviral drug resistance increases hepatocellular carcinoma: a prospective decompensated cirrhosis cohort study. <i>World Journal of Gastroenterology</i> , 2013 , 19, 8373-81	5.6	8
323	Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. <i>World Journal of Gastroenterology</i> , 2013 , 19, 8822-30	5.6	31
322	Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation. <i>World Journal of Gastroenterology</i> , 2013 , 19, 9189-97	5.6	24
321	Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis. <i>World Journal of Gastroenterology</i> , 2013 , 19, 1342-8	5.6	20
320	MT1M and MT1G promoter methylation as biomarkers for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014 , 20, 4723-9	5.6	49
319	Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma. <i>World Journal of Gastroenterology</i> , 2014 , 20, 5165-70	5.6	10
318	Molecular diagnosis and treatment of drug-resistant hepatitis B virus. <i>World Journal of Gastroenterology</i> , 2014 , 20, 5708-20	5.6	28
317	Then and now: the progress in hepatitis B treatment over the past 20 years. <i>World Journal of Gastroenterology</i> , 2014 , 20, 401-13	5.6	40
316	Virus-related liver cirrhosis: molecular basis and therapeutic options. <i>World Journal of Gastroenterology</i> , 2014 , 20, 6457-69	5.6	32
315	When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response. <i>World Journal of Gastroenterology</i> , 2014 , 20, 7207-12	5.6	6
314	Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy. <i>World Journal of Gastroenterology</i> , 2014 , 20, 7675-85	5.6	31

313	Association of human leukocyte antigen DQB1 and DRB1 alleles with chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2014 , 20, 8179-86	5.6	14
312	Baseline HBsAg predicts response to pegylated interferon- α b in HBeAg-positive chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , 2014 , 20, 8195-200	5.6	14
311	Preventing infective complications in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 9691-8	5.6	10
310	Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit. <i>World Journal of Gastroenterology</i> , 2014 , 20, 11595-617	5.6	39
309	Management of antiviral drug resistance in chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2014 , 20, 11641-9	5.6	16
308	Noninvasive assessment of liver fibrosis in patients with chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2014 , 20, 12031-8	5.6	19
307	Hepatitis B viral load affects prognosis of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014 , 20, 12039-44	5.6	33
306	Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates. <i>World Journal of Gastroenterology</i> , 2014 , 20, 12045-55	5.6	3
305	Individualized management of pregnant women with high hepatitis B virus DNA levels. <i>World Journal of Gastroenterology</i> , 2014 , 20, 12056-61	5.6	18
304	Clinical characteristics and current management of hepatitis B and C in China. <i>World Journal of Gastroenterology</i> , 2014 , 20, 13582-90	5.6	17
303	Chemotherapy-related reactivation of hepatitis B infection: updates in 2013. <i>World Journal of Gastroenterology</i> , 2014 , 20, 14581-8	5.6	26
302	Chronic Liver Failure-Sequential Organ Failure Assessment is better than the Asia-Pacific Association for the Study of Liver criteria for defining acute-on-chronic liver failure and predicting outcome. <i>World Journal of Gastroenterology</i> , 2014 , 20, 14934-41	5.6	55
301	Hepatitis B vaccination in patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 15358-66	5.6	19
300	Management of chronic hepatitis B in severe liver disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 16053-61	5.6	12
299	Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates. <i>World Journal of Gastroenterology</i> , 2014 , 20, 17100-6	5.6	2
298	Antiviral therapies for hepatitis B virus-related hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2015 , 21, 3860-6	5.6	11
297	Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2015 , 21, 5524-31	5.6	9
296	Models for predicting hepatitis B e antigen seroconversion in response to interferon- α n chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , 2015 , 21, 5668-76	5.6	7

295	Precore/basal core promoter mutants quantification throughout phases of hepatitis B virus infection by Simpleprobe. <i>World Journal of Gastroenterology</i> , 2015 , 21, 6639-48	5.6	3
294	Impact of partial reimbursement on hepatitis B antiviral utilization and adherence. <i>World Journal of Gastroenterology</i> , 2015 , 21, 9588-97	5.6	9
293	Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies. <i>World Journal of Gastroenterology</i> , 2015 , 21, 10874-82	5.6	9
292	Hepatitis B among Asian Americans: Prevalence, progress, and prospects for control. <i>World Journal of Gastroenterology</i> , 2015 , 21, 11924-30	5.6	17
291	Application of nucleoside analogues to liver transplant recipients with hepatitis B. <i>World Journal of Gastroenterology</i> , 2015 , 21, 12091-100	5.6	8
290	Tenofovir rescue therapy in pregnant females with chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2015 , 21, 2504-9	5.6	21
289	Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , 2015 , 21, 2746-53	5.6	17
288	Prophylactic managements of hepatitis B viral infection in liver transplantation. <i>World Journal of Gastroenterology</i> , 2016 , 22, 165-75	5.6	11
287	Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016 , 22, 1497-512	5.6	38
286	Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α on virological and serological responses in chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , 2016 , 22, 10210-10218	5.6	10
285	Non-ALT biomarkers for markedly abnormal liver histology among Chinese persistently normal alanine aminotransferase-chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , 2017 , 23, 2802-2810	5.6	8
284	Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?. <i>World Journal of Gastroenterology</i> , 2018 , 24, 1825-1838	5.6	10
283	Increased occurrence of mutant rtI233V of HBV in patients receiving adefovir therapy. 2016 , 21, 9-16		10
282	Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. 2015 , 30, 32-41		15
281	Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice. 2019 , 34, 802-810		4
280	Management of Patients with Hepatitis B Virus Infection Who Receive Immunosuppressive Treatment or Chemotherapy. 2012 , 82, 149		3
279	Detectability and clinical significance of serum hepatitis B virus ribonucleic acid. 2015 , 4, 197-202		5
278	Pharmaceutical care outcomes in an outpatient human immunodeficiency virus treatment center in Jos, Nigeria. 2014 , 5, 57-61		3

277	Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B. 2015 , 21, 245-53	15
276	Antiviral efficacy of entecavir versus entecavir plus adefovir for hepatitis B virus rtA181V/T mutants alone. 2016 , 22, 37-42	5
275	Seroprevalence of Hepatitis B and C Viral Infections among Type 2 Diabetics: A Cross-sectional Study in the Cape Coast Metropolis. 2014 , 4, 719-22	9
274	Viral Load Pattern Among Hepatitis B Surface Antigen-positive Patients: Laboratory Perspective and Implications for Therapy. 2016 , 6, 95-9	3
273	Expression analysis of apolipoproteins AI & AIV in hepatocellular carcinoma: A protein-based hepatocellular carcinoma-associated study. 2018 , 147, 361-368	7
272	Greater prevalence of comorbidities with increasing age: Cross-sectional analysis of chronic hepatitis B patients in Saudi Arabia. 2019 , 25, 194-200	18
271	Predictive Factors for Sustained Remission after Discontinuation of Antiviral Therapy in Patients with HBeAg-positive Chronic Hepatitis B. 2016 , 67, 28-34	4
270	Entecavir for treatment of chronic hepatitis B: A clinical update for the treatment of patients with decompensated cirrhosis. 2012 , 02, 53-61	1
269	Patients with hematological malignancies and serological signs of prior resolved hepatitis B. 2012 , 4, 37-45	7
268	Screening for hepatocellular carcinoma by Egyptian physicians. 2015 , 7, 161-71	4
267	Management of hepatitis B in developing countries. 2011 , 3, 292-9	27
266	Transient elastography: Kill two birds with one stone?. 2013 , 5, 264-74	64
265	Noninvasive assessment of liver damage in chronic hepatitis B. 2013 , 5, 439-45	20
264	Chronic hepatitis B: Advances in treatment. 2014 , 6, 284-92	24
263	Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection. 2014 , 6, 652-9	11
262	Management of chronic hepatitis B before and after liver transplantation. 2015 , 7, 1421-6	17
261	Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. 2015 , 7, 1742-54	16
260	Antiviral treatment for chronic hepatitis B in renal transplant patients. 2015 , 7, 189-203	16

259	Hepatic manifestations of non-steroidal inflammatory bowel disease therapy. 2015 , 7, 2716-28	4
258	Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy. 2015 , 7, 539-47	12
257	Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification. 2015 , 7, 825-30	20
256	Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure. 2015 , 7, 954-67	37
255	Chronic hepatitis B infection in pregnancy. 2015 , 7, 1233-7	21
254	Hepatitis B among Inuit: A review with focus on Greenland Inuit. 2015 , 7, 1265-71	29
253	Adverse effects of oral antiviral therapy in chronic hepatitis B. 2017 , 9, 227-241	29
252	Liver transplantation in adults: Choosing the appropriate timing. 2012 , 3, 49-61	7
251	What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?. 2016 , 7, 387-96	6
250	Chronic hepatitis B: Enlarged perihepatic lymph nodes correlated with hepatic histopathology. 2013 , 5, 208-14	6
249	Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines. 2010 , 4, 15-24	13
248	A low viral load predicts a higher initial virologic response to adefovir in patients with Lamivudine-resistant chronic hepatitis B. 2010 , 4, 530-6	6
247	Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. 2011 , 5, 278-87	17
246	The clinical and laboratory characteristics of patients with chronic hepatitis B using current or past antiviral therapy in Korea: a multi-center, nation-wide, cross-sectional epidemiologic study. 2012 , 6, 241-8	6
245	The Efficacy and Safety of Peginterferon- α 2a in Korean Patients with Chronic Hepatitis B: A Multicenter Study Conducted in a Real Clinical Setting. 2013 , 7, 197-205	6
244	Hepatitis B core antigen expression in hepatocytes reflects viral response to entecavir in chronic hepatitis B patients. 2013 , 7, 462-8	3
243	Potential Efficacy of Pegylated Interferon- α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B. 2016 , 10, 611-6	3
242	Drug-Induced Liver Injury: Pattern Recognition and Future Directions. 2016 , 10, 27-36	34

241	A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels. 2017 , 11, 528-534	14
240	Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status. 2019 , 13, 197-205	9
239	Entecavir for the treatment of real-life chronic hepatitis B patients: a study from Saudi Arabia. 2013 , 33, 119-23	4
238	Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report. 2018 , 29, 259-269	16
237	Strategy to Overcome Drug Resistance That Develops during Treatment of Chronic Hepatitis B in Children. 2012 , 15, 63	2
236	Vaccination Coverage and Awareness of Hepatitis B Virus Among Healthcare Students at a University in Cyprus. 2019 , 31, 190-196	3
235	Expression profiles of circulating cytokines, chemokines and immune cells in patients with hepatitis B virus infection. 2014 , 14, e18892	22
234	Persistence of Anti-HBs Among Palestinian Medical Students After 18 - 22 Years of Vaccination: A Cross-Sectional Study. 2015 , 15, e29325	9
233	Autologous Peripheral Blood Stem Cell Transplantation Improves Portal Hemodynamics in Patients with Hepatitis B Virus-related Decompensated Cirrhosis. 2015 , 15, e32498	5
232	Efficacy of PEGylated Interferon in Treatment-Experienced Chinese Patients With HBeAg Positive Chronic Hepatitis B. 2016 , 16, e35357	3
231	Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. 2021 , 19, 541-565	74
230	Clinical outcome of a patient cohort with acute hepatitis B. 2013 , 68, 718-20	3
229	Theoretically informed correlates of hepatitis B knowledge among four Asian groups: the health behavior framework. 2012 , 13, 1687-92	19
228	Hepatitis B virus DNA negativity acts as a favorable prognostic factor in hepatocellular carcinoma patients. 2014 , 15, 9635-41	9
227	Efficacy of Prophylactic Entecavir for Hepatitis B Virus-Related Hepatocellular Carcinoma Receiving Transcatheter Arterial Chemoembolization. 2015 , 16, 8665-70	9
226	Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy. 2016 , 5, 212294	3
225	HBV/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases. 2021 , 8, 713981	5
224	Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B. 2021 , 9,	6

- 223 Serum hepatitis B core-related antigen as a surrogate marker of hepatitis B e antigen seroconversion in chronic hepatitis B. *World Journal of Gastroenterology*, **2021**, 27, 6927-6938 5.6 1
- 222 [Predictors for virologic response in management of chronic hepatitis B]. **2010**, 16, 1-4
- 221 Alanine aminotransferase is an inadequate surrogate marker for detecting lamivudine resistance. *World Journal of Gastroenterology*, **2010**, 16, 4691-6 5.6
- 220 Nonneoplastic Hepatobiliary Disease. **2011**, 1771-1827
- 219 Mechanisms of Resistance to Antiviral Agents *. **2011**, 1710-1728
- 218 Update on Management of Viral Hepatitis B. **2011**, 1, 49-52
- 217 Liver Transplantation. **2011**, 1431-1442
- 216 Histopathological Assessment of Liver Biopsy Specimen in the Context of HBV DNA and HBeAg in Patients with Chronic Hepatitis B. **2011**, 1, 83-88
- 215 Viral Infections. **2011**, 1037-1064 0
- 214 Liver transplantation. 238-273
- 213 HBV/HCV Co-infection and Mixed Cryoglobulinemia. **2012**, 227-231
- 212 Hepatitis B and D. 537-581
- 211 Maintenance Therapy with Oral Antiviral Agents. **2012**, 271-277
- 210 Infections in Leukemia and Hematopoietic Stem Cell Transplantation. **2012**, 309-365
- 209 Clinical Approach to Treatment of Viral Infections. **2012**, 111-116
- 208 Viral Hepatitis. **2012**, 400-410
- 207 Liver transplantation. **2012**, 1662-1673.e2
- 206 Three cases of chronic hepatitis B in that interferon therapy was indicated. **2012**, 53, 853-861

205	Hepatitis B and Hepatitis D Viruses. 2012 , 1077-1087.e6		0
204	Hepatitis B Infection. 2012 , 65-70		
203	Krankheiten der Leber und Gallenwege. 2012 , 429-440		
202	Chronic Hepatitis B in Pregnancy. 2012 , 83, 50		
201	Therapy for HBV Infection in Hemodialysis Patients: Is it Possible?. 2012 , 12, 153-157		
200	Hepatitis B and Asian Americans. 2013 , 251-265		
199	Cancer: An Ongoing Risk for Asian American Communities. 2013 , 203-213		
198	The A, B, Cs (+ D + E) of hepatitis. 2012 , 18, 75-84		
197	Approach to the Patient With Abnormal Hepatic Laboratory Tests. 2013 , 1437-1443		
196	Transient Elastography (Fibroscan [®]): A New Look of Liver Fibrosis and Beyond. 2013 , 3, 70-77		1
195	Virological profile of hepatitis B infection in Black African HBsAg chronic carriers. 2013 , 03, 113-118		2
194	H. 2013 , 447-566		
193	Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients. <i>Clinical and Molecular Hepatology</i> , 2013 , 19, 273-9	6.9	2
192	Glomerular Diseases Associated with HIV, Hepatitis B, and Hepatitis C Infections. 2014 , 209-228		
191	The Geoepidemiology of Autoimmune Liver Disease. 2014 , 27-43		
190	Diagnostic Liver Immunology. 2014 , 45-53		
189	Management of Comorbid Medical Conditions in Schizophrenia. 2014 , 175-204		
188	Comparison of adefovir dipivoxil and pegylated interferon alpha-2a treatment in chronic hepatitis B patients. 2014 , 1, 26-32		

- 187 Medical Therapy of Hepatobiliary Diseases Associated with Ulcerative Colitis. **2014**, 439-456
- 186 Epidemiology of Hepatitis B and C in the United States. 322-331
- 185 Hepatitis Viruses: Hepatitis B and Hepatitis D. **2014**, 747-764 1
- 184 Hepatitis and Liver Failure in Infancy and Childhood. **2014**, 477-501
- 183 Liver Disease in Renal Transplant Recipients. **2014**, 247-255 0
- 182 Hepatitis B Virus (HBV) Infection in Pregnancy: Knowledge and Practice of Care Providers in Nigeria. **2014**, 04, 621-627 2
- 181 HBV Therapy and the Problem of Drug Resistance. **2014**, 1-15
- 180 Nucleoside Analog-treated Chronic Hepatitis B Patients showed Reduced Expression of PECAM-1 Gene in Peripheral Blood Mononuclear Cells in Bangladesh. **2014**, 4, 87-91
- 179 The Impact of Treating Chronic Liver Diseases on Hepatocellular Carcinoma Prevention. **2012**, 229-246
- 178 Oral Antiviral Therapy for Chronic Hepatitis B Virus Infection: Is Continuous Treatment Needed?. **2014**, 1,
- 177 Successful Treatment of Crizotinib-Associated Severe Hepatotoxicity in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. **2014**, 20, 35-38
- 176 Hepatitis B reactivation. **2014**, 125-134
- 175 Adefovir Dipivoxil, Tenofovir Disoproxil Fumarate or Lamivudine; Which is Suitable Monotherapy Medication in the Patients with Chronic Hepatitis B Virus Infection? One Year Experience. **2014**, 1,
- 174 Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy. *Clinical and Molecular Hepatology*, **2015**, 21, 242-8 6.9 3
- 173 Antibody response to hepatitis B vaccination in isolated anti-HBc positive subjects. **2015**, 141, 125
- 172 Is tenofovir disoproxil fumarate an all-powerful weapon in the treatment of chronic hepatitis B?. **2015**, 30, 23-6 1
- 171 Antiviral Drugs against Hepatitis Viruses. **2015**, 563-575.e3
- 170 Chapter 33. Infectious Disease. **2015**,

- 169 A Case of Hepatitis B Infection; Is It Transmitted via Blood Components?. **2015**, 10, o
- 168 Clinical, laboratory, and virological characteristics of patients with positive hepatitis B surface antigen in Upper Egypt. **2015**, 27, 32-37
- 167 Antiviral Agents. 1867-1893
- 166 Hepatitis B and D Viruses. 1841-1858 1
- 165 Approach to Gastrointestinal and Liver Diseases in Pregnancy. 834-858
- 164 Hepatitis B Recurrence: Major Milestones and Current Status. **2016**, 13-34
- 163 Hepatocellular Carcinoma Associated with Hepatitis B Virus. **2016**, 243-259
- 162 Liver Cancer Among Asian Americans. **2016**, 233-248
- 161 Rheumatic Diseases and the Liver. **2016**, 271-291
- 160 Tenofvir in treatment of Iranian patients with chronic hepatitis B virus infection: An open-label case series. **2016**, 5, 166-70
- 159 Molecular Methods for Identification of Cultured Microorganisms. 12.3.1.1-12.3.13.6
- 158 Nucleos(t)ide Analogue Based Therapy and Management of Patients. **2016**, 339-359
- 157 The Efficacy of Add-on Telbivudine Versus Switching to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Poor Responses to Adefovir. **2016**, 16, e31278
- 156 Hepatitis B and C Viruses. **2016**, 641-657
- 155 Hepatitis. **2016**, 113-137
- 154 Organ Transplantation in HBV-Infected Patients. **2016**, 361-397
- 153 Nonneoplastic Hepatobiliary Disease. **2016**, 1969-2030
- 152 Treating chronic hepatitis B virus: Chinese physicians' awareness of the 2010 guidelines. **2016**, 8, 762-9 1

151 Chronic Hepatitis B, C, and D. 69-95

150 TREND OF HEPATITIS B AND HEPATITIS C INFECTIONS IN A TERTIARY CARE MEDICAL INSTITUTE IN EASTERN INDIA. **2016**, 5, 2061-2064 1

149 Advances in the Treatment of Human Immunodeficiency Virus and Hepatitis B Virus Co-infection. **2016**, 5, 54-58

148 Relation between hepatitis B viral load and liver fibrosis assessed using transient elastography in patients with chronic hepatitis B virus infection. **2016**, 6, 65-69

147 Estrategias para el tratamiento de pacientes con infección por el virus de la hepatitis B sometidos a terapia inmunomoduladora: ¿es suficiente usar lamivudina?. **2016**, 8, S1-S5

146 Viral Hepatitis: Hepatitis B (& D). **2017**, 133-142

145 General Care of the Liver Patient. **2017**, 17-25

144 Clinicopathological Characteristics of a Group of Sub-Saharan African Patients with Chronic Hepatitis B Infection: A Gender Analysis. **2016**, 5,

143 ASSESSMENT OF THE ACTUAL AND POTENTIAL EPIDEMIOLOGICAL SITUATION OF THE VIRAL HEPATITIS C AND B BASED BY LABORATORY DATA IN THE DOCTOR PARAMONOV'S CLINIC IN SARATOV CITY AND SARATOV REGION. **2017**, 19, 94-97

142 Liver transplantation: Indications and general considerations. **2017**, 1737-1749.e2

141 The Hepatitis B Virus and Antiviral Drug Resistance: Causes, Patterns and Mechanisms. **2017**, 565-577 1

140 Liver transplantation in patients with fulminant hepatitis. **2017**, 1766-1780.e4

139 Methylation status of the estrogen receptor 1 promoter predicts poor prognosis of acute-on-chronic hepatitis B liver failure. **2017**, 109, 818-827 1

138 Antiviral Therapy in Chronic Hepatitis B With Mild Acute Exacerbation. **2017**, 10, 6-14

137 Youth. **2017**, 247-270

136 Obstetricians' and gynecologists' knowledge, education, and practices regarding chronic hepatitis B in pregnancy. **2017**, 30, 670-674 4

135 Hepatitis B in Solid-Organ Transplant Procedures Other Than Liver. **2017**, 15, 130-137 1

134 A Case Report of the Efficacy of Saenggan-tang-gagam in the Treatment of a Patient with Chronic Hepatitis B Who Showed Conversion of the Immune-Tolerant Phase to Immune-Clearance Phase during Hospitalization for Intracerebral Hemorrhage. **2017**, 38, 164-171

133 Hepatitis B Virus Reactivation and Management of Patients Undergoing Immunosuppression. **2018**, 315-341

132 Differential Diagnosis. **2018**, 361-464

131 Chapter 33: Infectious Diseases. **2017**,

130 Computed Tomography Liver Spleen Ratio as Predictive Marker of Liver Injury among Adult Filipina Early Breast Cancer Receiving Neoadjuvant Therapy from 2010-2016: A Six-Year Retrospective Study. **2017**, 2,

129 Viral Hepatitis B during Chronic Inflammatory Bowel Diseases at Fez University Hospital: Prevalence and Risk Factors. **2018**, 08, 17-26

0

128 Recurrent Primary Disease After Liver Transplantation. **2018**, 784-815.e14

127 Diagnostic Efficacy of Serum Factor IV Collagen of Hepatic Fibrosis Regression in Chronic Hepatitis B Virus Infected Patients. **2018**, 08, 241-254

126 Noninvasive Assessment of Disease Progression. **2018**, 117-126.e3

125 Treatment of Hepatitis B. **2018**, 485-500.e5

124 SEROPREVALENCE OF HEPATITIS B VIRUS SURFACE ANTIGEN IN PREGNANT WOMEN ATTENDING ANC CLINIC IN A TERTIARY CARE HOSPITAL IN WEST BENGAL. **2018**, 7, 2977-2981

123 KRONİK HEPATİT B ENFEKSİYONUNUNDA HEPATİK HASAR DZEYİNİN İNGRİMESİNDE M30 VE M65 ANTİJEN DZEYLERİNİN ETKİNLİĞİ

122 Hepatitis Arthritis: HBV and HCV. **2019**, 107-112

121 Relation between Knowledge, Attitude and Practice of Hepatitis B among Dental Undergraduates in the Kingdom of Saudi Arabia. **2019**, 20, 1447-1455

0

120 INFLUENCE OF AUTOLEUKOCYTE VACCINATION ON ACTIVITY LEVEL OF TUMOR NECROSIS FACTOR ALPHA IN PATIENTS WITH CHRONIC HEPATITIS B. **2019**, 72, 31-34

1

119 Viral Hepatitis. **2019**, 91-133

118 Evaluation of Noninvasive Liver Fibrosis Blood Markers in Patients with Chronic Hepatitis B and Hepatitis C. **2019**, 9, 153

117 Usefulness of Liver Fibrosis According to Classification of Image Score System In Abdominal Ultrasonography. **2019**, 42, 187-194

1

116 Characteristics of an Outpatient Cohort with HBeAg-Negative Chronic Hepatitis B. **2019**, 7, 2068-2074

1

115 Hepatit B virus enfeksiyonu nedenli karaciĖr nakillerde son yillardaki deĖim.

114 Understanding the hepatitis B core positive liver donor. **2019**, 60, 545-549

1

113 Hepatitis B screening rates and reactivation in solid organ malignancy patients undergoing chemotherapy in Southern Thailand. *Clinical and Molecular Hepatology*, **2019**, 25, 366-373

6.9 1

112 Sexually Transmitted Hepatitis. **2020**, 255-275

111 Hepatitis B virus reactivation: overview and management.

0

110 Hepatitis B Virus. **2020**, 255-272

109 Tenofovir does not induce renal dysfunction compared to entecavir in post-liver-transplant hepatitis B virus patients. **2020**, 99, 180-187

1

108 Acute B Virus Hepatitis with Fulminant Hepatic Failure Precipitating Crisis in Sickle Cell Disease. **2020**, 9, 173-175

107 Hepatitis C. **2020**, 273-286

106 Pathological characterization of occult hepatitis B virus infection in hepatitis C virus-associated or non-alcoholic steatohepatitis-related hepatocellular carcinoma. *World Journal of Meta-analysis*, **2020**, 8, 67-77

0.5

105 [The role of antiviral therapy in the management of patients with liver cirrhosis associated with chronic HBV and HCV infection]. **2021**, 66, 331-339

1

104 Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response. *Clinical and Molecular Hepatology*, **2020**, 26, 352-363

6.9 1

103 Improving the detection and care of people with hepatitis B and C. **2010**, 6, 363-5

102 Management of chronic hepatitis B patients: efficacy & limitation of nucleos(t)ide analogues. **2011**, 133, 11-3

3

101 Chronic hepatitis B: integrating long-term treatment data and strategies to improve outcomes in clinical practice. **2011**, 7, 1-16

3

100 Viral hepatitis in Hawai'i--differing perspectives. **2010**, 69, 3-20

2

99 HIV and Hepatitis B Virus Coinfection: Approach to Management: Case Study and Commentary. **2010**, 17, 273-286

1

98 Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. **2012**, 12, 1129-59

53

97	Risk stratification for Hepatitis B treatment in the molecular age. 2013 , 2, 129-31	
96	Bilirubin, aspartate aminotransferase and platelet count score: a novel score for differentiating patients with chronic hepatitis B with acute flare from acute hepatitis B. 2014 , 27, 60-64	4
95	Occult hepatitis B virus infection among human immunodeficiency virus-infected patients with isolated hepatitis B core antibody in Isfahan, Iran. 2014 , 19, S64-6	3
94	Virologic response and breakthrough in chronic hepatitis B Egyptian patients receiving lamivudine therapy. 2014 , 27, 380-386	3
93	Cohort profile: golestan hepatitis B cohort study- a prospective long term study in northern iran . 2014 , 6, 186-94	7
92	Noninvasive predictive models of liver fibrosis in patients with chronic hepatitis B. 2015 , 8, 961-71	5
91	Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors. 2015 , 28, 173-181	15
90	Toll-like receptor 2 promotes T helper 17 cells response in hepatitis B virus infection. 2015 , 8, 7315-23	14
89	Regulatory T cells and IL-17(+) T helper cells enhanced in patients with chronic hepatitis B virus infection. 2015 , 8, 8674-85	10
88	Lymphocyte CD64 increased in patients with chronic HBV infection. 2015 , 8, 10746-52	1
87	The Early Results of a New Health Care Program Implementation in HBV Screening: an Iranian Experience. 2015 , 7, 226-32	4
86	Recent epidemiological and clinical features of acute hepatitis B in a single center of China. 2015 , 8, 16652-7	1
85	Baseline prognostic factors and statistic model to predict early virological response in lamivudine-treated patients with chronic hepatitis B. 2015 , 8, 19258-65	
84	Comparison of the efficacy of tenofovir monotherapy versus tenofovir-based combination therapy in adefovir-experienced chronic hepatitis B patients: a systematic review and meta-analysis. 2015 , 8, 20111-22	2
83	Optimized combination therapies with adefovir dipivoxil (ADV) and lamivudine, telbivudine, or entecavir may be effective for chronic hepatitis B patients with a suboptimal response to ADV monotherapy. 2015 , 8, 21062-70	8
82	Towards the elimination and eradication of hepatitis B. 2015 , 1, 4-12	2
81	Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries. 2015 , 1, 103-10	14
80	Response to hepatitis B vaccination among HIV-infected adults in Vietnam. 2016 , 2, 102-6	1

79	Hepatitis B Virus-HIV Coinfection: Forgotten but Not Gone. 2014 , 10, 780-8	3
78	Current progress in the development of therapeutic vaccines for chronic hepatitis B virus infection. 2016 , 19, 692-704	9
77	Evolving New Strategies for the Medical Management of Chronic Hepatitis B Virus Infection. 2016 , 12, 679-689	1
76	Different Variants in Reverse Transcriptase Domain Determined by Ultra-deep Sequencing in Treatment-naïve and Treated Indonesian Patients Infected with Hepatitis B Virus. 2016 , 62, E1-8	5
75	A Review of Antiviral Use for the Treatment of Chronic Hepatitis B Virus Infection in Pregnant Women. 2017 , 13, 154-163	1
74	Early identification and linkage to care of persons with chronic hepatitis B virus infection--three U.S. sites, 2012-2014. 2014 , 63, 399-401	14
73	Sexually transmitted diseases treatment guidelines, 2015. 2015 , 64, 1-137	979
72	Sustained Off-Treatment Response After Discontinuation of Long-Term Nucleos(t)ide Analogue Treatment in HBeAg-Seronegative Hepatitis B: A Case Series. 2017 , 25, 114-117	1
71	Influence of Vitamin D Receptor Gene Polymorphisms on Response to Pegylated Interferon in Chronic Hepatitis B Egyptian Patients. 2018 , 6, 186-196	6
70	An update on hepatitis B, D, and E viruses. 2014 , 21, 157-63	16
69	Hepatitis B Virus Infection: What Is Current and New. 2019 , 26, 112-116	9
68	Hepatitis B: Screening, Awareness, and the Need to Treat. 2016 , 33, 19S-23S	1
67	Strategies to Improve Hepatocellular Carcinoma Surveillance in Veterans With Hepatitis B Infection. 2017 , 34, S30-S39	
66	Hepatitis B Virus Reactivation in the Setting of Immunosuppressive Drug Therapy. 2019 , 15, 585-592	
65	Oro-Dental Health of Patients with Chronic Hepatic Failure. 2020 , 11, 115-121	2
64	Seroepidemiology and Risk Factors of Hepatitis B Virus Infection: A Population-Based Azar Cohort Study. 2020 , 49, 2152-2160	
63	Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients under immunotherapy. 2021 , 79, 1012-1025	0
62	1,5-Anhydroglucitol Predicts Mortality in Patients with HBV-Related Acute-on-chronic Liver Failure. 2022 , 000, 000-000	

61	Viral Hepatitis B and C. Cure or Treatment?. 2014 , 4, 43-50		
60	Seroepidemiology and Risk Factors of Hepatitis B Virus Infection: A Population-Based Azar Cohort Study. 2020 , 49, 2152-2160		
59	Gamma-glutamyl transpeptidase-platelet ratio, systemic immune inflammation index, and system inflammation response index in invasive Aspergillosis. 2021 , 67, 1021-1025		0
58	Risk Factors Associated With Quality of Life in Patients With Hepatitis B Virus Related Cirrhosis.. 2021 , 12, 770415		0
57	On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty.. 2022 ,		2
56	Detection and Quantification of Hepatitis B Virus Genomes in Peripheral Blood Mononuclear Cells of Chronic Hepatitis B Virus Infection, Cirrhosis, and Hepatocellular Carcinoma Patients. 2022 , 21,		
55	Insights Into the Coinfections of Human Immunodeficiency Virus-Hepatitis B Virus, Human Immunodeficiency Virus-Hepatitis C Virus, and Hepatitis B Virus-Hepatitis C Virus: Prevalence, Risk Factors, Pathogenesis, Diagnosis, and Treatment.. 2021 , 12, 780887		1
54	Reply to "Treatment options for 3-5 cm solitary hepatocellular carcinoma-Need a closer look!". <i>Hepatology</i> , 2022 ,	11.2	
53	Present and future management of viral hepatitis.. <i>World Journal of Gastroenterology</i> , 2021 , 27, 8081-8102		0
52	Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon-lambda 3 induction in chronic hepatitis B patients.. 2022 ,		0
51	A long-term study of liver-related events in Caucasian hepatitis B patients with normal ALT values and high viremia.. 2022 , 85, 56-61		0
50	PAGE-B and REACH-B Predicts the Risk of Developing Hepatocellular Carcinoma in Chronic Hepatitis B Patients from Northeast, Brazil.. 2022 , 14,		0
49	KASL clinical practice guidelines for management of chronic hepatitis B.. <i>Clinical and Molecular Hepatology</i> , 2022 , 28, 276-331	6.9	2
48	Recurrent pulmonary cryptococcosis during chronic HBV infection: A case report.. <i>Medicine (United States)</i> , 2021 , 100, e28250	1.8	
47	Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial.. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	4
46	Chapter 33: Infectious Diseases. 2022 ,		
45	ADAM12 is an independent predictor of poor prognosis in liver cancer.. <i>Scientific Reports</i> , 2022 , 12, 66344.9		1
44	Maternal and Perinatal Infection in Pregnancy. 2017 , 1099-1129.e1		0

43	Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment. <i>World Journal of Gastroenterology</i> , 2022 , 28, 2251-2281	5.6	2
42	The unvirtuous cycle of discrimination affecting people with hepatitis B: a multi-country qualitative assessment of key-informant perspectives. <i>International Journal for Equity in Health</i> , 2022 , 21,	4.6	1
41	Improving Care for Patients with Chronic Hepatitis B via Establishment of a Disease Registry. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022 ,	3.2	
40	Viral hepatitis: A narrative review of hepatitis A&B. <i>World Journal of Meta-analysis</i> , 2022 , 10, 99-121	0.5	
39	Treatment of Liver Fibrosis: A 20-Year Bibliometric and Knowledge-Map Analysis. <i>Frontiers in Pharmacology</i> , 13,	5.6	0
38	Correlation between Results of Semi-Quantitative and Quantitative Tests for Hepatitis B Virus Surface Antigen among Patients Achieving Viral Suppression with Antiviral Treatment. <i>Diagnostics</i> , 2022 , 12, 1757	3.8	
37	HIV and Hepatitis Coinfection. 2021 , 412-424		
36	Post-liver transplant HBV infection (Review). 2022 , 24, 31-38		
35	JIGAR SIRROZI KASALLIGINI DAVOLASHDA QOʻLLANILADIGAN "PEGILATLANGAN INTERFERON ALFA-2A (PEG-INF-A)"SINTETIK DORI VOSITASINING KIMYOVIY TARKIBI VA USHBU KASALLIKDA HALQ TABOBATIDA FOYDALANILADIGAN OZIQ-OVQAT QOBHILMALARI. 2022 , 1, 283-303		
34	Hepatology (Liver and Bile Duct). 2022 , 119-165		0
33	Validation of Hepatocellular Carcinoma Risk Prediction Models in Patients with Hepatitis B-Related Cirrhosis. Volume 9, 987-997		0
32	Establishment and Characterization of an HBV Viral Spread and Infectious System following Long-Term Passage of an HBV Clinical Isolate in the Primary Human Hepatocyte and Fibroblast Coculture System. 2022 , 96,		1
31	A Phase 2 open label study of ledipasvir/sofosbuvir for 12 weeks in subjects with hepatitis B virus infection.		0
30	Inhibiting Sodium Taurocholate Cotransporting Polypeptide in HBV-Related Diseases: From Biological Function to Therapeutic Potential.		0
29	Investigation of the Effects of Total Oxidative Stress and Total Antioxidant Capacity on the Prognosis in Patients with Chronic Viral Hepatitis B. 2022 , 28, 85-88		0
28	Liver Disease During Pregnancy. 2022 , 117, 44-52		0
27	Impact of advanced practice providers on characteristics and quality of care of patients with chronic hepatitis B.		1
26	What is known about the care and support provided for an ageing population with lived experience of chronic viral hepatitis as they near end-of-life: A scoping review.		0

25	Gastrointestinal and Hepatic Complications in Cancer Patients. 1-18	○
24	Systematic review: Clinical outcomes of discontinuation of oral antivirals in hepatitis B-related liver cirrhosis. 10,	○
23	Anti-HBcore prevalence study in Kazakhstan.	○
22	Exposure to patients' sample and prevalence of Hepatitis B and C virus infection among health-care workers in a Nigerian Tertiary Hospital. 2022 , 21, 322	○
21	Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection.	7
20	Preclinical characterization of ABI-H2158, an HBV core inhibitor with dual mechanisms of action. 2023 , 209, 105485	○
19	The Liver Meeting 2016. 2-12	○
18	Predictive Value of Inflammatory Cytokines in Early Pregnancy for Liver Dysfunction in Pregnant Women with Hepatitis B.	○
17	Overlooked complication of Cushing's syndrome: Reactivation of hepatitis B.	○
16	Superoxide dismutase 2 as a predictor in patients with hepatitis B virus-associated acute-on-chronic liver failure.	○
15	Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferon. 13,	○
14	Antiviral therapy use and related outcomes in patients with cancer and viral infections: results from SWOG S1204. 2023 , 31,	○
13	Occult HBV Infection Reactivation in Non-Hodgkin's Lymphoma: An Update on Prevalence and Management. 70-78	○
12	Racial and Ethnic Disparities in Characteristics and Care Patterns of Chronic Hepatitis B Patients in the United States. 2023 ,	○
11	Hepatobiliary disease after bone marrow transplant. 2023 , 17, 129-143	○
10	Entecavir for children and adults with chronic hepatitis B. 2023 , 2023,	○
9	An Intersectional Approach to Hepatitis B. 2023 , 20, 4879	○
8	Establishment of a multi-parameter prediction model for the functional cure of HBeAg-negative chronic hepatitis B patients treated with pegylated interferon and decision process based on response-guided therapy strategy.	○

- 7 Impact of methylene-tetrahydrofolate reductase gene C677T and A1298C polymorphisms as a risk factor for hepatitis B virus infection. 1-13
- 6 Exploration of lipidic prodrug-loaded oil depot system for intramuscular prolonged delivery of entecavir.
- 5 Antibodies to Hepatitis B core antigen prevalence study in Kazakhstan. **2023**, 11,
- 4 ETS2 alleviates acute-on-chronic liver failure by suppressing excessive inflammation. **2023**, 95,
- 3 Chronicles of HBV and the Road to HBV Cure. **2023**, 3, 232-239
- 2 SOCS1 methylation level is associated with prognosis in patients with acute-on-chronic hepatitis B liver failure. **2023**, 15,
- 1 Approach to Elevated Liver Enzymes. **2023**,